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Summary of results. 
Chapter 1.
1. The distribution of aib-ARs stably expressed in NCB20 cells was 
predominantly associated with the plasma membrane. However, in some 
instances, a predominantly intracellular, non-perinuclear location was 
observed
2 . aib-ARs were distributed in a similar manner in cells at both high 
(8000fmol/mg) and lower (4000fmol/mg) receptor densities.
3. FLAG tagging to the N-terminus of the aib-AR resulted in the construct 
having lower affinity for prazosin than wildtype receptors indicating that the 
8 amino-acid tag has restricted access to the ligand-binding pocket.
4. GFP-tagging to the C-terminus of the aib-AR resulted in the construct 
having equivalent affinity for prazosin as the wildtype receptor, 
demonstrating that such fusion proteins do not perturb prazosin binding to 
ai-ARs.
5. Both GFP- and FLAG-tagged aib-ARs had lower affinity than wildtype 
receptors for QAPB in radioligand binding studies, yet their affinities were 
similar to that of wildtype in confocal analysis on live cells.
6 . Each construct was demonstrated to be functional using the Ca^^ indicator 
Fura-2 and both fluorimetric and imaging analysis set-ups.
7. QAPB binding to aib-ARs in live cells was validated using a GFP-tagged 
aib-AR cell line.
8 . Coupled with calcium imaging, a GFP-tagged ttib-AR cell line allowed the 
study of the distribution and active properties of aib-ARs in response to 
agonist.
9. aib-ARs have a basal level of movement between the plasma membrane and 
a non-perinuclear, intracellular compartment when stably expressed in 
NCB20 cells.
10. In response to agonist stimulation, and subsequent release of Ca"^ "^  from 
intracellular stores, aib-AR movement ceases, and resumes once Ca"^ "^  levels 
returned to baseline.
11. During prolonged (35minutes) agonist exposure, there was an obvious 
overall shift in the density of aib-ARs residing at the plasma membrane to 
the intracellular compartment.
12. QAPB binding to aib-ARs stably expressed in NCB20 cells initiated 
alterations in the cellular shape and rapid vesicular movement within the 
cell. Such observations suggest that QAPB enters via an endocytic pathway 
in the absence of agonist.
13. QAPB binding to ai-ARs does not elicit an intracellular Ca"^  ^response.
Chapter 2.
1. ai-AR subtype expression in hepatocytes is heterogeneous and displays a
unique form of plasticity: During prolonged culture, an increase in ai-AR 
density was observed. In both wildtype and knockout cells these sites were 
sensitive to RS 100329 (aiA-AR-selective) and BMY7378 (aio-AR- 
selective).
2. tti-AR expression undergoes ontogenic modulation during the life cycle of 
the mouse.
3. In the wildtype, there is a predominantly aie-AR population which shows a 
decrease in density between 3 and 4 months, likely to represent post- 
maturational decline, as seen in the rat.
4. In the knockout, at 3months, only a small population of ai-ARs exists 
compared to the substantial « ib-AR population in the wildtype. Up- 
regulation of an aiA-AR population between 3 and 4months is likely to be a 
compensatory mechanism to replace the aiB-AR subtype.
5. By 4months, a population of similar apAR density is reached in both 
strains, yet belong to different subtypes.
6 . In both wildtype and knockout cultured hepatocytes, «i-ARs are distributed 
throughout the cytoplasm of the cell. Minimal expression was associated 
with the plasma membrane.
Chapter 3.
1. QAPB bound specifically, and with high affinity, to ttpARs present on 
freshly dissociated (carotid artery) and cultured (carotid artery and thoracic 
aorta) smooth muscle cells.
2. In freshly dissociated cells, QAPB binding was predominantly intracellular; 
this was consistent in both wildtype and knockout cells.
3. In cultured vascular smooth muscle cells, QAPB binding varied 
considerably between individual cells, in both strains, and was influenced by 
the cellular morphology.
4. RS 100329 (aiA-AR-selective) was able to reduce the specific binding of 
QAPB in some of the cells analysed, from both aorta and carotid artery.
5. BMY7378 (am-AR-selective) was able to block the specific binding of 
QAPB in the majority of knockout cells studied, from both strains, and from 
both vessels. Less of an effect was observed in the wildtype.
6 . In knockout smooth muscle cells (carotid artery and aortic), a predominantly 
(XioAR population was expressed, whereas a mixture of all three is likely in 
the wildtype carotid artery.
7. Observations were made that wildtype carotid artery smooth muscle cells 
appeared to grow at a much slower rate than knockout cells.
8 . Using the transfection reagent Tfx™-50, it was possible to express GFP- 
tagged «ib-ARs in knockout aortic SMCs in situ under the control of both a 
viral, and a mouse aie-AR-specific promoter.
General Introduction
Historical background
The starting point for the development of the concept of the adrenoceptor (AR) 
system was in 1895, when Oliver and Schaffer demonstrated that in vivo injection 
of adrenal gland extract caused a rise in arterial blood pressure (Oliver and 
Schaffer, 1895).
Following the subsequent isolation of adrenaline (AD) as the active compound, it 
was shown by Dale (1913) that AD causes 2 distinct types of effect, namely 
vasoconstriction in certain vascular beds and vasodilation in others (Rang and 
Dale, 1991). Dale also showed that the vasoconstrictive component disappeared if 
the animal was injected with an ergot derivative prior to AD causing a drop, as 
opposed to a rise, in arterial pressure. Due to a disagreement with Langley 
concerning these results. Dale refused to interpret this as the existence of two 
distinct classes of receptor species. Subsequent to this, it was thought that this 
variation in effect was due to the release of different endogenous catecholamines 
called sympathins (sympathin I for inhibitory and sympathin E for excitatory), 
each one causing a different effect at the same receptor (Cannon and Rosenbleuth, 
1933).
Later, pharmacological work beginning with that of Ahlquist in 1948 clearly 
showed that several subclasses of adrenoceptor exist in biological systems. 
Ahlquist found that the rank order of potency for various catecholamines 
including noradrenaline (NA), adrenaline, and the synthetic catecholamine 
isoprenaline (ISO) fell into two distinct patterns, depending on the tissue being 
studied. He postulated the existence of two classes of receptor, alpha (a) and beta 
(P), defined in terms of agonist potencies: a: NA>AD>ISO and P: ISO>AD>NA.
It was then recognised that certain ergot alkaloids, which Dale had studied, acted 
as selective a-AR antagonists and that Dales' reversal experiments with such 
compounds reflected the P-AR effects of AD after a-AR blockade. Although 
compounds were available at that time to block a-ARs, it was not until 1958 that a 
compound became available to block P-ARs (Moran and Perkins, 1958; Powell 
and Slater, 1958) and so confirmed Ahlquist's classification. The use of these 
selective antagonists also suggested the existence of further subdivisions of both 
a- and p-ARs. Shortly afterwards, p-ARs were further subdivided into Pi- and P%- 
ARs depending on their location and polarity (Lands et al., 1967).
Brown and Gillespie set the ball rolling for subtypes of a-ARs in 1957. Their 
work and subsequent work in other laboratories looked towards the existence of 
pre- and post-junctional a-ARs, leading to the subclassification of a-ARs into ai- 
postjunctional and az-prejunctional sites based on anatomical and 
pharmacological properties (Langer, 1974).
Problems were created however when several groups demonstrated the presence 
of az-ARs postjunctionally on vascular smooth muscle (Drew and Whiting, 1979; 
Docherty et al. 1979; Timmermans et al., 1979) and also on various other tissues 
(Pettinger et al., 1976). This classification was thereafter clarified as exclusively 
pharmacological regardless of anatomical location (Starke and Langer, 1979; 
Berthelsen and Pettinger, 1977).
Pharmacological Characterisation
With the development of additional pharmacological tools as well as new 
techniques for studying drug-receptor interactions such as radioligand binding 
assays, it became apparent that the situation was significantly more complicated
with further subdivisions of the ai-ARs. Accumulating evidence of heterogeneity 
from several groups led McGrath, (1982) to propose a further subdivision of ai- 
ARs into aiA- and am-ARs. These functional studies, and others (Ruffolo, 1985) 
indicated that postjunctional responses mediated by ai-ARs could not be 
explained adequately on the basis of a single population of receptors. The first 
clear evidence for the existence of pharmacologically distinct subtypes of apARs 
was presented by Morrow and Creese, (1986) who showed evidence for receptor 
heterogeneity in rat brain. They found that the antagonists WB4101 and 
phentolamine competed for -prazosin labelled sites with high and low 
affinities, suggesting that the prazosin was labelling a heterogeneous population of 
receptors. The high affinity sites were termed aiA, while the low affinity sites 
were termed am.
Further ligand binding studies in other brain regions, vas deferens and spleen 
(Docherty, 1979; Han, 1987a; Gross, 1989) confirmed the previous classification 
of aiA and am subtypes showing high and low affinity, respectively for WB4101. 
From this study they also concluded that the contraction induced by the am-AR 
was independent of extracellular calcium while that induced by the aiA-AR relied 
on the opening of dihydropyridine sensitive calcium channels. However, this 
proposal of the source of calcium as a subtype discriminating feature did not hold 
for all tissues studied. A later publication demonstrated that both subtypes could 
stimulate EP3 to a similar extent from cells in culture (Han et al. 1990). It has since 
been shown that all the cloned receptors can induce the accumulation of IP3  
(Schwinn et al. 1991; Minneman and Esbenshade, 1994; Cotecchia et al. 1995; 
Theroux et al. 1996).
Further to this, Han et al. (1987b), went on to use both the alkylating agent CEC 
and WB4101. Again they found there were high and low affinity sites in rat brain 
for WB4101, and that CEC seemed to inactivate only the low affinity WB4101 
sites, although, quantitatively the number of sites inactivated by CEC compared to 
the low affinity WB4101 sites did not correlate well. Later work attributed this to 
an incomplete access of CEC to intracellular sites due to variations in 
experimental conditions (Minneman et al., 1988b).
In more recent studies, it has been recognised that the selectivity of CEC against 
the aiB-AR may depend upon its access to (XpAR subtypes rather than any 
differences in the structure of the « ia- and am-AR. In COS-7 cells expressing a p  
AR subtypes, the aia-AR seems to localise mainly intracellularly but the a^-AR 
localised at the cell surface such that CEC inactivated a lower proportion of aia- 
AR in intact cells, but nearly the same proportion as a^-AR when membrane 
preparations were incubated with CEC (Hirasawa et al., 1997). The a^-AR can 
also be inactivated by CEC. Since then, complications in the use of this site- 
directed alkylating agent and controversies over its selectivity in inactivating the 
recombinant apAR subtypes (Michel et al., 1993; Hirasawa et al., 1997) have 
pushed it into disfavour. Such work has indicated that subtype-specific subcellular 
localisation may constitute a new class of pharmacological properties in addition 
to ligand binding (Tsujimoto et al., 1998). This point will be addressed later.
The advent of further subtype selective antagonists assisted the current proposal of 
apAR subclassification. (+)-niguldipine and 5-methylurapidil (5-MU), were 
found to be selective for the aiA-AR subtype (Graziadei et al. 1989; Hanft and 
Gross, 1989; Gross et al. 1988), with 5-methylurapidil having an =70 fold 
selectivity for the aiA-AR subtype as opposed to only a 20-30 fold selectivity
exhibited by WB4101 in radioligand binding experiments (Hanft and Gross, 
1989).
Molecular studies
This classification however, was complicated by the cloning of the cDNAs or 
genes for the three distinct «i-AR subtypes, encoding at least one and possibly 
two subtypes not recognised previously on the basis of pharmacological or 
radioligand binding studies. Due to a limited number of subtype-selective 
antagonists, there was some confusion as to the identity of the cloned receptors in 
relation to their native counterparts.
The first of these receptors to be cloned was the hamster aib-AR (Cotecchia et al., 
1988), isolated from DDTi MF-2 hamster smooth muscle cells. Expression and 
pharmacological analysis of this construct in COS-7 cells showed low affinity for 
WB4101 and phentolamine, and proved to be associated with the accumulation of 
IP3 . These findings combined with functional and binding data from the native 
ttiB-AR, indicated that the cloned receptor represented the hamster ais-AR. A 
second receptor, which was identified soon after, was derived from a bovine brain 
cDNA library utilising a probe derived from the hamster aib-AR sequence 
(Schwinn et al., 1990). Analysis of this clone showed somewhat different results 
to that found with the aib-AR subtype. It had 10-fold higher affinity for the 
antagonist WB4101 and phentolamine, together with a high affinity for the 
agonist oxymetazoline. Although this pharmacological profile supported the 
classification of this receptor as an ttiA-AR, the sensitivity of the receptor to CEC 
(previously associated with aiB-AR), together with failure to detect mRNA 
expression in rat tissues with binding profiles consistent with the Œia-AR, led
authors to believe that this was in fact a novel adrenoceptor, and was thereafter 
named, aic-AR. A third clone was identified from a rat cerebral cortex library 
(Lomasney et al. 1991), with a high affinity for WB4101 and a distribution in rat 
tissues corresponding to the native aiA-AR from binding studies. It was therefore 
assumed that this clone represented the Œia-AR. Perez et al. (1991) soon after 
identified another cci-AR clone, using solution-phase library screening of a rat 
brain library. Based on evidence that it did not correspond to any of the criteria for 
the other two characterised clones, it was considered to be a novel oCi-AR and was 
named the ocia-AR. With the exception of two codons within the sequence of the 
aia- and aid-AR, it was soon after believed that these were in fact encoding the 
same receptor, generally accepted to be the «id-AR (Minneman and Esbenshade, 
1994).
A point was reached where, although the cloned aib-AR had a functionally 
defined counterpart, the cloned aid- and aic-AR did not, and similarly the 
pharmacologically defined aiA-AR was without a cloned partner. However, after 
much deliberation, it became generally accepted that the aic- clone should be 
renamed the aia- and that this cloned receptor corresponded to, and encoded for, 
the native aiA-AR (Heible et al. 1995). Originally, this possibility was dismissed 
because of the sensitivity of the bovine aic- clone to inactivation by CEC and 
failure to detect mRNA for this receptor subtype in the rat by northern blotting 
techniques, using a bovine sequence as the probe (Schwinn et al. 1990). However, 
alterations in the experimental conditions under which sensitivity to CEC was 
examined were found to influence results. Subsequent studies in the human, 
bovine (Schwinn et al. 1995) and a rat homologue (Laz et al., 1994) showed
reduced sensitivity to CEC under specified experimental conditions. The recent 
cloning and expression of the rat homologue of the bovine aic- clone has clearly 
shown that the rat aic-AR has the expected pharmacological characteristics of the 
pharmacologically defined a%A-AR. For example, Forray et al. (1994a) showed 
that the rat homologue exhibited higher sensitivity to the aiA-AR selective 
antagonist (+)-niguldipine compared to the bovine aic-clone. Also with the arrival 
of more sensitive technology in this field, namely RNAse protection assays and in 
situ hybridisation studies, mRNA for the aic-AR clone was thereafter found more 
widely distributed in tissues of the rat, compared to previous studies (Price et 
al. 1993, 1994a). Functional correlations were made thereafter by several groups 
showing that in fact the aic-AR clone represented the native aiA-AR (Blue et al., 
1995; Testa et al., 1995; Ford et al., 1994; Faure et al., 1994b).
Following the cloning and analysis of the human receptors (Ramarao et al., 1992; 
Hirasawa et al., 1993; Forray et al., 1994b; Esbenshade et al., 1995; Schwinn et 
al., 1995; Tseng-Crank et al., 1995), and identification of more selective drugs 
(Goetz et al., 1995), a general consensus was reached (Ford et al., 1994; Heible et 
al., 1995).
Confusion in the nomenclature and pharmacological identity of the cloned aw-AR 
was soon resolved with the arrival of the aio-selective antagonist BMY-7378 
(Goetz et al., 1995). It became apparent that the cloned aid-AR did in fact have a 
functional partner, and continuing studies show an indispensable role of this ai- 
AR subtype in the contraction of a wide variety of vessels in different species 
(Piascik et al., 1995, 1997; Kenny et al., 1995; Testa et al., 1995; Buckner et al., 
1996; Deng et al., 1996; Saussy et al., 1996; Villalobos-Molina et al., 1996, 1997; 
Ibarra et al., 1997; Hrometz et al., 1999).
Eventually, the uncertainty surrounding the subclassification of ai-ARs was 
eliminated, and the lUPHAR Committee (Heible et al., 1995) recommended the 
following nomenclature. The native « ia-AR corresponds to the cloned otia-AR, 
which is located on human chromosome 8 and was previously designated as aic- 
AR or aiA/c-AR. The native aig-AR corresponds to the cloned a%b-AR, which is 
located on human chromosome 5 and was always designated as aib-AR. The 
native am-AR corresponds to the cloned aw-AR, which is located on human 
chromosome 20 and was previously designated as aia-AR, aid-AR or a^d-AR. 
Subscripts in capital and lower case designate pharmacologically defined and 
cloned receptors, respectively. The genes and/or cDNAs encoding the three 
subtypes have been cloned in rats and humans (Heible et al., 1995), and species 
homologs for some subtypes have additionally been cloned in hamsters, bovine, 
rabbits and mice (Cotecchia et al., 1998; Schwinn et al., 1990; Alonso-Llamazares 
et al., 1995; Miyamoto et al., 1997; Suzuki et al., 1997; Xiao et al., 1998).
cCiL-adrenoceptor pharmacology
There is functional evidence for further heterogeneity, particularly for a subtype 
with a low affinity for prazosin (Muramatsu et al., 1990; Garcia-Sâinz et al., 
1992a; Heible et al., 1995; Ford et al., 1996; Leonardi et al., 1997; Smith et al., 
1997; Shannon Kava et al., 1998; Hirai et al., 2001). However, to date, these 
putative additional subtypes have resisted identification by biochemical and/or 
molecular techniques. Therefore, the possibility remains that additional 
adrenoceptor subtypes may exist. This variability led to the proposal for division 
of the class into am-AR and aiL-AR, based on sensitivity to prazosin (Flavhan 
and Vanhoutte, 1986; Muramatsu et al., 1990). When the recombinant ai-ARs
were identified, it was found that all three; aia-AR, ttib-AR and a^-AR subtypes 
had 'aie' characteristics, based on radioligand binding assays with transfected 
cells. Antagonists were identified, such as RS17053 (Ford et al., 1996), which had 
high potency and selectivity for the aiA-AR subtype, but about 1 0 0 -fold lower 
potency in functional assays reflecting 'Qil' characteristics. Other antagonists 
appear to show the opposite selectivity pattern (Heible and Ruffolo, 1996). Based 
on functional assays using cells transfected with the recombinant aia-AR, and on 
the effect of receptor environment on antagonist affinity, it has been proposed that 
the « 1L-AR represents an affinity state of the aia-AR (Williams et al., 1996; Ford 
et al., 1997). This may explain why efforts to clone a discrete protein having ociL- 
AR characteristics have been unsuccessful.
Splice variants
Three splice variants of the human 0 Cia-AR have been cloned which differ in 
length and sequence of their C-terminal domains (Hiraswa et al., 1995), and 
additional splice variants and truncated products have been reported (Chang et al., 
1998). However, no pharmacological or signalling differences are observed on 
expression of these different splice variants. The truncated products do not bind 
radioligands, and their biological significance is still obscure (Chang et al., 1998). 
To date, four isoforms of the human «la-AR have been identified. These have 
been named aia-i-, otia-2 -, 0 (ia-3 -, ocia-4 - and they all diverge in sequence at their 
carboxy termini (Chang et al., 1998; Hirasawa et al., 1995). It has been shown that 
when all four isoforms are expressed in cell lines and IP3 accumulation measured, 
all the isoforms display (XiL-AR pharmacology (Ford et al., 1997; Chang et al..
1998). Interestingly, a recent study indicated that human-cloned «la-AR isoforms 
display 0 Cil-AR pharmacology in functional studies (Daniels et al., 1999).
The aiL-AR is mainly associated with mediating NA-induced contraction of the 
lower urinary tract of man (Muramatsu et al., 1994, 1995; Ford et al., 1996) and 
animais, for example rabbit (Leonardi et al., 1997; Shannon Kava et al., 1998; 
Deplanne and Galzin, 1996). In addition, a pharmacological profile consistent 
with this subtype has been reported in a variety of blood vessels (Muramatsu et 
al., 1990, 1995; Smith et al., 1997; Van der Graaf et al., 1996a).
Multiple subtypes
Why are there so many «i-AR subtypes? Emerging evidence suggests that 
different subtypes and splice variants have different patterns of tissue expression, 
coupling efficacy and regulation. Knowledge on the functional relevance of 
subtypes and splice variants is limited, and even less is known about the 
physiological significance of the truncated forms of Œia-ARs. There is evidence 
that for other GPCRs, co-expression of a functional 'full' receptor and a truncated 
isoform may result in a decreased response of the system i.e., the ability of a 'full' 
receptor to generate a response is negatively modulated by the truncated isoform 
(Okuda-Ashitaka et al., 1996; Schôneberg et al., 1995; Le Gouill et al., 1999). It is 
tempting to speculate whether expression of such truncated receptors play a role 
in a physiological context, modulating cell responsiveness.
Species Differences in Tissue Distribution
tti-ARs are present in many tissues and play important roles in the maintenance of 
homeostasis. These receptors participate in many essential physiological
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functions, such as sympathetic neurotransmission, myocardial inotrophy and 
chronotrophy, modulation of hepatic metabolism, uterine contraction, regulation 
of water and electrolyte metabolism, modulation of vascular tone, and contraction 
of smooth muscle in the genitourinary system. It has been shown that the genes 
for the three subtypes of oci-AR are expressed in discrete, tissue-specific patterns 
in the same organism (Price et al., 1994a). Knowledge of ai-AR subtypes that 
participate in a given function has essential physiological importance and could 
allow for specific therapeutic intervention.
In the liver, «i-ARs have numerous roles; modulate glycogenolysis, 
gluconeogenesis, and synthesis of urea, fatty acid metabolism, to name but a few. 
It is interesting that one ai-AR subtype seems responsible for all these actions 
within the one species, yet great variation is recognised between species: rabbit 
(Garcia-Sainz et al., 1992b), dogs (Garcia-Sainz et al., 1995c), cats (Garcla-Sainz 
et al., 1996a) and humans (Garcia-Sainz et al., 1995d) mainly express aiA-ARs 
whereas expression of the Œib subtype has been detected in the livers of a fish 
{Ichtalurus punctatus) (Garcia-Sainz et al., 1995b), and rodents such as rats, mice 
and hamsters (Garcia-Sainz et al., 1994). Coexpression of otiA and «ib-ARs has 
been observed in the liver of monkeys (Garcia-Sainz et al., 1996b).
It is tempting to speculate that the differences observed between subtypes may be 
due to experimental age differences between species. Evidence does exist to 
suggest that «i-AR subtype modulation can occur with age (Gurdal et al., 1995a, 
b; Xu et al., 1997; Ibarra et al., 1997; Rudner et al., 1999; Shen et al., 2000; 
Yamamoto et al., 2001). This will be discussed in chapter 2.
Although this principle also applies to many other organs and tissues, it is at 
present best exemplified in the liver. Therefore caution should be made when
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extrapolating data from non-human models, as the information may be 
misleading. Human liver mainly expresses aiA-ARs at both mRNA and receptor 
protein levels (Garcia-Sainz et al., 1995d; Price et al., 1994b). The four splice 
variants have been detected with marked predominance of the ocia-i-AR isoform at 
the mRNA level (Chang et al., 1998). Similarly, Œia-AR mRNA predominates in 
the following human tissues: heart (Price et al., 1994b) (splice variants aiA-4 and 
otiA-i); cerebellum (Price et al., 1994b); cerebral cortex (Price et al., 1994b), and 
prostate (Price et al., 1994b; Forray et al., 1994b; Faure et al., 1994b) (ocia - 4  
isoform) (Chang et al., 1998). am-AR mRNA is present in high concentrations in 
human spleen and kidney, while a^-A R  mRNA predominates in human aorta 
(Price et al., 1994b). However, mRNA levels do not necessarily correlate with 
receptor protein levels and also functional response. Species variations and these 
limitations make it necessary to study all these aspects in human tissue. It is 
obvious that information regarding functional roles, tissue distribution, and 
density of the different tti-AR subtypes is far from complete in the normal healthy 
human being. Even less is known about all these aspects under conditions such as 
growth or ageing and in different disease states.
Subtype selective ligands: current status
Increasing effort is currently being put into the design of subtype-selective 
compounds in order to achieve tissue or organ selective ai-AR blockade. 
Although a number of antagonists selective for the native and cloned aiA/a-AR 
and ttiD/d-ARs are now available, e.g., WB4101, (-t-)-niguldipine, 5-MU, 
tamsulosin, Rec 15/2739, RS-17053, KMD-3213, Ro 70-0004 and RS-100329,
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B8805-033 and L-771,688 (SNAP 6368) for the Œia-AR subtype (Han et al., 
1987b; Gross et al., 1988; Boer et al., 1989; Forray et al., 1994b; Eltze et al., 
1996; Ford et al., 1996; Testa et al., 1997; Williams et al., 1999; Murata et al., 
1999; Chang et al., 2000), or BMY-7378, MDL 73005EF and cystazosin for the 
ttiD-AR subtype (Goetz et al., 1995; Saussy et al., 1996; Bolognesi et al., 1998), 
the lack of antagonists sufficiently selective for the ttie-AR is a persistent problem 
in ai-AR characterisation. CEC was originally identified as an « ib-AR selective 
alkylating agent (Han et al., 1987b), however, complications in the use of site- 
directed alkylating agents and controversies over its selectivity in inactivating the 
recombinant oci-AR subtypes (Michel et al., 1993; Hirasawa et al., 1997) has 
omitted its use in several laboratories. Presently, spiperone is the only antagonist 
known for retaining a moderate selectivity (approximately 5-fold) for native or 
cloned (XiB/b-AR over Œia-ARs both in radioligand binding and functional 
experiments, whereas its selectivity for ociB-AR over aio-AR is at the most, by a 
factor of three (Michel et al., 1989; Blue et al., 1995; Kenny et al., 1995; Schwinn 
et al., 1995; Eltze et al., 1999). The presumed Œib-AR selectivity of other 
antagonists, e.g., risperidone (Sleight et al., 1993) and cyclazosin or its (+)- 
entantiomer (Giardinâ et al., 1995, 1996), initially found in binding studies, 
however, could not be confirmed in subsequent functional experiments (Eltze, 
1996; Stam et al., 1998). In contrast, the quinazoline compound, L-765,314 
(Patane et al., 1998), has been shown to be aiB-AR selective both in binding and 
functional experiments (Chang et al., 1998). Recently, a novel aiB-AR selective 
compound with no direct chemical resemblance to other ai-AR antagonists, 
AHllllOA, has been characterised through binding experiments with native or 
cloned oci-AR subtypes in different animal tissues (rat, hamster and bovine) and
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human tissues, displaying an approximately 1 0 - and 2 0 -fold selectivity to «ib 
relative to «ia and ocm-ARs, respectively, and an affinity rank order at these 
subtypes of aiB>cxiA>ociD (King et al., 1994; Giardinâ et al., 1996; Saussy et al.,
1996). Presently, A H llllO A  is listed as the only recommended selective 
antagonist for this subtype (see Alexander and Peters, 2000), but it also has 
functional affinity at aio-ARs in rat aorta (King et al., 1994). Further proof of its 
general utility has recently been quashed by a report by Eltze et al. (2001), who 
claim that this compound also interacts with (%2 -ARs, and thus may be unsuitable 
for ai-AR subtype characterisation, at least in functional studies involving smooth 
muscle (Eltze et al., 2001).
Development of « ia-AR selective antagonists has been the most successful. The 
first ttiA-AR selective antagonist to be identified was WB4101 (Morrow and 
Creese, 1986), which has about 20-fold higher affinity for the ociA-AR than otiB- 
AR subtype. This limited selectivity, combined with an intermediate affinity for 
the aiD-AR subtype, has limited its usefulness in differentiating between 
subtypes. Subsequently, 5-MU (Gross et al., 1988) and (-f-)-niguldipine (Boer et 
al., 1989) were identified as Œia-AR selective antagonists. These drugs had a 
greater selectivity between Œia-AR and « ib-ARs (80-500 fold) and a low affinity 
for the aiD-AR subtype, making them useful for distinguishing subtypes in 
radioligand binding assays (Han and Minneman, 1991). However, each of these 
drugs has other properties that limited their use in functional experiments. 5-MU 
is a partial agonist at serotonin 5-HTia receptors, while (+)-niguldipine is a 
dihydropyridine Ca'^ '^  channel antagonist. A derivative of (-f-)-niguldipine, SNAP 
5089 was developed which is highly ccia-AR selective but has a much lower
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affinity for voltage-gated Ca"^ "^  channels (WetZel et al., 1995). Interest in this area 
has been strong, since aiA-AR selective antagonists may have significant 
therapeutic advantages in treatment of BPH (Nagrathnam et al., 1998). The 
moderately Œia-AR selective antagonist tamsulosin has been introduced for this 
purpose (reviewed in Hieble and Ruffolo, 1996).
The partial serotonin 5-HTi a receptor agonist BMY-7378 has been shown to be a 
selective antagonist at the «id-AR subtype, with about 1 0 0 -fold higher affinity for 
the aiD-AR than the ociA or aiB-AR subtype (Goetz et al., 1995). This drug has 
proven useful in clarifying functional roles for the ocm-AR subtype (Piascik et al., 
1995). Buspirone, a close structural analogue of BMY-7378, has recently been 
reported as another compound able to functionally discriminate Qid-AR from the 
other known «i-AR subtypes in various tissues (Eltze et al., 1999).
There is a clear need for additional selective agonists and antagonists, particularly 
for the ttiB-AR and ttm-AR subtypes. Such compounds would be very useful in 
allowing quantitative evaluation of the distribution of subtypes by radioligand 
binding assays, and in defining their functional roles. However, the lack of clearly 
defined potential therapeutic applications for such compounds reduces the 
likelihood of their identification.
Structure-function relationship of the cci~AR subtypes
ai-ARs belong to the superfamily of GPCRs. All GPCR sequences share the 
presence of seven hydrophobic regions that are believed to form a bundle of a- 
helical transmembrane domains (TMDs), connected by alternating intracellular 
and extracellular loops (Khorana et al, 1992). Mutational analysis of several 
GPCRs has revealed that the TMDs contribute to the formation of the ligand-
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binding pocket, whereas the amino acid sequences of the intracellular loops seem 
to mediate receptor-G protein coupling (Khorana et al., 1992; Savarese et al., 
1992). Agonist binding to a GPCR is believed to induce a conformational change 
in the receptor that can result in its productive coupling to G proteins, thus leading 
to intracellular events. In spite of site-directed mutagenesis and biophysical 
studies on different GPCRs, which have provided many insights into the structure- 
function relationships of these proteins, a consistent structural description of the 
molecular changes underlying the process of receptor activation is still lacking. 
The TMDs of the three ai-ARs show 65-75% of amino acid identity when 
compared among each other. Potential sites of phosphorylation by protein kinase 
C (PKC) (Houslay et al., 1991) and protein kinase A (PKA) (Clark et al., 1988) 
are present in the intracellular domains of all three receptor subtypes, suggesting 
that protein phosphorylation might play a role in receptor regulation. Such 
phosphorylation events and their potential regulatory purpose will be discussed 
later.
Structural determinants of selectivity
Several studies have focused on the molecular interactions of the endogenous 
catecholamines, AD and NA, with different AR subtypes. The majority of work 
done on ai-ARs has focused on the ocib-AR subtype which is thought to be 
prototypic of this group of receptors. However, the ligand-binding pocket must be 
distinct in each of the different receptor subtypes, since they can discriminate 
between a wide variety of synthetic agonists and antagonists (Hwa et al., 1995). 
Using oxymetazoline, cirazoline and methoxamine as aiA-AR selective agonists, 
Hwa et al. (1995) used site-directed mutagenesis to identify critical residues in
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«la-AR and ociy-ARs responsible for apparent differences in agonist binding 
potencies. They found that conversion of Ala^ ®"^  to valine in the TMD V and 
Leu^ '^^  to methionine in the TMD VI of the aib-AR subtype increased the affinity 
of these selective agonists until they were similar to their affinities for the aia-AR 
subtype. The reciprocal double mutant in the ocia-AR decreased the affinities of 
these agonists so that they were similar to the (Xib-AR. Hwa et al. (1995) 
developed a model suggesting that these two residues are critically involved in 
subtype-selective agonist binding, and may interact structurally within the 
receptors. Similar studies with antagonists and the use of aia/aib-AR chimeras 
allowed identification of residues involved in subtype-selective antagonist binding 
(Zhao et al., 1996). This study suggested that TMD VI and a portion of the second 
extracellular loop are critically important in subtype-selective antagonist binding. 
In particular, three adjacent residues located on the extracellular loop of TMD V 
appeared to be fully responsible for the higher antagonist affinity for Œia-ARs. 
This suggests that oci-AR antagonists may bind near the surface of the receptor, 
rather than deep within the TMDs, like agonists. Involvement of TMD II in 
specifying the selectivity of niguldipine derivatives between the otiA-AR and am- 
AR subtypes was also reported by Hamaguchi et al. (1996). Ongoing studies in 
Cotecchia's laboratory and others, are investigating the interaction pattern of 
different antagonists at oci-AR subtypes. Other than these studies, little is known 
about the molecular determinants of the pharmacological differences between the 
ai-AR subtypes. Additional information would clearly be useful in helping to 
predict structures of additional subtype-selective drugs.
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Consequences of agonist activation o/ai-ARs
Agonist activation of a GPCR not only results in the G protein-dependent 
activation of effector systems, but also sets in place a series of molecular 
interactions that allow for 1) feedback regulation of G protein coupling, 2) 
receptor endocytosis, and 3) signalling through G protein-independent signal 
transduction pathways (Lefkowitz, 1993; Ferguson et al., 1996; Ferguson and 
Caron, 1998; Krunpnick and Benovic, 1998; Hall et al., 1999; Luttrell et al., 1999; 
Schôneberg et al., 1999). Such work has intimated that the functional activity of 
GPCRs extends far beyond the traditional model of: receptor-^ G proteins 
effector.
GPCR activity represents a coordinated balance between molecular mechanisms 
governing receptor signalling, desensitisation, and resensitisation. Receptor 
desensitisation, the waning of GPCR responsiveness to agonist with time, 
represents an important physiological 'feedback' mechanism that protects against 
both acute and chronic receptor over-stimulation.
Three families of regulatory molecules are known to contribute to the GPCR 
desensitisation process: second-messenger-dependent protein kinases, G protein- 
coupled receptor kinases (GRKs) and arrestins (reviewed by Lefkowitz, 1993; 
Ferguson et al., 1996; Ferguson and Caron, 1998; Krupnick and Benovic, 1998). 
It is now recognised that the same regulatory molecules that contribute to agonist- 
stimulated receptor desensitisation (GRKs and p-arrestins), initiate and regulate 
GPCR endocytosis, intracellular trafficking, and resensitisation (e.g., Tsuga et al., 
1994; Ferguson et al., 1995, 1996; Zhang et al., 1997; Oakley et al., 1999).
In addition to signalling via heterotrimeric G proteins, it is now recognised that 
GPCRs act as scaffolds promoting the formation and compartmentalisation of G
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protein-independent signal transduction complexes. A growing number of 
proteins have been identified that bind GPCRs and either couple GPCRs to G 
protein-independent signal transduction pathways or alter G protein specificity 
and agonist selectivity (reviewed by Hall et al., 1999).
GPCR-mediated signal transduction can be attenuated (desensitisation) with 
relatively fast kinetics (within seconds to minutes after agonist-induced 
activation). This process is characterised by functional uncoupling of receptors 
from heterotrimeric G proteins, which occurs without any detectable change in the 
total number of receptors present in cells or tissues (Clark, 1986). A highly 
conserved mechanism of rapid desensitisation involves ligand-dependent 
phosphorylation of receptors by second messenger-dependent protein kinases 
namely PKA and PKC, GPCR kinases (GRKs) (Benovic et al., 1990) and some 
receptors with tyrosine kinase activity (Hadcock et al., 1992). GRK-mediated 
receptor phosphorylation promotes the binding of p-arrestins, which disrupt the 
interaction between receptors and G proteins (Lefkowitz et al., 1998a). This rapid 
process, for certain GPCRs is associated with a process called sequestration, 
which involves a physical redistribution of receptors from the plasma membrane 
to intracellular membranes (e.g. Fonseca et al., 1995). This process of GPCR 
internalisation is thought to promote de-phosphorylation of receptors by bringing 
them near to an endosome-associated phosphatase. De-phosphorylation and 
subsequent recycling of receptors back to the plasma membrane contributes to a 
reversal of the desensitised state (resensitisation), which is required for full 
recovery of cellular signaling potential following agonist withdrawal (Lefkowitz 
et al., 1998b).
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Differential regulation of ai-AR subtypes; functional significance 
Differential regulation within a family of receptors is frequently associated with 
the susceptibility of members to be modified by phosphorylation. Subtypes of ai- 
AR and P-ARs seem to be subject to desensitisation according to their 
susceptibility as kinase substrates (Liggett, 1993, 1998; Kurose and Lefkowitz, 
1994). Limited information is available about the phosphorylation of ai-AR 
subtypes.
Two main types of desensitisation of GPCRs are now recognised, namely 
homologous (reduced response in agonist-activated receptor only), and 
heterologous (reduced response in agonist-activated receptor, other receptors or 
distal signalling components unrelated to the original stimulus).
Regulation of adrenoceptors by phosphorylation, and functional consequences, 
have been studied extensively with the p2 -AR. With view to the three known ai- 
AR subtypes, namely aia, ccib and a^-AR, information has been limited, most of 
which is based on data from the hamster aib-AR subtype. However, recent 
information concerning the phosphorylation state of the other two subtypes has 
important functional regulatory implications for this group of receptors (Vazquez- 
Prado et al., 2000; Garcia-Sâinz et al., 2001). One of the important physiological 
consequences of this regulatory feature is its contribution to changes in the 
subcellular localisation of ai-AR subtypes and cellular responsiveness to their 
activation, (McCune et al., 2000). Therefore, I have discussed what is currently 
known about phosphorylation of a%-ARs in some detail.
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aib-AR homologous desensitisation
Leeb-Lunderberg et al. (1987) first observed attenuation of agonist-induced ocib- 
AR response in hamster DDTi MF-2 cells. This desensitisation of receptor 
response was accompanied by a marked decrease in the number of surface 
receptors, termed internalisation (Leeb-Lundberg et al., 1987). Several groups 
have demonstrated that agonist stimulation markedly increases receptor
phosphorylation using the hamster aib-AR transfected into rat- 1  fibroblasts 
(Lattion et al., 1994; Diviani et al., 1996, 1997; Vâzquez-Prado et al., 1997). 
Truncation of the receptor carboxyl terminus impairs agonist-dependent
phosphorylation and desensitisation, inferring a critical role of this domain in the 
regulatory function of this ai-AR subtype (Lattion et al., 1994). The
phosphorylation events involved are understood to be instrumented by G protein 
receptor kinases (GRKs) 2 and 3 (Diviani et al., 1996) and the phosphorylation 
sites involved in this GRK-mediated desensitisation of ocib-ARs located in the 
carboxyl tail are Ser"^ °*, and Ser"^ ®^ (Diviani et al., 1997). In addition to this,
studies have shown that different receptors may be under different levels of 
control by these protein kinases (lacovelli et al., 1999). Second messenger- 
dependent PKC is believed to have no influence on agonist-dependent
phosphorylation of the hamster aib-AR (Lattion et al., 1994).
Interestingly, there are great differences in agonist-induced internalisation of «ib- 
ARs, probably depending on the cell type. Thus, in human embryonic kidney 293 
(HEK 293) cells, stably expressing hamster aib-ARs, it was observed that NA 
induced a rapid and striking internalisation of cell surface receptors (Fonseca et 
al., 1995). In contrast, the agonist-stimulated ocib-AR internalisation that is 
observed in rat- 1  fibroblasts is much slower and involves only a relatively small
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proportion of the total surface receptors (Lattion et al., 1994; Vâzquez-Prado et 
al., 1997). In DDTi MF-2 cells, agonists induce -30% ttie-AR internalisation in 
30minutes (Leeb-Lundberg et al., 1987; Cowlen and Toews, 1988). It has been 
observed that surface-sorting and agonist-promoted internalisation of ocib-A Rs in 
this cell type are two independent processes involving different components of the 
cellular endocytic machinery. Basal surface-sorting was sensitive to breveldin A, 
an inhibitor of vesicular transport, and that agonist-promoted internalisation was 
sensitive to actin depolymerisation agents such as cytochalasin D and mycaloide 
B (Hirasawa et al., 1998). Real-time optical monitoring of agonist-mediated 
internalisation of aib-ARs tagged with GFP, in mouse aT3 cells, indicated that 
the receptor internalised and redistributed in intracellular compartments, was 
within minutes of exposure to agonist (Awaji et al., 1998). Although PKC does 
not appear to play a role in the agonist-mediated phosphorylation of aib-ARs 
(Lattion et al., 1994), it seems to do so in receptor internalisation (Fonseca et al., 
1995; Awaji et al., 1998). Using constitutively active aib-AR mutants, it has been 
observed that when different receptor domains are mutated, divergent effects on 
receptor phosphorylation and internalisation take place. Thus agonist-independent 
activity of aib-AR mutants does not necessarily correlate with any of the 
parameters (Mhaouty-Kodja et al., 1999). Recently, Wang et al. (2000) have 
identified distinct carboxyl-terminal domains that mediate the internalisation and 
down-regulation of the hamster aib-AR. They have generated and characterised 
receptor constructs that should prove useful for elucidating in greater detail the 
molecular mechanisms regulating both the expression and the localisation of aib- 
ARs (Wang et al., 2000).
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Expression of arrestin proteins attenuated aib-AR-mediated PIP2 hydrolysis and a 
dominant negative arrestin mutant inhibited adrenoceptor internalisation, in 
agreement with what has been observed with other GPCRs (Diviani et al., 1996; 
Mhaouty-Kodja et al., 1999).
All of these studies have been done using the hamster aiB-AR endogenously 
expressed in DDTi MF-2 cells or transfected cell models. Garcfa-Sainz et al. 
(1999a) have recently observed agonist-mediated phosphorylation of the human 
ocib'AR.
Heterologous desensitisation
It has been observed that many GPCRs are desensitised via feedback regulation 
by second-messenger-stimulated kinases, such as PKA and PKC. This type of 
desensitisation is classed as heterologous, since any activator that can increase 
cAMP or DAG has the potential to induce the phosphorylation and desensitisation 
of any GPCR containing the consensus phosphorylation sites for PKA and PKC. 
Other signalling proteins containing such consensus sites can also be 
phosphorylated, and, as a consequence, their function can be modified. Similarly, 
a single receptor type can be phosphorylated and desensitised by multiple protein 
kinases (Nambi et al., 1985). In addition to second-messenger-activated kinases, 
some receptors with endogenous protein tyrosine kinase activity have been shown 
to induce the phosphorylation in tyrosine residues of GPCRs, such as p2-ARs, and 
lead to desensitisation (Hadcock et al., 1992; Baltensperger et al., 1996; Karoor 
and Malbon, 1996). In the case of «ib-ARs, there is evidence that PKC plays a key 
role in heterologous desensitisation/phosphorylation. Reported heterologous 
phosphorylation events involving aib-ARs are discussed later.
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It has been observed in vitro that PKA can phosphorylate (Xis-ARs purified from 
DDTi MF-2 cells (Bouvier et al., 1987) on the third intracellular loop of the 
mouse «ib-AR fused to glutathione-S-transferase (Alsonso-Llamazares et al.,
1997). However, there is no evidence suggesting that such PKA-mediated 
phosphorylation might take place in vivo and less is known on its possible 
consequences.
aib-AR phosphorylation by phorbol esters
It was first shown using rat hepatocytes that activation of PKC with phorbol esters 
blocked aiB-AR action (Corvera and Garcia-Sainz, 1984; Corvera et al., 1986; 
Garcia-Sâinz et al., 1985a). This finding was confirmed by similar studies using 
DDTi MF-2 cells (Leeb-Lundberg et al., 1985). Purified aiB-AR from DDTi MF- 
2 cells has been shown to be phosphorylated by PKC and this phosphorylation 
was increased by agonist (Bouvier et al., 1987). This phenomenon has been 
further explored, and investigators have observed the ability of phorbol esters to 
induce the phosphorylation of this adrenoceptor subtype using transfected rat- 1  
fibroblasts (Lattion et al., 1994; Diviani et al., 1997; Vâzquez-Prado et al., 1997). 
Also the sites of phosphorylation involved are contained within the carboxyl- 
terminal (Lattion et al., 1994), and have since been identified as Ser^ '^* and Ser'^ ^^  
(Diviani et al., 1997). Data also suggests the existence of another, uncharacterised 
site of action of PKC out with the carboxyl domain (Diviani et al., 1997). Recent 
studies by Garcia-Sâinz et al. (1999a) show that the human aib-AR expressed in 
mouse fibroblasts is also phosphorylated in response to activation of PKC by 
phorbol esters. Such phosphorylation is associated with blockade of aib-AR- 
mediated increases in cytosolic Ca"^ "^  and phosphoinositide hydrolysis in whole
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cells; phosphorylation is also associated with inhibition of adrenergic-stimulated 
[^^S]GTPyS binding in membranes, which suggests receptor-G protein uncoupling 
(Garcia-Sainz et al., 1999a). The actions of phorbol esters were blocked by PKC 
inhibitors and by overnight treatment with phorbol esters that lead to PKC down- 
regulation (Garcia-Sainz et al., 1999a). Yang et al. (1999) have studied the human 
aib-ARs expressed in rat-1 fibroblasts and observed that treatment for 24 hours 
with phorbol esters did not change receptor density or cause functional 
desensitisation. The action of phorbol esters on aib-ARs seems to involve several 
processes. It has been observed that the blockade of the receptor function is very 
rapid, which is consistent with receptor phosphorylation and uncoupling from G 
proteins. Such uncoupling has been detected as a loss in the ability of GTP and 
hydrolysis-resistant analogues to modulate agonist-binding affinity, i.e., 
conversion of the receptors to the low affinity state (Jagadeesh and deth, 1988; 
Beeler and Cooper, 1993) and also as a decreased aie-AR agonist-mediated 
[35s]GTPyS binding (Garcia-Sainz et al., 1999a; Alcântara-Hemândez et al., 2000; 
Vâzquez-Prado et al., 2000).
When transfected into rat-1 fibroblasts, the ai-AR subtypes are differentially 
regulated by activation of PKC (Vâzquez-Prado et al., 1996). Activation of PKC 
with phorbol esters blocked the actions on aib and aid-ARs whereas those 
mediated through the aia-ARs were not altered (Vâzquez-Prado et al., 1996). 
Activation of PKC not only induces the blockade/desensitisation of ai-ARs, but 
also alters the subcellular distribution of these receptors in some cells (Lynch et 
al., 1985; Cowlen and Toews, 1988; Jagadeesh and Deth, 1988; Beeler and 
Cooper, 1995; Fonseca et al., 1995). Fonseca et al. (1995) showed that PMA 
induces aib-AR internalisation to endosomes when stably transfected in HEK 293
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cells. This effect is also induced by agonists and blocked by the PKC inhibitor, 
staurosporine, suggesting a physiological role of PKC in agonist-induced receptor 
internalisation (Fonseca et al., 1995). The lysosomotropic agent, chloroquine, 
which inhibits receptor recycling (Mellman et al., 1986) has been shown to have a 
similar action as PMA (Covera and Garcia-Sainz, 1984) on the inhibition of « ib- 
AR action in hepatocytes, and the involvement of PKC seems likely (Garcia-Sainz 
et al., 1998a).
Heterologous ait-AR phosphorylation
Receptors coupled to Gq increase PIP2 hydrolysis, generating DAG and IP3 . Such 
DAG can activate PKC and putatively induce aib-AR phosphorylation and 
desensitisation. Vazquez-Prado et al. (1997) have shown that activation of 
endothelin E T a receptors endogenously expressed in rat- 1  fibroblasts stably 
expressing transfected aib-ARs induced a marked and rapid phosphorylation and 
desensitisation of these receptors (Vâzquez-Prado et al., 1997). Such effects were 
only partially blocked in the presence of either an inhibitor of protein kinases or 
protein tyrosine kinase, yet completely abolished in the presence of both 
(Vâzquez-Prado et al., 1997). Analysis of the residues involved in the 
phosphorylation events revealed phospho-serine and phospho-threonine, but no 
phospho-tyrosine (Vâzquez-Prado et al., 1997). Intracellular Ca' '^^seems to play a 
small role in the aib-AR phosphorylation induced by endothelin (Garcia-Sâinz et 
al., 1999b) and is insensitive to the phosphatdylinositol-3-kinase (PI3-K) 
inhibitor; wortmannin (Vâzquez-Prado et al., 1997). Collectively, these data 
suggest an indirect phosphorylation event that does not involve PKC.
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In addition to endothelin, it has been observed that bradykinin can also induce 
aib-AR phosphorylation (Leeb-Lundberg et al., 1987; Medina et al., 1998). The 
receptor phosphorylation induced by bradykinin in rat- 1  fibroblasts stably 
expressing aib-ARs was of small magnitude as compared to that induced by 
endothelin and no evidence of desensitisation was observed in whole cells 
(Medina et al., 1998).
Receptors for lysophosphatidic acid are expressed endogenously in rat-1 
fibroblasts. Fibroblasts stably expressing the aib-AR undergo a rapid, intense and 
sustained aib-AR phosphorylation as a result of activation of LPA receptors 
(Casas-Gonzalez et al., 2000). The effect of LPA on aib-AR was blocked by pre­
treatment with pertussis toxin (Casas-Gonzalez et al., 2000), the protein kinase 
inhibitor; staurosporine, wortmannin, but not blocked by the tyrosine kinase 
inhibitor; genistein. Collectively these data suggest that LPA mediates its actions 
on the aib-AR via G, and subsequent phosphorylation is mediated by PKC 
through activation by PI3-kinase (Casas-Gonzalez et al., 2000). Functional 
consequences of LPA treatment of rat-1 fibroblasts stably expressing aib-ARs 
suggest that such phosphorylation events are associated with receptor-G protein 
uncoupling (Casas-Gonzalez et al., 2000).
The effect of EGF on the phosphorylation of the aib-AR has also been studied 
recently by del Carmen Medina et al. (2000). Similar observations were made to 
those found with LPA, indicating a similar sequence of events leading to the 
growth factor-induced functional uncoupling of the aib-AR (del Carmen Medina 
et al., 2 0 0 0 ).
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Phosphorylation of and ajd-ARs
Much information is known about the phosphorylation/desensitisation of the aib- 
AR, but only recently has any work been done on the aia and a^-ARs (Vazquez- 
Prado et al., 2000; Garcia-Sâinz et al., 2001). Garcia-Sâinz et al. (2001) have 
shown that rat aid-ARs, stably expressed in rat-1 fibroblasts, are phosphorylated 
in the basal state and that such phosphorylation is increased in response to NA and 
PMA. In addition, they have shown that there is cross-talk with other receptors 
endogenously expressed in rat- 1  fibroblasts, i.e., activation of the receptors for 
endothelin, bradykinin and LPA induces a^-A R posphorylation (Garcia-Sâinz et 
al., 2001). NA and PMA mediated phosphorylation of aia-AR stably expressed in 
rat-1 fibroblasts but was much less than that observed for the aib-AR (Vazquez-
Prado et al., 2000). Limited effects of phorbol esters were also noted in relation to 
functional response on the aia-AR subtype (Vazquez-Prado et al., 2000). The role
of these phosphorylations in a physiological context is as yet unknown.
Role of protein phosphatases
The phosphorylation state of a receptor results from the balance between the 
activities of the protein kinases and protein phosphatases that act on it. However, 
little is know about the role(s) of protein phosphatases in receptor phosphorylation 
and function. It has been suggested that endocytosis via clathrin-coated vesicles is 
crucial for resensitisation of some GPCRs (Zhang et al., 1997). Receptors proceed 
from these vesicles to endosomes where they are de-phosphorylated and 
resensitised by a mechanism that is proposed to involve a conformational change 
in the receptor brought about by acidification of the endosomal compartment
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(Zhang et al., 1997). In this regard. Pitcher et al. (1995) have shown previously 
that a latent oligomeric form of phosphatase 2A actively de-phosphorylates the P2 - 
AR in vitro and Shih et al. (1999) have reported that phosphatase 2A and 2B are 
associated with P2-ARS. It has also been observed that okadaic acid, an inhibitor 
of phosphatases, induces both augmentation and inhibition of P2 -AR-mediated 
stimulation of cAMP accumulation (Clark et al., 1993). Inhibition of the ser/thr 
phosphatase, calcineurin, enhances desensitisation and phosphorylation of 
adipocyte Pi-AR (Bahouth et al., 1996).
In the case of ai-ARs, Alcântara-Hemândez et al. (2000) have reported that a 
complex interplay seems to exist between PKC and phosphatases to modulate aib- 
AR phosphorylation and function. Their studies with phosphatase inhibitors 
suggest that phosphatases-1, 2A and 2B could be involved in modulating receptor 
phosphorylation in vitro. Their data also suggest that inhibition of phosphatases 
increases the phosphorylation state of aib-ARs, and that this effect seems to 
involve PKC. In spite of inducing an intense receptor phosphorylation however, 
okadaic acid alters aib-AR actions to a much lesser extent than the direct 
activation of PKC by PMA (Alcântara-Hemândez et al., 2000).
Subcellular distribution and phosphorylation
It is tempting to speculate that the susceptibility to phosphorylation may play a 
role in determining the subcellular distribution of ai-ARs under basal, agonist- 
stimulated and cross-talk-regulated conditions. This subject is addressed in detail 
later.
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Signal Transduction
It has been known for some time that ai-ARs are coupled to phosphoinositide 
turnover/calcium signalling (Fain and Garcia-Sainz, 1980). However, it soon 
became clear that this signalling pathway did not completely explain all (Xi-AR 
actions (Morgan et al., 1984; Garcia-Sâinz et al., 1985) and that activation of oci- 
ARs stimulates multiple pathways (Morgan et al., 1984; Garcfa-Sâinz et al., 
1985b; Cotecchia et al., 1990; Ferez et al., 1993). Such multiple signalling seems 
to involve different G proteins and to depend on the repertoire of signalling 
molecules expressed by particular cell types (Perez et al., 1993).
Relative coupling efficiencies
The three cloned cci-AR subtypes have been found to have different coupling 
efficiencies to PLC through the Gq/n family to increase intracellular calcium, 
suggesting variations in intrinsic activities among receptor subtypes (Vazquez- 
Prado et al., 1996; Theroux et al., 1996; Chen et al., 1999; Ruan et al., 1998). In 
general, it has been observed that the ctia-AR subtype is more effective that the 
aib-AR subtype, and that the aw-AR is usually the least effective of the three 
(Vazquez-Prado et al., 1996; Theroux et al., 1996; Chen et al., 1999; Ruan et al., 
1998).
Schwinn et al. (1991) first reported that the aia-AR was more efficient than the 
ttib-AR in activating IP3 formation. Perez et al. (1993) studied the coupling of 
expressed aib-AR and (Xw-ARs to different signalling pathways in different cell 
lines. Their studies showed that both subtypes coupled to PIP2 hydrolysis through
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a PTX-insensitive G protein, although the coupling efficiencies of the two 
subtypes were not directly compared.
A systematic comparison of recombinant human «i-ARs expressed at similar 
densities in human embryonic kidney 293 cells found that agonist-occupied oti- 
AR subtypes showed substantial differences in their ability to increase both IP3 
accumulation and intracellular Ca"^ "^  (aia>otib>otid; Theroux et al., 1996). Similar 
results were obtained in human SKNMC neuroepithelioma cells, where different 
maximal responses were obtained following activation of each subtype, both for 
IP3 formation («iaXXib^cxid) and Ca^^ release (aiA>0CiB>ctiD). Taguchi et al. 
(1998) also compared the coupling of tti-AR subtypes to these responses, and 
examined activation of PKC in rat-1 fibroblasts. A similar order of coupling 
efficiency was observed for the three subtypes for IP3 formation (aia^aib>otid) 
and Ca"^ "^  (otia>cXib>aid) responses, although the receptors were expressed at 
higher and variable densities.
G protein coupling
oci-ARs belong to the family of Gq/n-coupled GPCRs, which initiate signals by 
activating PLC-dependent hydrolysis of PIP2 . This enzyme generates the second 
messengers IP3 , which releases Ca"^ "^  from intracellular stores, and DAG, which 
synergises with Ca"^ "^  to activate PKC (Minneman, 1988a; Hieble et al., 1995). The 
Gq/11 family of G proteins contains four a  subunits, oCq and an  which are co­
expressed in most cells, and a ^  and aie which show much more restricted 
distribution. Coupling of individual ai-AR subtypes to different a  subunits of the 
Gq/] 1 family has been examined by transient over-expression of both receptor and
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G protein a  subunits in monkey kidney COS-7 cells. These studies showed that all 
three «i-AR subtypes could couple to PLC through Oq and an , only a ^  and a%b 
subtypes coupled to au , and only a%b coupled to ai6 (Wu et al., 1992). Coupling 
of all three ai-AR subtypes to both Gq and Gn has been supported by studies 
from Wise et al. (1995). These investigators showed that agonist treatment of rat-1 
fribroblasts expressing a^ , a%b or aw-ARs accelerated degradation of both aq and 
an . These studies suggest that individual receptors can activate multiple G protein 
a  subunits, but also support some specificity in G protein activation. Studies 
utilising cells that normally express three of the four Gq/n a  subunits compared to 
cells with each of the three a  subunits knocked out have shown that when one of 
the family members is removed, the remaining members can fully compensate for 
its absence (Xu et al., 1998). More recent studies have suggested that signalling 
specificity may be conferred by interaction with RGS (Regulators of G Protein 
Signalling) proteins (Xu et al., 1999a). The domains of the aib-AR involved in 
coupling to Gq/n-mediated PLC activation were first studied by Cotecchia et al. 
(1990). Using chimeric aib/Pz-AR constructs, these investigators demonstrated the 
critical importance of the third cytoplasmic loop in coupling to IP3 formation, and 
the relative unimportance of the C-terminal tail. This is similar to results with 
many other GPCRs, and is supported by studies showing that over-expression of 
the third cytoplasmic loop of the aib-AR inhibits coupling of this receptor, but not 
other receptors, to IP3 formation (Luttrell et al., 1993). Recombinant aib-ARs 
have also been reported to couple to other G proteins, particularly Gao (Blitzer et 
al., 1993) and Gas (Horie et al., 1995) following over-expression, although the 
functional relevance of this coupling is not yet clear. Studies with specific G
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protein antibodies have supported the hypothesis that native « ib (but not ttiA or 
aio) ARs can also couple to Goq in rat aortic smooth muscle (Gurdal et al., 1997), 
suggesting a functional role for this coupling.
A high-molecular-weight class of G proteins, named Gh, has been described (Das 
et al., 1993; Nakaoka et al., 1994; Baek et al., 1993). These proteins seem to be 
multifunctional with both transglutaminase activity and signalling activities 
(Nakaoka et al., 1994). There is evidence that such proteins may mediate cti-AR 
activation of PLC (Das et al., 1993; Nakaoka et al., 1994; Baek et al., 1993). It has 
been reported that activation of Gh occurs only by transfected aib and «id 
subtypes, and not (Xia (Chen et al., 1996), and is independent of its 
transglutaminase activity. However, the role of Gh in cellular responses to 
catecholamines is still obscure. Studies involving Gh/Tissue Transglutaminase II 
knockout mice indicate both that Gh is functionally coupled to tti-ARs, and that 
other GTP-binding transglutaminases are unable to substitute for Gh in ai-AR- 
mediated signalling (Nanda et al., 2001). Surprisingly, since aiB-ARs have been 
reported to play a significant role in maintaining normal vascular tone, and hence 
in blood pressure homeostasis (Cavalli et al., 1997), it seems odd that there is a 
lack of change in either blood pressure or parameters of left ventricular function in 
Gh knockout mice. This would suggest either that Gh in the vasculature contributes 
minimally to aiB-AR-mediated vasoconstrictor responses, or that in the absence 
of Gh, vascular tone can be maintained by compensatory signalling pathways 
(Nanda et al., 2001). Interestingly, cardiac-specific over-expression of Gh results 
in mild hypertrophy and ventricular fibrosis, as well as impaired cardiac function 
(Small et al., 1999), a phenotype that is consistent with that obtained by over-
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expression of either the wild-type «ib-AR (Akhter et al., 1997) or a constitutively 
active otib-AR mutant (Milano et al., 1994b).
Coupling to other second messenger systems
A variety of other signalling pathways have also been shown to be activated by 
ai-ARs (Minneman, 1988). These include cAMP accumulation, Ca^  ^ influx, 
arachidonic acid release, phospholipase D activation and mitogenic responses:
cAMP accumulation There is clear evidence that cAMP accumulates in response 
to oci-AR activation (Morgan et al., 1984; Cotecchia et al., 1990; Perez et al., 
1993; Nomura et al 1993; Chen et al., 1999) and that this cAMP accumulation 
induces phosphorylation of the cAMP response element and activates 
transcription (Lin et al., 1998). «i-AR-mediated cAMP accumulation results from 
direct receptor activation of Gs and possibly via indirect pathways secondary to 
phosphoinositide turnover (Horie et al., 1995).
C à^ influx The mechanisms by which Ca^ "^  influx is increased following oci-AR 
activation are not always completely clear. As with most Gq/n linked receptors, 
activation of ai-ARs often activated a considerable Ca'^ '^  influx which is not 
voltage-gated and not blocked by dihydropyridine Ca^^ blockers (Minneman, 
1988). In rat portal vein myocytes, for example, (%i-ARs cause Ca"^^-activated 
Ca"^ "^  influx that replenishes intracellular Ca'^ '^  stores through a mechanism 
involving a n  (Macrez-Leprêtre et al., 1997). Similarly, activation of ai-ARs in
rat aorta also activates considerable Ca"^ "^  entry subsequent to the initial increase in 
intracellular Ca"^ "^  (Noguera et al., 1997). However, ai-AR activation also 
increases dihydropyridine-sensitive Ca^  ^ influx (presumably through voltage-
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gated channels) in some tissues but not others. Zhang et al. (1998) showed that 
activation of oci-ARs potentiated L-type Ca'*’'^  currents in rat ventricular myocytes 
in a PKC dependent manner, suggesting that such effects may be secondary to 
increases in intracellular Ca^ "^  and activation of PKC. However, ai-ARs may also 
couple directly to activation of Ca^^ channels in some cells. In rat medullary 
thyroid carcinoma 6-23 cells, activation of aib-like ARs increased 
dihydropyridine-sensitive Ca^  ^ influx in a manner independent of release of 
intracellular Ca"^ "^ , activation of PLC and/or activation of PKC (Esbenshade et al., 
1994). Since this increase in intracellular Ca"^ "^  was blocked by removal of 
extracellular Ca"^ "^ , and occurred even in the presence of thapsigargin, it suggested 
that there might be a direct coupling between these receptors and voltage- 
dependent Ca^  ^influx.
Arachidonic Acid Other signalling pathways have also been shown to be 
activated by cci-ARs. Burch et al. (1986) showed that stimulation of oci-ARs in a 
rat thyroid cell line increased release of arachidonic acid (AA), which in turn 
mediated a NA-stimulated cell replication. Other studies have shown that 
stimulation of tti-ARs can cause A A release in many cells (Kanterman et al., 
1990; Blue et al., 1994), either through activation of PLA% (Kanterman et al., 
1990; Nishio et al., 1996; Xing and Insel, 1996) or phospholipase D (Ruan et al., 
1998). Some evidence suggests that such increases in A A release require 
extracellular Ca"^ "^  but are independent of increases in intracellular Ca"^ "^  
(Kanterman et al., 1990), suggesting a role for PLAi. Studies in rabbit aortic 
smooth muscle cells support the involvement of a pertussis toxin sensitive G 
protein (Nishio et al., 1996), while other studies provide evidence for the 
involvement of PKC or MAPK pathways. Perez et al, (1993) directly compared
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activation of AA release by aib and aid-ARs after over-expression in two 
different cell lines. Their studies found that both subtypes can cause this response 
in both cell lines, but by different mechanisms. In COS-7 cells, AA release was 
mediated through PLA2  activation, involved a PTX-sensitive G protein, and 
required Ca"^ "^  influx through dihydropyridine-sensitive channels. In CHO cells, 
however, slightly different mechanisms were observed. Even though CHO cells 
lack voltage-sensitive Ca"^  ^channels, both subtypes were still able to activate AA 
release. Therefore a%b- and aid-AR subtypes can couple to PLA2  activation via a 
PTX-sensitive pathway in CHO cells, and a single ai-AR subtype can activate 
AA release through different mechanisms in different cells.
More recent studies have shown that AA release occurs downstream of MAPK 
pathways. In Madin-Darby canine kidney cells, immunoprécipitation studies 
combined with specific inhibitors showed that an 85-kD cytosolic PLA2 was 
activated by ai-AR stimulation. PD 98059, a specific inhibitor of MAPK 
pathways, which also inhibited AD-promoted AA release, blocked this activation. 
Down-regulation or inhibition of PKC also blocked MAPK activation and AA 
release. Therefore, ai-ARs appear to regulate AA release through phosphorylation 
dependent activation of PLA2 by MAPK, subsequent to activation of PKC in these 
cells (Xing and Insel, 1996). Whether this represents a general mechanism for ai- 
AR activation of PLA2 it is not yet known.
PLD activation Activation of phospholipase D (PLD) also appears to be involved 
in the action of a%-ARs (Ruan et al., 1998; Balboa and Insel, 1998; Llahi et al., 
1992). Such activation seems to be induced by increases in calcium or PKC 
activation. Most evidence suggests that it is the increase in cytosolic Ca^ "^  rather
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than in PKC that mediates PLD activation, through, so far, poorly defined 
mechanisms (Balboa et al., 1998; Llahi et al., 1992). Interestingly, activation of 
PKA due to cAMP accumulation may modulate PLD and AA release (Ruan et al., 
1998). Balboa and Insel. (1998) studied activation of PLD stimulated by AD in 
Madin-Darby canine kidney cells. They found that although AD stimulated PKCcc 
and PKCe, this was not associated with activation of PLD. Furthermore, blocking 
PLC activation with neomycin did not significantly decrease AD-stimulated PLD 
activity. Chelation of extracellular Ca"^ "^  markedly inhibited PLD activation, 
suggesting a role for Ca"^ "^  in PLD activation by a%-ARs. Ruan et al. (1998) 
studied ai-AR-mediated stimulation of arachidonic acid release by activation of 
PLD in rat-1 fibroblasts. After over-expression, aia-ARs increased AA release, 
cAMP levels, and PLD activity. The increase in AA release was attenuated by 
inhibition of PLD, and by increases in cAMP caused by forskolin or addition of a 
non-hydrolyzable analogue of cAMP. They also showed that all three subtypes of 
ARs were able to activate PLD in these cells, although to different extents 
(aia>ocib>ocid). Therefore, all three ai-AR subtypes appear to be able to activate 
PLD, although the mechanisms may differ in different cell types.
Mitogenic responses Signalling to the nucleus has become a major area of 
research in recent years. It is clear that tti-AR activation may result in mitogenesis 
and that, as previously mentioned, constitutively active mutants are tumorigenic 
(Allen et al., 1991), that is, ai-AR genes could be considered as protooncogenes. 
An initial action, in response to agents that induce cell growth and proliferation, is 
the expression of early genes such as c-fos and c-jun expression. It has been 
shown that «i-AR activation induces c-fos and c-jun expression in a large variety
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of cells including cardiac myocytes (Iwaki et al., 1990), rat aorta, cultured 
vascular smooth muscle cells (Okazaki et al., 1994), hépatocytes (Gonzâlez- 
Espinosa and Garcia-Sâinz, 1996), and cells transfected with different receptor 
subtypes (Theroux et al., 1996; Garcia-Sâinz et al., 1998b; Hu et al., 1996). Ail 
three subtypes seem to be able to induce c-fos and c-jun expression (Chen et al., 
1999; Garcia-Sâinz et al., 1998; Hu et al., 1996). Signalling via increased 
intracellular calcium concentration and activation of PKC seems to participate, but 
important differences have been observed (Chen et al., 1999; Iwaki et al., 1990; 
Okazaki et al., 1994; Gonzâlez-Espinosa and Garcia-Sâinz, 1996; Garcia-Sâinz et 
al., 1998; Hu et al., 1996).
(Xi-AR stimulated DNA synthesis and activation of MAPK involved activation of 
PI3-K via a PTX-sensitive G protein (Hu et al., 1996). Tyrosine phosphorylation 
of multiple cellular proteins has been observed (Xin et al., 1997), It is interesting 
that differences in the signalling pathways of aia-AR and aib-ARs have been 
observed involving PI3-K, p2P^ ® and MAPK (Hu et al., 1999a). Neither calcium 
nor PKC seems to mediate aia-AR activation of MAPK in transfected PC 12 cells 
(Berts et al., 1999).
Myocytes ai-AR agonists stimulate hypertrophy in cultured neonatal rat 
ventricular myocytes (LaMorte et al., 1994), and over-expression of a 
constitutively active mutant of the aiB-AR in cardiac myocytes induces 
myocardial hypertrophy in transgenic animals (Milano et al., 1994b). Other 
studies have shown that ai-ARs can activate various MAPK pathways in many 
cells and tissues, and may play an important role in regulating cell growth 
(Ramirez et al., 1997; Spector et al., 1997; Alexandrov et al., 1998; Lazou et al..
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1998). Zechner et al. (1997) studied the role of cci-AR stimulated MAPK in 
myocardial cell hypertrophy. Treatment of myocardial cells with the oci-AR 
agonist phenylephrine induced the hallmark features of cardiac cell hypertrophy: 
increases in cell size, sarcomeric organization, and induction of certain cardiac- 
specific genes. Phenylephrine, in the presence of propranolol to block P-ARs, also 
stimulated the dual-phosphorylation of p38 MAPK, extracellular signal regulated 
protein kinase, and to a lesser extent, c-Jun-NH2 terminal kinase. They further 
showed that a specific p38 inhibitor was able to block all the hypertrophic 
responses stimulated by phenylephrine, suggesting that ai-ARs can affect cardiac 
cell hypertrophy by activation of p38 MAPKinases.
Ramirez et al. (1997) also studied the effect of oti-AR activation on cardiac cell 
hypertrophy, specifically transcriptional activation of atrial natriuretic factor gene 
expression by tti-AR stimulation and over-expression of Ras. Treatment with 
phenylephrine activated extracellular signal regulated kinases and c-Jun-NH2 
terminal kinase. However overexpression of Ras activated only c-Jun-NH2 
terminal kinase and caused little increase in extracellular signal regulated kinase 
activity. This study suggests that a pathway involving Ras and c-Jun-NH2 terminal 
kinase is involved in oti-AR regulated atrial natriuretic factor gene expression.
Hepatocyes Spector et al. (1997) studied the role of tti- and P2 -AR stimulated 
MAPK in quiescent and regenerating rat hepatocytes. ai-ARs activated all three 
arms of MAPK pathway in quiescent cells. However, p38 MAPK played a more 
important role than extracellular signal regulated kinases, since a specific p38 
inhibitor effectively inhibited cell proliferation.
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Smooth muscle cells Different subtypes of ai-ARs may play different roles in 
controlling growth, differentiation, and cell fates through selective activation of 
one or more MAPK pathways. Chen et al. (1995) studied the regulation of 
vascular smooth muscle growth by AR subtypes. Although all three subtypes of 
ARs are expressed in these cells, only the aie-AR subtype appeared to be 
involved in smooth muscle cell growth. Blocking the other subtypes actually 
potentiated the response. These authors proposed that prolonged stimulation of 
«IB-ARs induces hypertrophy of arterial smooth muscle cells, and other ARs 
attenuate this response. Studies by Xin et al. (1997) showed that NA caused rapid 
and transient activation of extracellular signal regulated protein kinases and 
increased protein synthesis and cell size. These responses were inhibited by the 
selective protein kinase inhibitor, PD 98059. These data combined with 
pharmacological analysis suggest that smooth muscle cell growth induced by NA 
may be mediated by am-ARs that couple to activation of extracellular signal 
regulated kinase cascades (Xin et al., 1997).
PC12 cells Minneman et al. (2000) stably transfected PC12 with ai-ARs to 
define pathways linking these receptors to mitogenic responses. Nerve growth 
factor (NGF) acts through tyrosine kinase receptors in these cells to activate 
MAPK pathways and cause the cells to differentiate into a neuronal phenotype. 
The mechanisms involved include receptor autophosphorylation, binding of She 
and Grb2, and activation of Sos, Ras, and Raf (Davis, 1993). Stimulation of aia- 
ARs in PCI2 cells also activate MAPK pathways and causes differentiation 
(Williams et al., 1998). This response involves the tyrosine kinase C (Berts et al.,
1999). Also, different ai-AR subtypes activate different mitogenic responses
40
(Zhong and Minneman, 1999). This group directly compared the coupling of ai- 
AR subtypes to mitogenic responses in PC 12 cells. They expressed each subtype 
under control of an inducible promoter, and compared their coupling to common 
second messenger responses as well as their ability to activate various MAPK 
pathways. At similar receptor densities, coupling to IP3 and intracellular Ca"^ "^  was 
similar to that observed in other cell lines (aia>aib>aid). For mitogenic responses, 
the aia-AR subtype was able to strongly activate all three arms of the pathway 
(extracellular signal regulated kinase, c-jun-NH^-terminal activated kinases, and 
p38 MAPK), the aib-AR was weaker in stimulating these responses, and the aid- 
AR only weakly activated extracellular signal regulated kinases.
Subsequent experiments using reporter constructs (API, SRE, CRE, NFkB, and 
NEAT) to examine transcriptional responses, have revealed a pattern of coupling 
efficiencies similar to that observed previously with second messenger and 
MAPK responses (aia>aib>otid). Comparison of the three human subtypes 
showed that the aia-AR activated all five reporters, the aib-AR showed smaller 
effects, and the aid-AR was ineffective. aia-AR activation caused a much wider 
array of transcriptional responses than growth factor receptor activation. The 
transcriptional respones to aia-AR activation were not linearly related to second 
messenger generation, and could not be predicted from the known G protein 
coupling specificity of the receptors. As inhibitors of a variety of second 
messenger, MAPK, and tyrosine kinase pathways, all block differentiation in 
response to NE, but not NGF, it appears that ttia-AR-induced differentiation 
requires a complex interplay of signals. This supports the hypothesis that GPCR 
signalling pathways are not linear cascades resulting in second messenger
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formation and activation of specific targets, but must involve networks of 
interacting signals.
Alexandrov et al. (1998) showed that activation of p38 MAPK by ai-ARs in rat-1 
cells had a negative effect on activation of extracellular signal regulated kinases. 
However, the significance of this regulation and its consequences are not known. 
Other studies have compared the efficiencies of the three ai-AR subtypes in 
activating mitogenic responses. Siwik and Brown (1996) studied the regulation of 
protein synthesis by ai-AR subtypes in cultured rabbit aortic vascular smooth 
cells. Competition binding studies with subtype selective antagonists showed that 
these cells express mainly aie-ARs (75%) relative to Œia-ARs (25%). These 
subtypes increased protein synthesis in proportion to their relative abundance. 
Therefore, aiB-ARs predominated in coupling to metabolic responses, in contrast 
to reports that contractile reponses in the same tissue are preferentially mediated 
by otiA-ARs. Wenham et al. (1997) studied the coupling of three ai-AR subtypes 
in cultured neonatal rat cardiac myocytes. Although mRNA transcripts for all 
subtypes were detected, binding sites for only the ociA- and otiB-ARs were 
detected. This study showed that phenylephrine-induced activation of MAPK 
cascades appeared to be mediated by a subtype resembling most closely the 
pharmacological profile of the aiB-AR. These studies support the idea that 
mitogenic responses may be caused by multiple oci-ARs.
Therefore, clear differences exist among the three ai-AR subtypes in their ability 
to activate various mitogenic responses, although the functional significance is not 
yet known.
Keffel et al. (2000) have recently investigated the differential coupling of the 
human oti-AR subtypes to growth promotion and inhibition in CHO cells.
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Maximum elevation of intracellular calcium by the three subtypes occurred with 
the rank order of (Xia>GCid>otib- In contrast, activation of the ERK, JNK and p38 
forms of MAPK occurred with the rank order aid>aia>otib- ocia-AR stimulation 
inhibited basal and growth factor stimulated [^H]-thymidine incorporation by 
74%, and this was extenuated by p38 inhibition. In contrast, aid-AR stimulation 
enhanced cellular growth by 136%, and this was blocked by two distinct inhibitors 
of ERK activation. Previous work in rat-1 fibroblasts (Ruan et al., 1998; Schwinn 
et al., 1995; Taguchi et al., 1998) or CHO cells (Horie et al., 1995), has 
demonstrated that the three subtypes of «i-ARs, activate the same signalling 
pathways, but are capable of doing so with different efficiencies. Keffel et al. 
(2000), have shown that, in terms of cell growth, when expressed in CHO cells, 
each subtype is capable of exerting quantitatively similar, yet opposite effects. 
otid-AR and aia-AR can cause stimulation and inhibition of growth, respectively. 
Their data has also demonstrated that a given receptor subtype, e.g., human aia- 
AR can cause stimulation and inhibition of ERK forms of MAPK in CHO cells 
and rat- 1  fibroblasts, respectively, despite similar expression levels.
It is clear that ai-ARs can activate a variety of MAPK pathways to regulate 
various cellular functions. The mechanisms involved in this regulation are likely 
to depend on the particular cellular environment and phenotype. The multiple 
pathways may also interact with each other in unexpected ways.
Hu et al. (1999b) have characterised phosphorylation of tyrosine proteins as an 
early event in the ai-AR-induced protein kinase signalling cascade, which may be 
responsible for regulation of catecholamine stimulation of mitogenic effects in 
human vascular smooth muscle cells. Activation of tyrosine phosphorylation by 
ai-ARs was independent of the activation of PKC but dependent on intracellular
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in these cells, suggesting that the intracellular Ca"^ "^  plays a critical role in «i- 
AR signaling pathways not only for smooth muscle contraction but also for cell 
growth.
G protein independent pathways
In recent years, several reports have appeared in the literature describing various 
physiological consequences of receptor stimulation that do not seem to be 
mediated by G protein activation (reviewed in Hall et al., 1999). Novel techniques 
have revealed associations of such receptors with a variety of intracellular partners 
other than G proteins. In some cases, these partners are known receptor- 
interacting proteins, such as arrestins and GRKs, which were thought previously 
to be involved only in receptor desensitisation. In other cases, they are novel 
partners that were not known previously to interact with hepatahelical receptors. 
No such interactions have yet been reported for ai-AR subtypes. However, it has 
been reported that the consensus motif for the binding of the immediate-early 
gene Homer to metabotrophic glutamate receptors is found in the C-terminal tail 
of the aid-AR, but not the aia-AR or aib-AR (Tu et al., 1998). If such interactions 
occur in the ai-AR family, it might provide additional understanding of the 
biological importance of the C-terminal splice variants which have been reported 
(Hirisawa et al., 1995; Chang et al., 1998).
Transcriptional regulation o/ttiB/b-ARs
In order to understand the molecular mechanisms involved in the regulation of a%- 
AR subtype expression, several groups have focused on control at a 
transcriptional level, in particular the aib-AR. Of interest is the regulation of this
44
subtype under a variety of physiological and pathological conditions. Therefore, 
the rat aib-AR gene has been cloned, and its regulatory elements identified (Gao 
et al., 1993, 1994). To determine potential transcriptional control elements, 
extensive analyses have been carried out on the untranslated region of the rat 
(Deng et al., 1994b; Kanasaki et al., 1994; Gao et al., 1993, 1994 and 1995) and 
human (Ramarao et al., 1992) aib-AR gene. The human and rat aib-AR genes 
share certain features in their upstream and downstream regulatory regions. The 
first 500bps upstream from the translation start site are 87% homologous 
(Kanasaki et al., 1994). Both species contain a cAMP response element (Ramarao 
et al., 1992; Kanasaki et al., 1994; Gao et al., 1993) and a common transcriptional 
start site that is thought to encode the 2.7 kb aie-AR sequence found in most 
tissues and in other species (Gao et al., 1995). They also share a homologous 
polyadenylation site (Graham et al., 1996).
However, both species also contain some notable differences and unique features. 
The human otib-AR gene does not contain TATA or CAAT boxes, but does 
contain a second putative polyadenylation site (Ramarao et al., 1992). The human 
ccib-AR gene also possesses consensus Spl binding sites consistent with 
promoters of other housekeeping genes (Ramarao et al., 1992). In contrast, the rat 
ctib-AR gene contains a transcriptional promoter site with putative TATA and 
CAAT box (Gao et al., 1995) and recognition sites for liver-specific 
transcriptional factors. The rat otib-AR gene also contains AP I and AP-2 binding 
sites (Gao et al., 1993), as well as thyroid and glucocorticoid response elements 
(Gao et al., 1993).
Gao et al. have reported the most striking difference between rat and the human 
otib-AR. The aib-AR gene found in rat liver contains three different transcriptional
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promoters, a feature not found in the human aib-AR gene (Gao et ah, 1995). Gao 
et al. (1994) believe that the three promoters (termed PI, P2 and P3) account for 
the presence of three different mRNA transcripts (2.3, 2.7 and 3.3kb) found in 
different tissues. The 3.3-kb transcript was detected only in the liver and brain 
(Gao et al., 1994; McGehee et al., 1990, 1991). The 2.3-kb transcript was found in 
DDTi MF-2 hamster smooth muscle cells (Hu et al., 1993b) and in extremely low 
levels in the liver (Gao et al., 1993). The 2.7-kb species has been detected in 
various amounts in a number of rat tissues (Lomasney et al., 1991; McGhee et al., 
1990, 1991), and is believed to be the most prevalent ttib-AR species (McGhee et 
al., 1991). Gao et al. (1995) have expanded their aib-AR transcriptional 
characterisation with a DNase I footprint analysis of the middle transcriptional 
promoter (P2, which leads to the 2.7-kb message), using rat liver extracts. Three 
protected areas were found and termed footprints I, II and III. Two distinct DNA- 
binding proteins were found in the area defined by footprint I: aCP-1 trancription 
factor and a unique protein that Gao and colleagues labelled as an a-adrenergic 
receptor transcription factor (a-ARTF).
The a-ARTF was present in the brain, liver, spleen, kidney and lung, with notable 
absence in the heart. Expression of a pCAT reporter construct containing sections 
of the P2 promoter in DDTi MF-2 cells demonstrated that the deletion of areas 
containing each of the three defined footprints inhibited P2 promoter activity (Gao 
et al., 1994, 1995). Because the 2.7-kb transcript is found in the heart, Gao et al. 
postulate that its transcription may be mediated by heart-specific transcription 
factors, and tissue-specific differences in transcriptional regulation could account 
for the ability of hyperthyroidism to produce up-regulation of the a^-A R  in the
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heart and lung, with simultaneous downregulation of the aiB-AR in the liver 
(Lazar-Wesley et al., 1991).
Subsequent experiments have identified the sequence specific factors that interact 
with the dominant P2 promoter, including NFl, CPI, AP2, and CREB (Gao et al., 
1995, 1997; Chen et al., 1997). Further data have shown that NFl and Spl are the 
major transcription factors involved in controlling the P2 promoter in liver and in 
DDTI MF-2 smooth muscle cells, respectively (Chen et al., 1997). NFl has been 
reported to act as a transcriptional silencer, e.g., gene for collagen (Rossi et al., 
1988) and activator e.g., p53 gene (Furlong et al., 1996). This, however, is the 
first report for NFl acting either as a positive or as a negative regulator for the 
same gene in a cell-specific manner. Further studies in rat liver have shown that a 
non-DNA binding protein interacts with NFl and suggests that its activity may be 
modulated by cell-specific cofactors (Gao et al., 1998). Identification of these 
cofactors should provide researchers with the key to understanding the underlying 
mechanisms involved in the transcriptional activity of the otiB-AR gene. Dao et al. 
(1998) have since further characterised the PI promoter and identified its three 
sequence-specific binding sites. One of these has been identified as an SV40 core 
enhancer-like sequence element, which plays a positive regulatory role in PI 
promoter activity. The protein binding to this core sequence is cell-type specific, 
which may explain the tissue-restricted expression of 2.3kb « ib-AR mRNA (Dao 
et al., 1998).
Zuscik et al. (1999), have since cloned, sequenced and analysed a 3.4kb mouse 
aiB-AR promoter fragment. Sequence analysis and comparison with known rat 
and human aiB-AR promoter sequences has led these authors to hypothesise that, 
whereas there is substantial similarity between the three, sufficient divergence has
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occurred that shows some level of species specificity. This group have also 
confirmed that this mouse promoter fragment is able to regulate reporter gene 
expression in response to the competency of a given cell to express ttiB-ARs. 
Regulation of promoter function has also been observed by cAMP and hypoxia 
(Zuscik et al., 1999).
The transcriptional elements for the Œia-AR and am-AR have not been so 
extensively characterised as those for the (XiB-AR subtype. Promoter region 
analysis by Faure et al. (1994b) revealed three different aiA-AR transcripts (5.0, 
3.9 and 3.0-kb) and two am-AR transcripts (3.0 and 1.7-kb) in the human 
prostate. There is evidence that the human ociA-AR is alternatively spliced, with 
the detection of three transcripts that differ only in their C-terminal tail (Hirasawa 
et al., 1995). In contrast, Laz et al. (1994) detected only a 4.0-kb in the heart and 
kidney. A single 3.0-kb fragment for the cciA-AR has been detected in various 
tissues studied, with the exception of the prostate (Lomasney et al., 1991).
Hamster DDTi MF-2, rat and rabbit smooth muscle cells have also been 
extensively used to study the transcriptional regulation of the oti-ARs. Treatment 
of these smooth muscle cell lines with various hormones has been shown to 
upregulate the levels of the « ib-AR and (Xm-AR. In DDTi MF-2 hamster vas 
deferens smooth muscle cells, glucocorticoids increase the levels of the ttiB-AR 
with no change in mRNA stability (Sakaue et al., 1991). Other hormones that 
increase aiB-AR mRNA in DDTi MF-2 cells are testosterone and aldosterone, but 
not P-estradiol or progesterone (Sakaue et al., 1991). Hu et al. (1993) found that 
4h treatment with the protein synthesis inhibitor cyclohexamide could induce up- 
regulation of (XiB-AR mRNA in DDTi MF-2 cells. Up-regulation occurred even
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with the addition of puromycin, another inhibitor of protein synthesis. This 
provided evidence that cyclohexamide exerts its actions by binding directly to 
transcriptional elements rather than by an indirect mechanism involving protein 
synthesis (Hu et al., 1993a). In contrast. Bouvier et al. (1987) and Cowlen et al. 
(1987, 1988) have reported that short-term treatment (minutes) of DDTi MF-2 
cells with cyclohexamide causes down-regulation of the aiB-AR. Increasing 
cAMP levels with forskolin or the cAMP analogue CPT cAMP has been shown to 
increase the abundance of ttiB-AR and mRNA (Morris et al., 1991). Also, these 
treatments did not change the stability of the mRNA for aiB-AR indicating an 
effect on gene expression (Morris et al., 1991). Interestingly, the same study 
showed that the activation of p2 -AR also caused up-regulation of the a^-A R  by a 
cAMP-dependent mechanism. Schachter and Wolfe (1995) have since reported 
similar findings. More recent work by Gao et al. (1997) indicates that both the 
CRE and the AP2 element in the P2 promoter contribute to basal as well as 
cAMP-induced transcription of the aiB-AR in this cell type. These findings 
subsequently initiated investigation of aiB-AR mRNA regulation in rat pineal 
gland, as mammalian pineal function is regulated by NE acting through aiB-AR 
and pi-ARs. In this study, Coon et al. (1997) observed an increase in Œib-AR 
mRNA that was due to the activation of p-ARs. Second messenger analysis 
indicated that «ib-AR mRNA is increased by agents that increase cAMP, 
including dibutyrl cAMP, cholera toxin, forskolin, or vasoactive intestinal peptide 
(Coon et al., 1997). These authors concluded that ociB-AR mRNA can be 
physiologically regulated by a p-AR-dependent enhancement of cAMP. They also 
observed that in vivo and in vitro changes in aiB-AR mRNA were not
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accompanied by similar changes in (XiB-AR binding, indicating that turnover of 
(XiB-AR protein is significantly slower than that of Œib-AR mRNA and that post- 
transcriptional mechanisms must play an important role in regulating aiB-AR 
binding (Coon et ah, 1997).
Hypoxia-sensitive regions of the aiB-AR gene have also been identified that may 
confer the differential hypoxic increase in aiB-AR gene transcription in aorta, but 
not in vena cava smooth muscle cells (Eckhart et al., 1997).
Several other reports exist in the literature showing changes in Œib-AR expression 
due to conditions that are associated with hepatocyte de-differentiation 
(Bevilacqua et al, 1991; Kost et al., 1992; Kunos et al., 1987, 1995; Rossby et al., 
1991). This will be discussed in more detail in chapter 2.
The role of PKC in regulating ais-AR transcription
Conflicting information about the role of PKC activity on gene transcription has 
recently been found in different animal species. Using the PKC inhibitors H7 and 
saurosporine, Hu and colleagues (1993) showed that DDTi MF-2 cells utilise 
PKC to up-regulate the « ib -A R . This upregulation was not dependent on 
activation of calcium channels. Hu et al. (1993b) also noted that PMA induced up- 
regulation of ociB-AR mRNA transcription but did not alter mRNA stability, ruling 
out post-transcriptional regulatory mechanisms in the expression of the ttiB-AR. 
In contrast to these data, Izzo et al, (1994) have shown that activation of PKC with 
NA in cultured rabbit aortic smooth muscle cells decreased aiB-AR mRNA and 
(XiB-AR receptor levels. The Œib-AR transcription rate increased slightly, but this 
was outweighed by the increased degradation of the aiB-AR mRNA (Izzo et al.,
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1994). One explanation for the opposite effects found in the hamster and rabbit 
may be the expression of two isoforms of PKC or the expression of different 
PKC-dependent proteins (Izzo et al., 1994).
Yang et al. (1998b) have demonstrated that MDCK cell ais-ARs can be down- 
regulated by phenylephrine and is accompanied by activation of PKC. However, 
PKC activation does not appear to mediate this agonist-induced down-regulation.
Zhu et al. (1996) reported that exposure of a particular clone of CHO cells stably 
expressing the hamster aib-AR, to adrenaline for 24 hours led to an up-regulation 
of aib-ARs rather than an expected down-regulation. In further studies, the same 
group have found that this up-regulation was an atypical response to agonist 
treatment (Bird et al., 1997). The possibility that PKC activation might be 
involved was investigated. The PKC inhibitor staurosporine indicated that PKC 
was not involved, yet surprisingly, this compound induced up-regulation of the 
aib-AR. This up-regulation did not involve PKC and could be blocked by the 
tyrosine kinase inhibitor, genistein. In the other clones tested, agonist and 
staurosporine induced down-regulation of the aib-AR. These results suggest that 
perhaps a novel mechanism can be activated by AD and staurosporine involving 
tyrosine kinases in this cell type.
Vasoactive receptors appear to be able to modulate each other's expression. 
Treatment of rat aortic smooth muscle cells with angiotensin II has been shown to 
increase expression of ai-ARs with a concomitant increase in both aio-AR and 
aiB-AR mRNA (Hu et al., 1995). This process depended on the presence of PKC 
but not calcium.
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TSH was shown to increase expression of the (Xig-AR in two rat thyroid cell lines 
(Kanasaki et al., 1994; Meucci et al., 1994). These effects are apparently cAMP- 
dependent because deletion of a cAMP response element caused the loss of cAMP 
sensitivity. Increased aiB-AR mRNA transcription was also noted following 
treatment with dibutyryl cAMP or theophylline, the increased transcription of aiB- 
AR mRNA was not accompanied by changes in aiB-AR mRNA degradation 
(Deng et al., 1994a).
AgCy development and changes in the aj-AR subtypes
Many studies have demonstrated that the number and abundance of different ai- 
AR subtypes change with age. This is exemplified in the rat liver. Studies 
beginning in the early 80's were the first to report such ontogenic modulation of 
cti-ARs (McMillian et al., 1983). The aiB-AR is found in low levels in 
hepatocytes isolated from foetal liver and in increasing amounts in early 
adulthood (Rossby et al., 1991). Van Ermen and Fraeyman, (1992) have also 
shown using -prazosin binding to plasma membranes from livers of 2-4 day, 
2-3 month and 24-26 month rats, that an increase in a^-A R  receptor density 
occurs upon maturation and thereafter a post-maturational decline. Previous 
studies by Borst and Scarpace, (1990) are in agreement with such work who 
reported a decrease of 39% in ai-AR density in 25 month old female rats as 
compared to those at 5 months. Controversy does exist however in recent work by 
Shen et al. (2000), using subtype selective antibodies to each of the three tti-AR 
subtypes. They reported that the abundance of ttiB-AR immunoreactive protein 
was at least twofold higher in the neonatal (1 week old) than in the adult (2-3 
month old) liver. In addition, they have reported that receptor protein for all three
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subtypes does exist at both ages, with a slight, but not significantly different 
increase in Œia-AR immunoreactivity in the adult liver.
Most distribution studies to date have detected only aie-AR mRNA in the rat 
liver, with no detection of 0 Cia-AR mRNA (Lomasney et al., 1991; Price et al., 
1994a; Rokosh et al., 1994). However, Scotfield et al. (1995), using RT-PCR, 
detected a minor component of the ociA-AR in the liver.
Rudner et al. (1999) have shown that human vascular ai-AR subtype distribution 
is modulated with age (Rudner et al., 1999). Their results reveal age-related 
increases in mammary artery oti-AR density (but not saphenous vein) and a switch 
from aiA-AR predominance in younger adults to 0CiB>0tiA in older patients. In the 
rat heart, the content of « ib-AR has been shown to decrease with age (Kimball et 
al., 1991). Aging affects the influence of calcium channel-blockade on potassium- 
induced contraction of the aorta, with old aortas (>19 months) being more 
sensitive than younger (2 months) vessels (Wanstall et al., 1989)
Previous studies by Gurdal et al. have demonstrated that oti-AR function differs 
with age (Gurdal et al., 1995a, b). The same group used a combination of 
radioligand binding. Northern and Western blot analysis to show that the 
distribution of ai-AR subtypes changes with age in rat aorta (Gurdal et al., 1995a, 
b). They demonstrated that young aorta (1 month) contains more mRNA for the 
aiB-AR and more receptor, with a decrease in aiB-AR with age (24 months) and 
no change in aio-AR mRNA or receptor. They also provided evidence that the 
abundance and functional contribution of the 0 Cia-AR may increase with age.
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Other studies suggest age decreases all ai-ARs (Xu et a l, 1997). Age-related 
changes seem to be vessel specific, with rat renal ais-AR mRNA declining 
without change in mesenteric/pulmonary oci-ARs (Xu et al., 1997). Similarly, age 
does not uniformly affect the expression of the three (Xi-AR subtypes in different 
tissues (Shen et al., 2000). Studies by this group have shown that Qib-AR proteins 
were less abundant in the heart and the brain of neonatal rat than of the adult, 
while the reverse was true in the liver. aiA-AR and am-AR did not change 
significantly with age in the heart, liver or kidney but increased in the brain. It 
would thus appear that in some tissues such as the heart, both Qia-AR and aiB-AR 
play an important functional role in the neonatal period while ai-AR agonists 
modify cardiac functions in the adult primarily via ttiB-AR as previously 
suggested (Michel et al., 1994; Deng et al., 1996, 1998). Furthermore, age 
increases functional aio-ARs in resistance vessels compared with otiA-AR 
predominance in young rats (Ibarra et al., 1997). Data from clinical studies have 
demonstrated less blood pressure perturbation in elderly patients with tamsulosin 
(« ia/ocid -selective antagonist) compared with alfuzosin (non-selective) (Buzelin 
et al., 1997), suggesting importance of « ib -A R s  with aging in resistance vessels of 
humans.
Yamaoto et al. (2001) have recently reported differences in the expression of a%- 
ARs in the bladders of neonatal and adult rats. Pre-junctional, « ia - A R s  are 
functionally expressed in the bladder of both neonatal and adult rats, whereas 
post-junctional « ib /d -A R s  are present only in older adult rats (Szell et al., 2000; 
Yamaoto et al., 2001b).
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ai-ARs and vascular smooth muscle
Heterogeneity of vascular ai-ARs was recognised quite early (Flavahan and 
Vanhoutte 1986); however, because of the confusion in identifying 
pharmacologically defined ocm-ARs in native tissues and the lack of a specific 
aiD-AR antagonist until 1995, most studies attempted to define relative roles of 
aiA-AR and ais-ARs in vasoconstrictor responses to «i-AR agonists (Tian et al., 
1990; Piascik et al., 1991; Aboud et al., 1993; Oshita et a l, 1993) although data 
could not be fully explained by this assumption (Oriowo and Ruffolo. 1992).
The challenge of the functional studies has been to isolate the contribution of each 
oti-AR subtype to contraction, because multiple subtypes may co-exist in the same 
blood vessel and be activated by the non-selective ai-AR agonists used in such 
studies. In addition, the literature survey clearly indicates that regional differences 
in the distribution and density of each subtype may vary across vascular beds 
within the same species and across species. Another aspect of characterising 
vascular «i-ARs has been to try to combine conflicting functional, receptor 
subtype binding and molecular data in a constructive manner to develop a 
complete picture of vascular ai-AR pharmacology. Most isolated blood vessel 
studies have employed Schild analysis (Arunlakshana and Schild, 1959) to 
measure the affinity constants (pA2 ) of subtype-selective antagonists for vascular 
ai-ARs and correlate this with values (pKi) obtained from receptor binding 
studies of cloned or native ai-ARs. Another strategy has been to assess the ability 
of CEC to antagonize NE- or phenylephrine-induced contractions to decide 
whether ajA-AR (CEC-insensitive) or aie-AR and am-AR (CEC-sensitive) 
mediate the vascular response (e.g., Ibarra et al., 2000). While thus far, these
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strategies have been successfully used to subclassify vascular «i-AR subtypes, the 
subtypes identified in some blood vessels have to be considered provisional due to 
contradictory reports or incomplete characterisation with a number of subtype 
selective antagonists, i.e. pharmacological classification of receptor subtypes has 
been determined by an investigator's faith in certain compounds.
Because of their importance in controlling peripheral resistance, it is of great 
therapeutic interest to know which subtypes are located in which vascular beds 
and the contribution of each subtype to sympathetically mediated 
vasoconstriction. However, determining their distribution and correlating this with 
a functional response is still problematic.
Recent reports have shown that rat arteries express the three oci-ARs at the mRNA 
level (Piascik et al., 1995). However, binding and functional studies have 
indicated the predominance of one or two of the subtypes, and correlation between 
these different approaches has not been direct. This has greatly complicated the 
precise definition of the roles of each subtype.
Functional studies have shown that aiA-ARs mediate contraction, at least in part, 
in a number of rat isolated blood vessels, including tail, renal, and mesenteric 
arteries (Villalobos-Molina et al., 1996, 1997; Piascik et al., 1997; Ibarra et al.,
1997). These results have been correlated with high amounts of mRNA for aiA- 
ARs in several of these vessels (Piascik et al., 1995), suggesting that this receptor 
is indeed involved in contraction. The role of aie-ARs in the contraction of 
vascular smooth muscle is less clear. aio-ARs are functionally expressed in 
arteries such as aorta, iliac, carotid, mesenteric, femoral, and renal (Piascik et al., 
1995, 1997; Kenny et al., 1995; Testa et al., 1995; Buckner et al., 1996; Deng et 
al., 1996; Saussy et al., 1996; Villalobos-Molina et al., 1996, 1997; Ibarra et al..
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1997; Hrometz et al., 1999). Conflicting reports exist regarding the mouse aorta. 
Using aiB-AR knockout mice, Cavalli et al. (1997) found a reduced respone to 
phenylephrine suggesting a role for the aiB-AR subtype, whereas Daly et al. (in 
press), used the same knockout model, in conjunction with selective antagonists, 
revealing a dominance for the aio-AR subtype. Yamamoto et al. (2001a) have 
since confirmed this observation. Contraction in dog and rabbit aorta is reported to 
be via aiB-AR (Murumatsu et al., 1991; Suzuki et al., 1990).
Thus far, no systematic study of the expression of the (X] -ARs and correlation to 
function has been done. Piascik and co-workers have used a subtype-specific 
antibody to show that the aiB-AR can be detected in a series of peripheral blood 
vessels (Piascik et al., 1997). In spite of this widespread distribution, the receptor 
was not linked to the activation of contraction in a majority of the arteries in 
which it was expressed. This observation has led this group to believe that a 
receptor can be expressed in a blood vessel yet have no role in its contractile 
response.
Work on the localisation of the «z-AR has shown that there is a differential 
cellular localisation of these receptors (von Zastrow et al., 1993). In transfected 
fibroblasts, the cczc-AR was localised to the cell membrane and intracellular 
compartments whereas the (XzA-AR was found exclusively on the cell membrane. 
In COS 7 cells transiently transfected with GFP/ai-AR constructs, the aia-AR 
was localised in a perinuclear fashion whereas the aib-AR was detected 
throughout the entire border of the cell (Hirasawa et al., 1997). Such work led 
Piascik's group to determine the distribution of all «i-AR subtypes in peripheral 
arteries and therafter assess their functional expression (Hrometz et al., 1999).
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Using rat-1-fibroblasts stably transfected with all three ai-ARs and subtype 
selective antibodies, Hrometz et al. (1999) have supported the idea that oci-ARs 
are expressed not only on the cell surface, but also in intracellular compartments. 
They have also examined the distribution of ai-ARs in cells cultured from 
femoral and renal arteries to determine if differences in receptor localisation could 
modulate ai-AR responsiveness in vascular smooth muscle cells. Such work has 
shown that all three subtypes are expressed. However, the abundant expression of 
the ttiB-AR subtype, associated with the plasma membrane, does not correlate 
with the subtype responsible for contraction in these blood vessels. Although 
similarities do exist between recombinant and native systems, there is still no 
explanation for the lack of correlation between subtype distribution and functional 
expression. Thus, this evidence indicates that cellular localisation alone, does not 
modulate contraction, and that perhaps the « ib-AR subtype exists at this location 
for some other purpose. Piascik et al. (1997) have suggested a contractile role for 
aiB-ARs in mesenteric arteries only. The possibility arises that ocm-ARs in 
general may be more functionally relevant in other aspects of vascular function. 
The mechanisms controlling the linkage between receptor expression and the 
regulation of smooth muscle contraction are far from understood. In smooth 
muscle cells different subtypes could be expressed predominantly in intracellular 
compartments and be sequestered from the cell surface. In this fashion a receptor 
could be expressed but not localized to the cell membrane where it can be 
activated by hydrophilic agonists (Hrometz et al., 1999).
In terms of drug action, distribution of ai-AR subtypes has several important 
implications. Pharmacological agents must exert their effects by penetrating the 
cell membrane, either by diffusion or via transmembrane carriers. NE is taken up
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and accumulated by SMCs that express ai-ARs (Avakian and Gillespie, 1968). 
The transporter responsible, the extraneuronal monoamine transporter (EMT), 
formerly known as Uptakez, has been cloned (Grundemann et al., 1998a). A 
similar carrier is responsible for the uptake of catecholamines in the liver 
(Grundemann et al., 1998b). The physiological actions of the majority of released 
neurotransmitters are terminated by their removal from the extracellular space. 
The blockade of these membrane transport proteins, results in attenuation of 
metabolism of ME, indicating this to be their physiological function. The 
functional expression of intracellular ai-ARs opens the possibility that these 
transporters function to deliver catecholamines to intracellular receptors. These 
transporters are regulated by corticosteroids, indicating a possible role in the 
regulation of oci-AR-mediated function. It has been reported that glucocorticoids 
induce expression of aiB-AR (Sakaue and Hoffman, 1991) and |3-AR (Collins et 
al., 1988; Hadcock et al., 1988; Jazayeri et al., 1988) genes in smooth muscle 
cells, emphasising a possible role for these transporter proteins in AR mediated 
function.
Transgenics and murine ai-ARs
Presently, pharmacological analysis of the ai-AR subtypes is limited by the 
relatively poor selectivity of antagonists; none of which could be regarded as 'gold 
standards'. This has led to a lack of consensus on subtyping of ai-ARs in general. 
In vivo studies to assess specificity of the functional responses mediated by 
distinct ai-AR subtypes have been hampered by the fact that the subtype-selective 
drugs are only moderately selective and might interact with both other adrenergic 
and non-adrenergic receptors. Thus, the functional implications of ai-AR
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heterogeneity and their physiological relevance remain largely unknown. 
Recently, targeted gene disruption has been increasingly used to elucidate the in 
vivo functions of receptor subtypes. Thus, to contribute to the understanding of the 
physiological roles of the ai-AR subtypes in vivo Cotecchia and colleagues have 
been using gene targeting to create knockout mice lacking the aie-AR (Cavalli et 
al., 1997). This «ib-AR knockout mouse model provides a useful tool to clarify 
the functional specificity of different ai-AR subtypes. Daly et al. (in press) have 
used this particular knockout mouse model to demonstrate that the aio-AR 
subtype is predominantly responsible for contraction of mouse thoracic aorta and 
carotid artery. Since the aiB-AR was removed from the equation, a 
straightforward comparison was permitted with controls. Minor changes in 
antagonist potency between wildtype and knockout indicate only a small role for 
the aiB-AR in these vessels.
A full understanding of the functional significance of adrenoceptor heterogeneity 
awaits the knockout of all AR subtypes as well as the intercross among different 
knockout models. Studies of these mice have yielded intriguing observations, but 
their interpretations are limited by the scarcity of knowledge regarding the 
physiological characteristics of murine ai-ARs relative to those of other species. 
In the mouse, studies at the mRNA level have been performed by RT-PCR 
(Alonso-Llamazares et al., 1995; Cavalli et al., 1997) and northern analysis 
(Garcia-Sainz et al., 1994). They have detected aiA-AR mRNA in the heart, lung, 
liver, spleen, kidney, aorta, adipose tissues and several brain regions, including 
the cortex and cerebellum. ociB-AR mRNA was detected in all of these tissues, 
although at somewhat lower abundance in the spleen and adipose tissue. aio-AR 
mRNA was detected in all of these tissues, although its presence in liver was seen
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in one (Alonso-Llamazares et al., 1995) but not another (Cavalli et al., 1997) 
study. Radioligand binding studies by Yang et al. (1998a), have detected and 
characterised oci-AR subtypes in a variety of murine tissues. The overall 
pharmacological profile of murine oci-AR subtypes appears to be similar to that in 
other species. However, the quantitative and qualitative ai-AR subtype expression 
in a given tissue appears to differ considerably between species (Yang et al., 
1998a). Several reports in the literature show that expression of ai-ARs in 
humans varies quite considerably from animal models.
Introduction to the thesis
Internalisation of GPCRs after activation by agonists is a well-documented 
phenomenon in recombinant cell lines, although equivalent understanding in 
native cells is lacking.
Several techniques have been developed over the years to try to map the location 
of GPCRs within cells. The introduction of foreign epitope tags on to cDNAs 
encoding receptor proteins has become a standard technique to facilitate the study 
of receptor dynamics. The technique of 'epitope tagging', first described by Munro 
and Pelham in 1984, is a recombinant DNA method for making a gene product 
immunoreactive to an already existing antibody. The process typically involves 
inserting a polynucleotide encoding a short continuous epitope onto/into a gene of 
interest and expressing the gene in an appropriate host. Epitope tagging has 
become a standard molecular genetic method for enabling rapid and effective 
characterisation and localisation of the protein products of cloned genes. The 
alternative and more traditional approach; raising antibodies to the encoded 
protein itself, is usually successful, but it is slow, costly and unpredictable. The
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attraction of epitope tagging (typically 6-30 amino acids) is that they do not add 
new biological activity to the protein, and hence retain structure and function of 
the native receptor. However, this is not to say that large additions cannot retain 
normal function, e.g., green fluorescent protein (GFP) (>200 amino acids). More 
recently, GFP has been introduced for use as an autofluorescent epitope tag. By 
virtue of its ability to allow the real time visualisation of protein function in living 
cells, GFP may supplant all previous techniques for studying the cellular 
regulation of proteins. Tagging of GPCRs with the Green Fluorescent Protein has 
enabled the direct visualisation of real-time trafficking of GPCRs in living cells. 
Such analyses have provided crucial insights into the mechanisms involved in 
controlling GPCR function (reviewed by Milligan, 1999; Kallal and Benovic, 
2000). Much effort has gone into developing several GFP variants to try and 
maximise fluorescence intensity when excited at certain wavelengths. In 
particular, Stanley Falkow and colleagues at Stanford University (Cormack et al., 
1996) have developed EGFP vectors that encode the GFPmutl variant, which 
contains the double substitution of Phe^ "^  to Leu and Ser^  ^ to Thr. Based on 
spectral analysis, EGFP fluoresces 35-fold more intensely than does wildtype 
GFP when excited at 488nm (Cormack et al., 1996). This increased sensitivity 
provided by EGFP improves its use as a bioluminescent reporter and, this is what 
has been used for all GFP work within this thesis.
However, much of the evidence for this comes from the use of recombinant cell 
lines. Equivalent experiments with live, native cells have thus far not been 
explored due to technical limitations.
Attempts made to bridge this gap, have seen the arrival of fluorescent ligands, as a 
means of monitoring GPCRs. Previous work by Prof. McGrath's group has
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demonstrated the fluorescent ligand binding properties of the high affinity ligand, 
QAPB (BODIPY-FL prazosin), for oti-ARs (McGrath et al, 1996; Daly et al.,
1998). This work has established the technique of fluorescent ligand binding (at 
nanomolar concentrations) and its application for the study of receptors in both 
recombinant and native, single, living cells (Daly et a l, 1998; McGrath et al, 
1999; Mackenzie et al., 2000). The lipophilic nature of this compound allows it to 
bind to receptive sites irrespective of cellular location, whether associated with the 
plasma membrane or intracellular locations (Daly et a l, 1998; McGrath et al., 
1999; Mackenzie et al., 2000). Thus a major gain from the use of this fluorescent 
ligand is competitive ligand binding at the single cell level, revealing 
pharmacological data. A further advantage of the use of QAPB is its low level of 
fluorescence in the unbound state, thus allowing accurate measuments to be made 
under equilibrium conditions (Daly et a l, 1998). Although QAPB is non- 
selective, the use of selective competitive ligands enables precise identification of 
the subtype in question (Mackenzie et al, 2000).
The first assessment of a%-AR subcellular distribution was by Fonseca et al. 
(1995) who examined the subcellular dynamics of the aib-AR expressed in HEK 
293 cells and the importance of PKC-dependent phosphorylation in the process of 
desensitisation and internalisation of this receptor. Using antibodies specific for 
the aib-AR, they were able to show that the presence of NA caused a 
redistribution of the aib-AR on the plasma membrane from a diffuse, uniform 
pattern to a globular, non-uniform pattern. This group interpreted this change as 
the visualisation of ajb-AR internalisation. The phenomenon was reversed when 
NA was removed, and was blocked in the presence of prazosin. Using endosomal- 
specific antibodies, this group also demonstrated that aib-ARs were internalised
63
into endosomes. Stimulation of PKC and PMA mimicked the agonist-induced 
changes in receptor distribution, while the inhibition of PKC by staurosporine 
blocked agonist-induced receptor internalisation. Fonseca et al. (1995) concluded 
that stimulation of the aib-AR causes the activation of PKC-dependent 
phosphorylation, which mobilises cellular processes such as receptor mediated 
endocytosis and recycling of the aib-AR.
Recent evidence has indicated that oci-ARs are not exclusively localised at the cell 
membrane. Using GFP-tagged «i-ARs, Hirasawa et al. (1997) showed that the 
ttib-AR was expressed on the cell surface whereas the otia-AR was expressed in 
intracellular compartments. Although a significant amount of aib-AR is located at 
the plasma membrane, there is a distinct fraction located intracellularly (Awaji et 
al., 1998; Tsujimoto et al., 1998; Stevens et al., 2000). This however, is 
substantially more pronounced for the aia-AR (Awaji et al., 1998; Tsujimoto et 
al., 1998). Interestingly, intracellular aia-ARs in LLCPK cells have been shown to 
be rapidly recruited to the cell surface by treatment with either a high 
concentration of the ai-AR selective agonist, phenylephrine, or combinations of 
subthreshold levels of both phenylephrine and neuropeptide Y (Holtback et al.,
1999).
Significant levels of intracellular aid-ARs have also been recorded by monitoring 
their binding by QAPB (Daly et al., 1998).
Piascik and co-workers, using subtype selective antibodies, have also confirmed 
that the ocib-AR is predominantly located at the cell surface, and aia-AR and aid- 
ARs are located in a perinuclear orientation (Hrometz et al., 1999; McCune et al.,
2000). Recent data suggests that a similar distribution pattern of tti-ARs is found 
in native systems (Mackenzie et al., 2000; Hrometz et al., 1999; McCune et al.,
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2000). Mackenzie et al. (2000) have reported remarkable similarities between the 
intracellular distribution of «la/A-AR binding sites in recombinant and native 
systems. They found that in prostatic smooth muscle cells, 40% of the Œia-AR 
population was intracellular, particularly around the nucleus, which could 
represent binding in the Golgi and may include both newly synthesised and 
recycling stores of receptors. Similarly, in vascular smooth muscle cells, aiA-AR 
and ttiD-ARs are localised in a perinuclear fashion similar to that observed in tti- 
AR transfected fibroblasts (Hrometz et al., 1999; McCune et al., 2000). This 
group also reported the ajB-AR to be associated with the cellular periphery in 
vascular smooth muscle cells, consistent with studies in recombinant cells 
(Hrometz et al., 1999; McCune et al., 2000). These data argue that the cellular 
localisation of cti-ARs is not an epiphenomenon of experiments in recombinant 
cell lines, but rather is characteristic of cells natively expressing these receptor 
subtypes.
An increasingly active area of interest, with regard to the localisation of ai-ARs in 
native systems, is the apparent lack of correlation between the subcellular 
distribution of ai-AR subtypes and their role in contraction of blood vessels. 
GPCRs are thought of, traditionally, to mediate their effects whilst located at the 
plasma membrane, thus allowing exposure to the extracellular environment.
The use of pharmacological approaches and antisense oligonucleotide technology 
has provided evidence to suggest that the activation of smooth muscle contraction 
is caused by a single receptor in any given artery and that the ai-AR subtype 
responsible varies throughout the vasculature (Piascik et al., 1995, 1997; Hrometz 
et al., 1999). Regarding the expression of the ais-AR subtype in particular, some 
studies have approached this question by quantifying mRNA levels in several
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different rat blood vessels. However, such work has shown no significant 
difference in Qib-AR mRNA content between various vessels (Guarino et al., 
1996). Experiments using antibodies raised against the a^-A R  (Fonseca et al.,
1995) and antisense technology have complemented the earlier mRNA studies 
(Piascik et al., 1997; Hrometz et al., 1999). However, from a functional 
perspective, only the mesenteric resistance artery exhibits an antisense-evoked 
reduction in contractile responses to agonist (Piascik et al., 1997; Hrometz et al.,
1999). These findings have led this group to explore possible mechanisms to 
account for the observation that expression in blood vessels is not sufficient to 
link an ai-AR to contraction. They have focused on subcellular localisation of oti- 
AR subtypes as a factor that modifies the ability of these receptors to regulate 
cellular function. Examination of the cellular localisation and signalling properties 
of the ttib-AR and a^-ARs expressed in rat-1 fibroblasts has been informative. 
Data show that the aib-AR exhibits expected GPCR activity regarding cellular 
localisation, agonist-mediated internalisation, and coupling to second messengers 
(McCune et al., 2000). In their native environment, ociB-ARs are situated at the 
cellular periphery in smooth muscle cells derived from renal and femoral arteries. 
However, inhibition of the expression of only one, the Œia-AR in renal and the 
« 1D-AR in femoral arteries, reduced the contractile response to agonist (Hrometz 
et al., 1999). This evidence indicates that cellular localisation alone is not a 
control point in modulating contraction, and the possibility arises that (X ib-A Rs in 
general may be more functionally relevant in other aspects of vascular function 
The subcellular distribution of ocw-ARs is not consistent with the traditional 
model. In unstimulated fibroblasts, the aid-AR was detected in a perinuclear 
orientation and co-localised with arrestin 2  in a compartment containing the
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transferrin receptor, an endosomal marker. This, combined with intracellular 
signalling data have provided strong evidence that the aid-AR is constitutively 
active and, as a result, is localised to intracellular compartments involved in 
receptor recycling (McCune et al., 2000). The cellular localisation of a 
constitutively active mutant (A293K, Kjelsberg et al., 1992) of the «ib-AR 
transiently expressed in COS 1 cells, showed a significant degree of aib-AR 
internalisation and suggested that perhaps receptor internalisation in the absence 
of agonist is a property common to constitutively active (Xi-ARs. Association of 
constitutively active aib-AR mutants with arrestin 2 has also been demonstrated 
(Mhaouty-Kodja et al., 1999). In contrast, Stevens et al. (2000) have recently 
reported that stable expression of constitutively active mutants (CAMs) of the aib- 
AR in HEK293 cells, with mutations D142A or A293G, are heavily concentrated 
at the plasma membrane, with little evidence of an intracellular loci (Stevens et 
al., 2000). Another constitutively active mutant of the aib-AR, that has had a 
small segment of the distal region of the third intracellular loop replaced with the 
equivalent segment of the Pi-AR, stably expressed in HEK293 cells, shows a 
substantially greater fraction of sites located intracellularly compared with that 
seen in the wild-type receptor. In addition, the pattern of distribution, rather than 
being perinuclear, was present in small punctate vesicles distributed throughout 
much of the cytoplasm (Stevens et al., 2000). However, considerably lower levels 
of expression than the other constructs, can possibly explain this observation, and 
suggests that perhaps only a fraction of the receptors in clones with high 
expression levels become relocated to the plasma membrane, leaving the 'excess' 
at their site of synthesis in the Golgi apparatus.
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The aid-AR is somewhat of a mystery, and has not been studied to the same 
extent as the other two subtypes in molecular terms, although its functional role in 
large blood vessels is well documented (Kenny et al., 1995; Martinez et al., 1999). 
Theroux et al. (1996) showed that this receptor was weakly coupled to second 
messenger pathways. Yang et al. (1997) were unable to detect a significant degree 
of expression of the aio-AR in a variety of rat tissues. These findings are 
consistent with the observations made by McCune et al. (2000), that the receptor 
is predominantly expressed in intracellular compartments due to constitutive 
activity. As a result, the ccid-AR is not as responsive to agonist activation as the 
other subtypes of the oti-AR. Studies with either transfected HEK 293 or SK-N- 
MC cells failed to demonstrate any constitutive function of the aid-AR (Theroux 
et al., 1996), yet expressed at similar receptor densities to the fibroblasts. 
However, previous studies also using stably transfected ocid-AR fibroblasts 
showed constitutive activation of the calcium response (Garcia-Sainz and Torres- 
Padilla, 1999c). The am-AR also binds most agonists but not antagonists with 
higher affinity than the other two ai-AR subtypes. This phenotype is a hallmark 
of constitutive activity (Samama et al., 1993). Constitutive activity is also 
associated with constitutive phosphorylation and, therefore, densensitization. The 
traditional model of GPCR signalling indicates that the receptor is de- 
phosphorylated and recycled back to the cell surface. Garcia-Sainz et al. (2001) 
have shown that the a^-AR is phosphorylated in the basal state, and this increases 
in response to agonist and PMA. The internalised pool of aid-ARs may represent 
the equilibrium component in the recycling process due to its constitutive nature. 
The possibility that the ocio-AR is constitutively active in cells where it is 
endogenously expressed would be very interesting. However, data obtained in a
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stably transfected cell line may not accurately represent the localisation and 
signalling characteristics of the native ai-ARs expressed in vascular smooth 
muscle cells. The ocm-AR is localised in a perinuclear orientation in vascular 
smooth muscle cells similar to that observed in fibroblasts, suggesting constitutive 
activity in cells that endogenously express this (Xi-AR subtype (McCune et al., 
2000).
The mechanisms controlling the linkage between receptor expression and the 
regulation of smooth muscle contraction are far from understood. In smooth 
muscle cells different subtypes could be expressed predominantly in intracellular 
compartments and be sequestered from the cell surface.
Recent technical advances are creating new ways to analyse expression of tti-AR 
subtypes in native systems. As mentioned previously, Zuscik et al. (1999), have 
recently cloned, sequenced and analysed a 3.4kb mouse am-AR promoter 
fragment. This promoter is capable of activating transcription of reporter gene 
expression in response to the competency of a given cell to express aie-ARs. 
Given the lack of highly selective ligands for this ai-AR subtype, similar 
promoter-reporter constructs could be valuable tools when screening numerous 
cells/tissues for ai-AR competency. Therefore, using GFP as a valuable reporter 
tool, a construct designed to drive the cell/tissue-specific expression of the ttiB- 
AR gene could prove invaluable in the screening of native cell lines for a^-A R 
expression. This, combined with pharmacological and functional data available, 
should hopefully ease this currently elusive situation. If the subtype location is 
common in various tissues/cells, it could indicate a possible cell-specific
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functional location of the ais-AR, although, as is evident, contraction may not be 
the main functional role of this subtype.
The ultimate objective of the project was to study two related fundamental aspects 
of receptor biology in which recent advances using recombinant cell lines have 
not yet been translated into an equivalent understanding in tissues, i.e., receptor 
subcellular distribution and internalisation.
I was given the task of designing a molecular strategy to analyse the subcellular 
distribution of ai-ARs in recombinant and native systems, in an attempt to 
uncover the similarities and differences between the two. It was also anticipated 
that I would further this and demonstrate receptor distribution within the walls of 
resistance arteries.
The aib-AR was chosen as a starting point for two reasons: firstly, it is under 
continuous study at a molecular and cellular level; secondly. Prof. McGrath's 
group have validated their techniques on the recombinant receptors (McGrath et 
al., 1996) and several groups have identified tissues whose pharmacology 
suggests the presence of « ib-ARs, although their functional role is less well 
defined. Most importantly an « ib-AR knockout mouse has been successfully 
generated, displaying a diminished pressor response to oci-AR agonists (Cavalli et 
al., 1997) suggesting an important role of the aiB-AR subtype in cardiovascular 
functions.
Fortunately, at the start of the project, a colony of aiB-AR knockout mice 
(Cotecchia et al., 1997) was established in our laboratory, which was invaluable to 
me in my attempts to uncover the pharmacological nature of this «i-AR subtype. 
Also, a recently developed technique enabling the analysis of «i-AR subcellular 
distribution within live cells (McGrath et al., 1996) allowed me further scope.
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Chapter 1.
The development of recombinant aib~adrenoceptor cell lines.
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Chapter 1 
Introduction
The general aim of this project was to develop a molecular method in order to 
localise, identify and quantify ai-AR subtypes within heterogeneous tissues, where 
ligand binding is inappropriate. The two species of interest were human (to relate to 
clinical issues) and mouse (to enable the use of genetic manipulation). Despite 
obvious differences, many basic aspects of development, physiology, and GPCR 
function are well conserved between mice and humans and, in many instances, the 
development of mouse models to aid in the study of human disorders shows promise 
and may serve as a convenient experimental platform.
Traditional Pharmacological methods rely on the use of available drugs to identify 
populations and subtypes of receptor, hence every subtype having an anatomical 
location and a putative selective ligand. Molecular biology has allowed the isolation 
and cloning of genes for receptor subtypes for which there are no defined subtype- 
selective ligands or native tissue. Therefore, it is necessary to combine multiple 
technologies in an attempt to understand structure, function, location and regulation 
of individual receptor subtypes at both a subcellular and tissue level.
One of the fundamental issues facing pharmacologists is the ability to dissect out the 
mechanistic and functional differences between ai-AR subtypes. The ability to do so 
is critical, for in many cases the need to discriminate between related subtypes is of 
therapeutic significance.
Studies of ai-AR subtypes in tissues where they are endogenously expressed are 
frequently complicated by the presence of many different cell types and coexisting 
receptor subtypes. The analysis of individual subtypes in this situation is also
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frustrated by the lack of reliable subtype-selective agents. This is best illustrated by 
the lack of antagonists that have a high affinity for the aie-AR subtype and can 
distinguish it from both aiA- and aio-ARs. So, from a therapeutic perspective, the 
ultimate goal is to develop highly selective agents for each oci-AR subtype.
The use of cell lines that endogenously express known complements of tti-AR 
subtypes, or are stably transfected with receptor cDNAs, provides valuable tools for 
studying the pharmacological properties and functional characteristics of individual 
receptor subtypes. Cell lines expressing a single AR subtype can be identified and 
used to study their signalling properties in the absence of other subtypes. Different 
receptor subtypes can be expressed in the same cell line, allowing direct comparison 
of their pharmacology and signalling properties in the same cellular phenotype.
Using established cell lines expressing cDNAs makes it possible to obtain high levels 
of receptor expression thereby permitting more detailed pharmacological analysis, as 
well as second messenger generation. In most cases, heterologous expression is 
carried out in cell types that are null for ai-ARs to allow the analysis of single cci-AR 
subtypes in a defined system, and in addition can provide easy access to human 
receptors outside their native tissues. Unfortunately, ligand binding and intracellular 
signalling mechanisms are affected by cell type, receptor density and the presence 
and relative amounts of particular signalling elements in the chosen host cell line. 
Therefore, caution must be taken when interpreting results from such heterologous 
expression systems (Perez et al., 1993; Zhu et al., 1996; Bird et al., 1997). One 
potential way around this is the current development of lines of transgenic knockout 
mice, which are lacking a particular subtype (Smiley, 1998). ocig-AR knockout mice 
are currently being studied in our laboratory.
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Another important consideration is post-translational modifications. For example, 
some receptors require glycosylation events that are crucial for their functional 
expression within the cell. An example of this is vasoactive intestinal peptide 1 
receptor, where glycosylation of two out of four sites is necessary and sufficient to 
ensure correct delivery of the receptor to the plasma membrane when expressed in 
COS 7 cells (Couvineau et al., 1996). Therefore, nothing can be predicted with any 
certainty about the suitability of an expression system for a particular receptor but 
some general guidelines can be drawn from the literature.
The promoter present also influences the choice of expression system, which must be 
active in the cell line to be transfected. Different vectors with different promoters 
may achieve their maximal expression in different cell lines. All expression systems 
used in this chapter harboured the CMV promoter that can achieve high-level 
constitutive expression. The same mammalian cell line was also used throughout. 
Another important factor to be considered in choosing a vector is the selectable 
marker(s) encoded by the vector, which provide antibiotic resistance for obtaining 
stably transfected cells. The mouse aib-AR was subcloned into the vector pRK-5 
(figure 1.3), which lacked an antibiotic resistance marker to allow for expression in 
mammalian cells, therefore, co-transfection with pBabe^ ^®'^ ® (figure 1.3) to allow for 
selection with hygromycin was employed. All other expression vectors used in this 
chapter contained the G418 marker to allow for selection using geneticin (figures 1.6 
and 1.23).
The first step in my project was to obtain the cDNAs for the mouse (Prof. S. 
Cotecchia, Switzerland) and human (Pfizer, U.K.) «ib-ARs. A host cell line to 
express the recombinant receptors was thereafter decided. Several criteria were taken
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into consideration including lack of endogenous oci-ARs, suitable morphology for 
confocal analysis, and autofluorescence levels. Several cell lines were examined and 
mouse neuroblastoma x embryonic hamster brain NCB20 cells were chosen, supplies 
of which were gifts from Prof. Graeme Milligan, University of Glasgow and Merck, 
U.K. This cell line has previously been used to express p-ARs (Milligan et al., 1995), 
and also shown to endogenously express a 2 -ARs (Gleason and Hieble, 1991).
Stable cell lines were generated expressing both species of ociy-AR in the same cell 
type and at similai* receptor densities. A human aib-AR cell line with a receptor 
density double that found in the mouse otib-AR cell line was also generated, as a 
comparison.
The specific objective, initially, was to compare the binding properties of aib-ARs 
from the two species, first by radioligand binding using ^H-prazosin and then by 
fluorescent ligand binding using QAPB (structure, figure 1.4). The functionality of 
the recombinant receptors were assessed by measuring intracellular Ca"^  ^ levels in 
response to agonist stimulation. The details of these studies are contained within this 
chapter.
The next logical step was to validate the binding of QAPB to ai-ARs. QAPB has 
previously been demonstrated as a competitive antagonist (Daly et al., 1998). 
Binding and functional antagonism data show that, despite the modification of the 
molecule to incorporate the fluorescent tag, it retains the properties required of a high 
affinity pharmacological 'antagonist' ligand (Daly et al., 1998). Although the actions 
of this compound are specific to ai-ARs, at nanomolar concentrations, the non­
specific component increases in cells densely populated with ai-ARs introducing 
artefact, and therefore not allowing a true representation of the location of receptive 
sites.
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In order to validate the binding of this fluorescent compound, the rapidly developing 
technique of 'tagging' GPCRs created a couple of potentially useful options to us (see 
general introduction). The idea behind using 'tagged' receptors was that it would 
allow us to visualise the exact location of individual receptors and thereafter validate 
QAPB binding with co-localisation studies. The construction of a FLAG™ Epitope 
(DYKDDDDK) tagged mouse aib-AR is detailed in this chapter. The original 
description of the antibody to this sequence and its use as an epitope tag was in 1988 
(Hopp et al., 1988). The FLAG™ system relies on the fusion of the coding sequence 
of the octapeptide (AspTyrLysAspAspAspAspLys) to the coding sequence of the 
target receptor and expression in a suitable vector. The expressed FLAG fusion 
protein can be detected with anti-FLAG monoclonal antibodies, and the receptor 
visualised using a fluorescent conjugate. The sequencing, expression, 
pharmacological and functional analysis of this construct is also detailed within this 
chapter. Western blot analysis and immunofluorescence studies of the expressed 
receptor protein are also discussed.
Coincidentally, at this time, an EGFP-tagged human aib-AR construct became 
available to us, a gift from Gozoh Tsujimoto, Japan. This provided me with an ideal 
way of locating aib-ARs, in real time, and on intact cells. Problems associated with 
non-specific binding of the fluorescent ligand and antibodies were removed from the 
equation when using GFP as it requires no additional substrates and can therefore be 
monitored non-invasively in living cells. It also gave me further scope with the 
development of a system that would allow analysis of agonist-induced 
internalisation, a reported phenomenon of this subtype of a%-AR (Fonseca et al., 
1995; Hirasawa et al., 1997). The search for the mechanism of internalisation of the
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ttib-AR has occurred at a rapid pace because of the importance of internalisation in 
receptor function and regulation. All the work associated with the expression, 
pharmacological and functional analysis of the GFP-tagged construct expressed in 
NCB20 cells is described in this chapter.
Tagging techniques are known to have an artifactual effect on receptor folding and 
sorting. Hence, all experiments were performed with wildtype receptors in parallel 
whenever possible.
77
Chapter 1
Methods
Manipulation o f DNA
LB (Luria -Bertani) plates and LB broth
LB broth was made using the following ingredients: lOg tryptone (Sigma), 5g yeast 
extract (Sigma) and lOg NaCl were added to ~800mls of deionised water (dHzO)', 
pH was thereafter adjusted to 7.0. Volume was adjusted to 1 Litre, divided between 3 
X 500ml bottles, autoclaved and subsequently stored at 4°C until required. For agar 
plates, LB broth was made as above and bacto-agar added at 15g/L prior to 
autoclaving. LB agar was cooled to ~45°C and either 50pg/ml ampicillin (Sigma) or 
25|ig/ml kanamycin (Sigma) added prior to pouring. LB Agar was then poured into 
100mm plates and allowed to set. Plates were stored, inverted at 4°C until required. 
These plates allow the growth of bacteria harbouring plasmids that carry 
ampicillin/kanamycin resistance genes. Plates were streaked with bacteria using an 
inoculating loop which was sterilised by flaming and cooling.
Protocol to make competent bacteria
E. coli (DH5a™) bacteria were streaked out on a minimal plate (see above for plate 
preparation) and grown overnight at 37°C. 5mls of LB broth was inoculated with a 
single colony from this plate and grown up overnight. This was then added to a 
further lOOmls LB broth and grown until the optical density at 550nm was 0.48. This 
took 1.5-1.75 hours. Cells were then chilled on ice for 5mins followed by 
centrifugation at 2-3k for lOmins at 4°C. Each pellet was gently resuspended in 
20mls of buffer 1 (IM KAc, IM RbCb, IM CaClz, IM MnCl2 and 80% glycerol; 
pH5.8 with acetic acid, filter sterilised and stored at 4®C). Cells were then returned to
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ice for a further 5ruins and spun as before. Each pellet was then gently resuspended 
in 2mls of buffer 2 (lOOmM MOPS; pH6.5, IM CaCh, IM RbCli and 80% glycerol; 
pH6.5 with concentrated HCl, filter sterilised and stored at 4®C), chilled on ice for a 
further 15mins, divided into lOOpl aliquots and stored at -80°C until required. 
Competent HBlOl cells (Promega) were also used for some of the work within the 
thesis. HBlOl has long been a popular strain for propagating plasmids that do not 
allow a-complementation.
INVoF competent cells (supplied with cloning kit, Invitrogen) were used in 
conjunction with pCR®2.I. The genotype of ENVocF offers the following features: 
Blue/white screening of colonies via a-complementation of the N-terminal portion of 
p-galactosidase produced by the vector with the product of the (])80A/acZAM15 gene 
present in the cell line.
Transformations
All transformations involving competent DH5a's™, or competent HBlOl cells 
(Promega) were carried out as follows. An aliquot of competent cells was thawed on 
ice and 50pl per transformation was gently mixed with 1-lOng of plasmid DNA, left 
on ice for 15mins, heat shocked for 90secs at 42°C and returned to ice for a further 
2mins. 1ml of LB broth (pre-heated to 37°C) was added to each reaction tube and left 
for lOmins at 37°C then incubated on a horizontal shaker at 225rpm for a further 
50mins at the same temperature. Bacteria were then spun down briefly, the LB broth 
was removed, and the pellet resuspended in 100til and spread on selective plates. 
These were then incubated overnight as before.
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For transformations using pCR®2.1, LB plates containing 50pg/ml ampicillin were 
spread with 40pl of 40mg/ml X-gal (5-bromo-4-chloro-3-indolyl-p-D-gaIactoside) 
dissolved in dimethylformamide, and allowed to dry. Meanwhile the ligation mixture 
was centrifuged and placed on ice. One vial of INVoF’ competent cells was carefully 
thawed on ice and 2|xl of 0.5M (3-mercaptoethanol (supplied) gently stirred into the 
cells with the pipette tip. 2pl of ligation mix was also stirred into the thawed cells 
and the mixture then incubated for 30mins on ice. Cells were then heat-shocked at 
42°C for 30secs and placed back on ice for a further 2 nuns. 250|xl of SOC media 
(supplied) was added to each vial of cells and placed in a horizontal shaker at 37°C 
for 1 hour at 225rpm. Two LB plates, streaked with X-gal, were used per 
transformation. Each plate was spread with either 50 or 200p,l of the transformation 
mixture. Plates were left at room temperature for ISmins, then inverted and placed in 
an incubator overnight at 37°C. The following morning, plates were removed and 
placed in a cold room (4°C) for several hours, after which, colonies were selected for 
further growth and analysis.
Analysis o f colonies
Competent cells transformed with all vectors excluding pCR®2.1 were selected in a 
similar manner. An aliquot of transformed cells was spread on selective plates 
containing the appropriate antibiotic and incubated overnight at 37°C. Positive 
colonies were selected and grown-up for further analysis.
The pCR®2.1 vector contains the lac promoter and the lacZa cDNA which produces 
P-galactosidase and, in the presence of X-gal, will give blue colonies. If the insert 
has been successfully cloned into the plasmid, this will disrupt the lacZa cDNA and
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the colonies will be white. 15 colonies were selected from each transformation. Each 
colony was innoculated into 5mls of LB containing 50|Lig/ml of ampicillin and grown 
up overnight at 37°C in a horizontal shaker at 225 rpm. Plasmids were then isolated 
and subjected to restriction digestion to screen for the presence of the insert. Glycerol 
stock solutions of the positive colonies were made and stored at -70°C until required.
Plasmid isolation
Plasmids were purified using the Wizard™ Plus SV Minipreps DNA Purification 
System from Promega. A 3ml aliquot of overnight bacterial culture was centrifuged 
at 10,000g for 1 minute to pellet the cells. LB broth supernatant was removed and 
excess media removed from the pellet. Cells were then resuspended in 250|xl of cell 
resuspension solution (50mM Tris-HCl and lOmM EDTA). 250jLil of cell lysis 
solution was then added (0.2M NaOH and 1% SDS) and mixed by inversion. 5 
minutes later, lOpl Alkaline protease solution was added and again mixed by 
inversion. After no longer than 5 mins, 350p,l of neutralisation solution was added 
(4.09M guanidine hydrochloride; 0.759M potassium acetate; 2.12M glacial acetic 
acid: pH 4.2) and again mixed by inversion. The lysate was then centrifuged at 
13,000g for 15mins at room temperature. Clear lysate was then transferred by 
decanting into a spin column and centrifuged at 13,000g for a further 2mins. The 
column was then washed twice with column wash solution (60mM potassium 
acetate, lOmM Tris-HCl, pH 7.5; 60% ethanol) by spinning the wash through the 
column in the centrifuge. DNA was then eluted using 100|li1 of nuclease-free water 
and stored at -20°C until required.
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Primers
The mouse aib-AR primers were a gift from Susanna Cotecchia, Institute of 
Pharmacology, University of Lausanne, Switzerland.
Sense­
s’ CCACTCTAAGAACTTTCATGAGGACACC 3’,
Antisense­
s’ ATGCAGCTGCCACTGTCATCCAGAGAGT 3’.
The FLAG/mouse ajb-AR primers were custom made by Cruachem Ltd. West of 
Scotland Science Park, Glasgow. On arrival, both sets of primers were aliquoted and 
stored at -20°C until required. Frequently, the ends of insert DNA do not contain 
suitable restriction enzyme sites required for subcloning into the multiple cloning site 
(MCS) of an appropriate expression vector. This problem is resolved by using PCR 
to generate a site at the desired location. For this technique, the restriction enzyme 
site is designed into the 5’-end of the PCR primer. Because certain restriction 
enzymes inefficiently cleave recognition sequences located at the end of a DNA 
fragment, additional bases (at least three) were included in front of the enzyme 
recognition sites. An additional sequence, Kozak (Kozak, 1983) was also included to 
increase mRNA efficiency. The coding sequence of the mouse aib-AR was modified 
by PCR amplification using the amino-terminal primer-
5’AAAGCTAGCGCCACCATGGACTACAAGGACGACGATGACAAGAATCC
GGATCTGGACACCGGCC-3’,
an Nhel restriction site and the FLAG epitope tag were introduced. Using the 
COOH-terminal primer-
5’TTTTCTAGAGACCGCGGGCCCTTGAAAATC-3’, 
an Xbal restriction site following the stop codon was introduced.
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Polymerase chain reaction
All reactions were carried out using a Techne “progene” thermal cycler. Reaction 
conditions were slightly different for each set of primers used and have therefore 
been dealt with separately below.
Unless otherwise stated the reaction was carried out in a 50pl volume using the 
following:
FLAG/mouse aih-AR primers
5pi of lOxPCR buffer (Promega), 20pmol of each primer, 1.25pl of dNTP mix 
(lOmM, Promega), 3pi MgCL (25mM, Promega), 5pi of cDNA and O.Spl of Tag 
Polymerase enzyme (5units/pl, Promega). These components were made up to 50pl 
with sterile deionised water. The cycle programme used for FLAG/mouse ttib-AR 
primers was as follows: 94°C for 5 minutes followed by 40 cycles comprising 
dénaturation (94°C for 2 minutes), annealing (65°C for 1 minute) and extension 
(72°C for 2 minutes). This was followed by a further 10 minute extension period at 
72°C.
Mouse (Xi_h-AR primers
This reaction was set up in the same manner. The annealing temperature required 
was slightly lower, at 56°C.
For each primer set used, negative controls were run in parallel. These contained 
identical ingredients except that the cDNA template was replaced with sterile 
deionised water. At the end of each reaction, aliquots were electrophoresed on 1% 
agarose gels as described above, to allow for visualisation of PCR products. In the
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case of the FLAG tagged product, the entire PCR product was run on a gel, the 
amplified band excised, purified from agarose and stored at -20°C until required.
Restriction digests
A variety of restriction digests were carried out throughout this project. Analytical 
and small scale digests were usually carried out in 10-20pl reaction volumes using 
~lpg DNA. All other digests were scaled accordingly and incubated for enzyme- 
specific time periods and temperatures suggested by the manufacturers. Initially, 
when attempting to subclone the FLAG tagged product into pcDNA3.1 (4-), the PCR 
product DNA was extracted from the agarose gel, purified, then subject to restriction 
digestion using restriction enzymes Nhel and Xbal (Boehrinnger Mannheim) in 
conjunction with the appropriate buffer system. The cleavage sites for both of these 
enzymes lie within a few bases of the end of the DNA fragment which can cause 
decreased cleavage efficiency. Therefore the incubation period suggested by the 
manufacturer, was extended accordingly. Such digests were usually carried out in 
~50pl volumes using all the amplified DNA extracted from the gel, enzyme 
quantities etc, were scaled according to the concentration of DNA in each digest.
Alkaline phosphatase treatment
Calf intestinal phosphatase (CIAP) catalyses the hydrolysis of 5’-phosphate groups 
(Sambrook et al., 1989). This enzyme was used to prevent recircularisation and 
religation of the linearised cloning vehicle DNA by removing phosphate groups from 
both 5’termini. Restriction digested vector DNA was mixed with 3|xl of enzyme 
(CIAP lunit/pl, promega), 6p.l of lOx reaction buffer (Promega), made up to 60p,l
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with sterile deionised water and incubated for Ihour at 37°C. DNA was ‘cleaned up’ 
to remove any traces of CIAP.
DNA clean-up system
Wizard™ DNA Clean-Up System (Promega), was used to clean-up DNA from heat- 
stable restriction enzymes and alkaline phosphatase treatment according to the 
manufacturer's instructions.
Agarose gel electrophoresis
Unless otherwise stated, 1% agarose gels were used. In general, the percentage of 
agarose used depended on the molecular weight of the fragments being separated. 
Small fragments (<400bp) requiring a higher percentage gel than larger fragments 
(>3kb). The fragment sizes of interest ranged from ~l-8kb. Agarose was dissolved in 
50xTAE buffer (242g Tris Base, 57.1ml glacial acetic acid, 100ml 0.5M EDTA, pH 
8.0. pH was adjusted to 7.2 after making up to a final volume of 1 litre with distilled 
water). Gels were also run in this buffer at 100 volts. Ethidium bromide (0.5pg/ml) 
was used to stain gels in order to visualise the DNA on a UV transilluminator. 
Markers (0.07-12.2kb) (Boehringer Mannheim) were used at all times and samples 
were loaded with one-tenth volume of lOx loading buffer (0.25% bromophenol blue 
and 40% v/v glycerol in water).
Isolation o f DNA from agarose gels
DNA fragments were excised from agarose gels with a clean, sharp scalpel, 
minimising the removal of any excess agarose. Care was taken to ensure the gel was 
not over exposed to the UV rays. QIAquick Gel Extraction Kit (QIAGEN) was used
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according to the manufacturers instructions. Eluted DNA was aliquoted and stored at 
-20°C until required.
Quantitation of DNA
DNA was diluted in dHzO by a factor of 100, and the optical density measured at 260 
nm. A concentration of 50pg/pl gives a 260nm absorbance of 1. Therefore the 
concentration is 50 x O.D. at 260 nm x dilution factor = |xg/ml. Pure DNA has a 
260:280nm ratio of 1.8 (Sambrook et al., 1989).
Ligations
All ligation reactions, excluding those specific to the TA Cloning® Kit (Invitrogen), 
were set up aiming for a vector:insert ratio of 1:3, unless otherwise stated. The 
following components were made up in a final reaction volume of 20|il with 
autoclaved dH2 0  and incubated for 1 hour at room temperature: 100-200ng 
vector/ligation and the appropriate amount of insert, lunit T4 DNA ligase (Life 
technologies, Inc) and 4pl of 5x Ligase Reaction Buffer (Life technologies, Inc). 
Reactions specific to the TA Cloning® Kit involved the use of fresh PCR product, as 
degradation of the 3' A-overhangs occurs over time. To allow for a recommended 1:1 
ratio to be established, 2p,l of the pCR®2.1 vector and an appropriate volume of 
insert were mixed with 1|li1 of lOx Ligation Buffer, and T4 DNA Ligase (4.0 Weiss 
units) (both supplied). The total reaction volume of lOpl was incubated at 14°C 
overnight.
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Cloning o f DNA fragments
Attempts were made to subclone the amplified FLAG/mouse aib-AR fragment into 
expression vector pcDNA3.1(+) (Invitrogen) using restriction enzymes; Nhel and 
Xbal (Boehringer Mannheim). Due to experimental difficulties, Invitrogen's Original 
TA Cloning® kit, employing the vector pCR®2.1 (fig), was ultimately employed for 
this purpose. The advantages of using this kit include elimination of any enzymatic 
modifications of the PCR product or the need to use primers containing restriction 
enzyme sites. This kit is based on the fact that Taq Polymerase has a nontemplate- 
dependent activity which adds a single deoxyadenosine (A) to the 3’ ends of PCR 
products. The linearised vector supplied in this kit has single 3’ deoxythymidine (T) 
residues. This allows PCR inserts to ligate efficiently with the vector. Thereafter the 
insert was cut out using EcoRI (Promega) and subsequently subcloned into pDNA3.1 
(+)•
Sequencing
Samples to be sequenced were sent to PNACL, University of Leicester. Sequencing 
data was analysed using Chromas (version 2.0, beta 3) sequence analysis software.
Analysis of receptor constructs
Stable transfection ofNCBlO cells
Cells were grown to 60-80% confluence before transfection. Transfection was 
performed using DOTAP (Boehringer Mannheim) according to the manufacturers 
instructions. Mouse-ttib-AR cDNA was subcloned into the expression vector pRK5 
(figure 1.3a), and stably transfected clones were generated by co-transfection of
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pRK5 with (figure 1.3b) (Morgenstem and Land, 1990) at a ratio of
10:1. All other constructs were expressed in vectors harbouring the G418 resistance 
marker. To generate cell lines stably expressing the desired construct, Iday post 
transfection, cells were seeded and maintained in DMEM (Sigma) supplemented 
with 200|xg/ml Hygromycin (Boehringer Mannheim) (mouse-ttib-AR) and 400)Lig/ml 
Geneticin (Life technologies, Inc) (FLAG/mouse-aib-AR, human-ttib-AR and 
GFP/human-aib-AR). In both cases, a 'kill curve' was used to determine the 
concentration required to select for antibiotic resistant cells. Approximately two 
weeks post-transfection, discrete colonies became visible on the culture dishes, a 
selection of which were picked, and expanded to allow for further selection. Clonal 
expression of each subclone was examined initially by Confocal Microscopy and 
Radioligand Binding, then clones for further study were selected and expanded,
Confocal Microscopy
Two NOR AN odyssey confocal laser scanning microscopes were used in the course 
of this work. The vessel work was performed on an upright (Nikon Optiphot) 
configuration and the majority of the single cell work was performed on an inverted 
configuration (Nikon Diaphot) UV CLSM system. The upright microscope is fitted 
with a mixed gas UV laser (Coherent) and can deliver lines of 364, 488 and 525 nm, 
with barrier filters of 400, 515 and 529 nm, respectively. This system is optically best 
suited for UV and green fluorescent stains. The system is physically best suited for 
fixed cell/vessel work.
Argon Ion CLSM system: The inverted system is fitted with a single argon ion laser 
(OmniChrome) capable of delivering lines of 454, 488 and 529 nm and available 
barrier filters of 515, 550 and 610 nm. This system is optically best suited to dual
fluorescence work using green and red stains (i.e., fluorescein and rhodamine type 
stains). The system is physically best suited to work with single cells mounted on a 
specialised flow chamber.
Software
Identical parameters (brightness, contrast, laser intensity, excitation and emission 
wavelengths, slit size and frame averaging) were set in every experiment, unless 
stated otherwise. The objectives used throughout the project were Nikon x40, oil and 
Zeiss x40, water, in conjunction with the inverted and upright systems, respectively. 
The resolution in X and Y for the upright/invert microscopes using a x40 objective 
was 0.2pm/pixel. The Z resolution used when acquiring z-series was 0.3p.m.
Whole cell imase analysis
Images were collected and analysed using Universal Imaging's 'Metamorph' 
software. Cells were grown on coverslips for 24 hours prior to use, unless otherwise 
stated. Coverslips were mounted in a flow chamber (WPI) and placed on the stage of 
an invert (Nikon Diaphot) microscope fitted with a Noran Odyssey Laser Scanning 
Confocal Module. Fluorophores were excited using a 488 nm argon laser and 
detected with a 515 nm band pass filter. In all experiments, a 15p.m slit was used and 
all other parameters were kept constant. All cells were checked for viability using 
Propidium Iodide staining prior to every experiment.
Screening transfected subclones for homoseneitv
A single concentration of QAPB (InM) (Molecular probes) was added to a coverslip 
of cells representative of different transfected subclones. Images were acquired from 
around the entire coverslip to establish homogeneity.
89
QAPB
Using cell autofluorescence, a suitable group of cells was selected and the focal 
plane fixed by locking the focus motor. The system was then set to acquire images 
(64 frame averages, unless stated otherwise) at 1 minute intervals. After a baseline 
was established, typically 5-6 minutes, the first concentration of fluorescent ligand 
was added and allowed to equilibrate (i.e., until no further increase in fluorescence) 
for at least 5 mins. After equilibration the next concentration of fluorescent ligand 
was added, without washing, and given time to equilibrate as before. Once saturation 
had been reached the individual cells were outlined using Metaporph's define-region 
tool and the fluorescent intensity values representative of each concentration at 
equilibrium were recorded. Non-specific binding was defined as fluorescent binding 
in the presence of lOpM prazosin. The composition of the Hepes buffer used in all 
single cell work was as follows: NaCl 130mM, KCl 5mM, HEPES 20mM, Glucose 
lOmM, MgCl ImM, CaCl ImM.
GFP detection
Using GFP-associated fluorescence, suitable cells stably expressing the GFP-tagged 
human(Xib-AR construct (a gift from Tsujimoto) were chosen and images acquired. In 
co-localisation experiments, with QAPB, cells with relatively low GFP expression 
were selected and analysed as described above.
Immunofluorescence detection
Fixation was performed in 80% acetone for 5 minutes. Cells were subsequently 
washed briefly in PBS then permeabilized with 0.05% Triton X-100 (Sigma) in PBS 
for 30 minutes. The primary monoclonal antibody, anti-FLAG® M5 (Sigma-Aldiich) 
was then applied to cells at lOpg/ml in PBS containing 10% goat serum (DAKO) and 
0.05% triton X-100. Cells were subsequently kept in a humidified chamber on a
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Gyro-rocker at 10 rev/min for 1 hour at room temperature. Cyanine-conjugated 
Affinipure Goat Anti-Mouse IgG (H-hL) (Jackson ImmunoResearch Laboratories, 
Inc.) was diluted 1/200 in PBS containing 2% bovine serum albumin and 0.05% 
Triton X-100, and applied to cells for 1 hour at room temperature in darkness. Cells 
were then washed twice with PBS, and coverslips mounted using fluorescent 
mounting medium (DAKO). After immunocytochemical staining, cells were 
examined using a NORAN Odyssey CLSM with mixed gas UV laser using a x40 
water immersion objective.
Western blotting
Electrophoresis and blotting of protein were performed with the No vex XCell II 
Mini-Cell and Blot Module under reducing and denaturing conditions. All samples 
were prepared in 4x Laemmli sample buffer [Tris-base (0.24 M, pH 8.3), glycine (1.9 
M) and SDS (35mM)] and were heated at 55-60°C for 5 min before loading. 
Typically, 10-20 pg of protein was loaded in each lane of a 10% Tris-glycine gel. 
Electrophoresis was carried out in 4x Laemmli buffer for 1.25 hours at a constant 
current of 25mA. Proteins were transferred on to nitrocellulose membranes using the 
Trans-blot semidry transfer cell system (Biorad) for 30 mins at 20V at a limiting 
current of 500mA in transfer buffer (39mM Glycine, 1.3mM SDS, 20% methanol, 
48mM Tris, pH 9.2). Nitrocellulose sheets were blocked in wash buffer (150mM 
NaCl, ImM EDTA, 0.1% Triton X-100, lOmM Tris-HCl, pH 7.4) containing 3% 
BSA. Incubation with the primary antibody (Anti-FLAG M5 Monoclonal Antibody, 
1:2000 dilution of the stock. Sigma.) was carried out overnight at 4°C in blotting 
buffer (lOOmM MgCL, 0.5% Tween, 1% Triton X-100, 1% BSA, lOOmM Tris-HCl, 
pH7.4) containing 5% foetal calf serum (Life technologies, Inc). Membranes were
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then washed three times for 5 min at room temperature in wash buffer. Secondary 
antibody (Goat anti-mouse IgG-HRP, 1:2000 dilution, Transduction laboratories) 
incubations were for 2 hr at room temperature in blotting buffer. The blots were 
washed a further three times and developed using the ECL detection system 
(Amersham).
Radioligand binding assays 
Production o f plasma membrane fractions
Cells were grown to confluence then the cell layer harvested using a rubber 
policeman followed by centrifugation at 4000rpm for 3 minutes at room temperature. 
The cell pellet was resuspended in 1ml of Tris-HCl assay buffer (150mM NaCl, 
50mM Tris-HCl, lOmM MgCL, 5mM EDTA pH 7.4) and stored at -80°C until the 
following day. Cells were then homogenised using a pre-chilled teflon-in-glass 
homogeniser. The homogenate was centrifuged at 4000rpm for 5 minutes at 4°C, the 
supernatant recovered and centrifuged at 26,000rpm for 30 minutes at 4°C. The 
resulting membrane pellet was resuspended in 500)l i 1 of ice-cold Tris-HCl buffer and 
sheared by passage through a 26-guage needle. lOOpl aliquots were stored at -80°C. 
Protein concentrations were determined using BCA™ Protein Assay Kit (Pierce) 
using bovine serum albumin as the standard.
Screening cell lines for endogenous receptor expression
For initial screening, expression of (Xi and a 2 -ARs was estimated by measuring 
specific binding through a range of concentrations (0.05-10nM) of [^H]-prazosin 
(Amersham) and [^H]-yohimbine (Amersham), respectively.
Screening transfected subclones for receptor expression
92
Antibiotic resistant subclones were first screened for expression by measuring 
receptor density with a single concentration (InM) of [^H]-prazosin. Clones with 
high specific and low non-specific binding were expanded for further 
pharmacological and functional analysis.
Saturation analysis
For saturation experiments, membranes (lOpg of protein) were incubated in 
duplicate with increasing concentrations (0.05-lOnM) of [^H]-prazosin, in a final 
volume of 0.5ml of assay buffer (150mM NaCl, 50mM Tris-HCl, lOmM MgClz, 
5mM EDTA, pH 7.4), at room temperature for 30 minutes. Non-specific binding was 
defined as the binding retained on the filter and membranes in the presence of lOpM 
Phentolamine. Following equilibrium, bound and free ligands were separated by 
rapid filtration under vacuum through GF/C glass-fibre filters (Whatman, Maidstone, 
Kent, UK), using a Branded cell harvester. The filters were washed three times with 
ice-cold wash buffer (50mM Tris-HCl pH 7.4), transferred to scintillation vials 
containing Ecoscint™A (National Diagnostics). Filters were soaked overnight and 
counted.
Competition analysis
For competition experiments, membranes (lOpg of protein) were incubated with 
approximately the Kd concentration of radioligand in duplicate, together with 
increasing concentrations of competing agent. Inhibition of specific binding of [^H]- 
prazosin by ligands was analysed to estimate the IC5 0 (concentration of the ligand 
displacing 50% of specific binding). The inhibitory constant (Ki) was calculated from 
the IC5 0 by the equation of Cheng and Prusoff (1973). Ligands used in competition 
analysis included prazosin, QAPB, (R)-A-61603, R enantiomer of A-61603 (Dr. 
Michael Meyer, Abott Labs), BMY7378 (Research Biochemical Int, RBI). Binding
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isotherms from displacement studies were analysed by a non-linear least square 
parametric curve-fitting programme, GRAPHPAD prism® version 3.0, capable of 
iterative curve fitting to a single-site model.
Measurement of [Caf^]i 
Fluorimetric analysis
Cells were grown on glass coverslips then loaded (15mins at 37®C), with Fura-2 AM 
(l|xM) (Sigma, Dorset, U.K.). A rise or fall in [Ca^ ' J^i causes a corresponding effect 
in the Fura-2 fluorescence ratio recorded from cells loaded with this dye, and this 
allows receptor/voltage-mediated changes in [Ca^ "^ ], to be 
microspectrofluorimetrically monitored (Grynkiewicz et al., 1985). In the present 
study, Fura-2 fluorescence ratios, (excitation wavelength 340 and 380 nm), were 
recorded directly at 4 Hz intervals from single cells at room temperature. Data were 
digitised and recorded directly to computer disk using an interface and associated 
software (Version 5.2) obtained from Cairn Research Ltd (Faversham, Kent, U.K.). 
Calcium imaging
Cells stably expressing the GFP/human aib-AR were plated onto glass cover slips 
and grown overnight, then loaded (15 min at 3TC), with Fura-2 AM (1.5 |liM). Fura- 
2 loaded cells were then, mounted in a chamber attached to the stage of an Nikon 
Diaphot inverted microscope where the cells were superfused with physiological 
saline solution. An Optoscan monochromator (Cairn Research, Faversham, Kent 
U.K.), positioned between a 75W Xenon lamp and the epifluorescence port of the 
microscope, was used to alternate the excitation wavelength between 340, 380 and 
488 nm (band pass 10 nm) and to control the excitation frequency. Excitation light 
was reflected from a custom designed dichroic mirror through a Nikon 40x oil 
immersion FLUOR objective (NA=1.3). Fura-2/GFP emitted fluorescence light at
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515 nm was monitored either by a low noise COHU CCD camera or a 
photomultiplier tube with a bialkali photocathode. Images acquired with the CCD 
camera were stored and analysed digitally under the control of Meta Fluor imaging 
software (Universal Imaging Corp., West Chester, PA, USA). Images acquired for 
each excitation wavelength were collected every 1 sec; exposure to excitation light 
was always 80ms/image and the time interval between the acquisition of each images 
was ~2 msec. Cells were delimited by producing a mask that contained pixel values 
above a threshold applied to the 380 nm image and time-dependent changes in 
[Ca^ ]^i was calculated from the ratio of two background subtracted images.
Cell culture
NCB2ÜS were maintained in DMEM supplemented with 10% (v/v) foetal bovine 
serum and ImM L-glutamine in a 95% air and 5% CO2 atmosphere at 37°C. Stable 
cell lines were maintained in the presence of selective antibiotics. Clones expressing 
the mouse-aib were grown in media containing 200pg/ml hygromycin. For all other 
stable cell lines, 400pg/ml geneticin was used as the selective agent.
Freezing cells
Cells are grown to confluence in 75cm^ tissue culture flasks, culture media removed 
and replaced with fresh media containing 10% DMSO. Cells were removed from the 
bottom of the flask by gentle agitation, aliquoted into 1.5ml cryovials and placed in a 
‘Mr Frosty’ overnight at -70°C. Vials were then removed and filed in cryocanes and 
frozen down in liquid nitrogen.
Thawing cells
Cell ampoules were removed from cryocanes and placed in an incubator at 37°C for 
5mins. The aliquot was carefully added drop wise to 9mls of fresh media, spun down.
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resuspended in 5mls of media and added to 25cm^ flask, placed in incubator and 
maintained as normal.
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Chapter 1
Results
Construction o f FLAG-tagged mouse ajb-AR
The construction of an oligonucleotide that encoded the FLAG™ epitope 
(DYKDDDDK) to be inserted into pcDNA3.1 (+) was carried out in two separate 
stages. Firstly, the coding sequence of the mouse «ib-AR (figure 1.14, nucleotides 
724-2269) was modified by PCR amplification. Using the amino-terminal primer 
(see methods), an Nhel restriction site and the FLAG™ epitope were introduced. 
Using the COOH-terminal primer (see methods), an Xbal restriction site was 
introduced. Unfortunately, the amplified product (figure 1.15a), digested with 
Nhel and Xbal, could not be successfully ligated to pcDNA3.1(+). The activity of 
these restriction sites in the MCS of the expression vector was assessed (figure 
1.15b). The cleavage sites for both of these enzymes lie within a few bases of the 
end of the amplified fragment, which can cause decreased cleavage efficiency. 
Therefore the incubation period suggested by the manufacturer was extended 
accordingly; unfortunately to no further avail. Another consideration for the 
failure of this ligation was that both enzymes produced compatible ends. 
Ultimately, Invitrogen's TA Cloning® Kit was employed. Initially EcoRl was 
used to check that the amplified fragment had been successfully ligated to 
pCR®2.1 (figure 1.16a). Thereafter, Nhel and Xbal, were used to excise the insert 
from the MCS of pCR®2.1 (figure 1.16b) which was subsequently ligated to the 
sticky ends of pcDNA3.1(+). The construct was sequenced (figure 1.17) and 
expressed in NCB20 cells for pharmacological and functional analysis (figures 
1.18-1.22).
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Stable expression of functional aib-ARs in NCB20 cells 
mouse/human aih-ARs
NCB20 cells did not contain any detectable ^H-Prazosin binding sites before 
transfection with ocib-ARs (figure 1.1b). A small population of ocz-ARs was 
detected using Yohimbine (Kd 0.93±3.1, Bmax 15.87±18.73fmol/mg) (figure 
1.2, bottom). In contrast, when the cells were transfected with aib-AR constructs, 
clones were identified expressing specific binding sites for ^H-Prazosin on crude 
membrane fractions. All clones expressing the specific ^H-Prazosin binding sites, 
as identified by hygromycin (mouse aib-AR) or geneticin (human aib-AR) 
resistance, had equivalent affinity for the radioligand, consistent with oci-ARs, but 
differed in receptor density. Among the several clones screened, a clone 
expressing maximum receptor density of the ^H-Prazosin binding sites was chosen 
from both species, and used for further analysis. Scatchard analysis of the specific 
binding curve for ^H-prazosin binding to mouse and human ocib-AR membranes 
produced a Kd of 0.7 and 0.9nM respectively (Figure 1.8, Table 1). Competition 
studies demonstrated that 0.2nM ^H-prazosin binding was displaced from both 
mouse and human ocib-AR sites with high affinity by prazosin, with QAPB 
displacing ^H-prazosin with slightly lower affinity (Figure 1.9, Table 1). 
Consistent with the pharmacology of recombinant aib-ARs, both A-61603 (ctia- 
selective, Knepper et al., 1995) and BMY-7378 (aid-selective, Goetz et al., 1995) 
had low affinities for both species of aib-AR (Figure 1.9, Table 1).
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FLAG-tassedhnouse aij,-AR
The clone of NCB20 cells stably expressing the FLAG-tagged mouse aib-AR, that 
was selected and used for further analysis, showed a lower affinity for ^H- 
prazosin, and a receptor density that was a quarter of that in the wildtype clone 
(figure 1.19, Table 1). Competition analysis revealed that prazosin displaced 2nM 
^H-prazosin binding with slightly lower affinity from tagged receptive sites. In 
addition, a substantial difference in the ability of QAPB to displace ^H-prazosin 
was also observed at these sites (figure 1.20, Table 1).
GFP-tagged/human aih-AR
In contrast to the difference in affinity observed when an 8 amino acid (aa) 
epitope tag is attached to the N-terminus of the aib-AR, an equivalent affinity of 
^H-prazosin for the GFP-tagged (C-terminus, >200 aa) and the wildtype receptor 
was observed (figure 1.25, Table 1). Similarly, competition analysis demonstrated 
that unlabelled prazosin displaced 0.2nM ^H-prazosin from all sites with 
equivalent ability. However, the fluorescently labelled antagonist, QAPB, again 
showed a much lower ability to displace ^H-prazosin as was observed for the 
FLAG-tagged sites (Figure 1.26, Table 1).
Fluorescent ligand saturation binding on intact recombinant cells 
mouse/human aih-AR
Q APB-associated fluorescence binding was concentration-dependent in 
recombinant cells. Incubation with QAPB produced minimal background 
fluorescence using a working range starting at 0.4 up to a maximum of 30nM in 
non-transfected cells where ai-AR expression was negligible (figure 1.1a). In the 
presence of IjiiM prazosin, QAPB binding was significantly inhibited and the
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residue was used to calculate 'non-specific' binding. This residual fluorescence 
seen in transfected cells is found in the same regions in the cell that you find 
specific binding. QAPB-associated fluorescence seen in control cells (entirely 
non-specific) has a different distribution (figure 1.1a). This 'non-specific' binding 
is also greater in transfected cells compared to control cells, and is dependent on 
the density of receptors within the cell in question. So, although this binding at 
high concentrations of QAPB is resistant to prazosin (lp.M), it is receptor-related, 
and therefore cannot be termed as non-specific per se. The 'non-specific' 
component in all cells was almost negligible at low concentrations of QAPB, 
allowing the subcellular distribution of specific «ib-AR binding sites to be 
visualised. Receptor capacity of the cell line expressing the mouse ocib-AR was 
~4000fmol/mg. Two human aib-AR cell lines were generated, one with similar 
and the other with a receptor density double that of the mouse cell line. Intense 
staining of saturable intensity was observed in regions associated with the plasma 
membrane, at very low concentrations of QAPB, in both cell lines, at both 
densities (figures 1.5 and 1.7). In some cells, a distinct intracellular population of 
binding sites was also apparent (figure 1.5, middle, left), presumably dependent 
on the stage each cell was at in its cycle. These results indicate that the ocib-AR is 
located predominantly at the cell periphery. The 'non-specific' binding seen at 
higher concentrations of QAPB was distributed in a similar manner, since 
receptor-related, yet resistant to prazosin.
FLAG-tagged mouse ccih-AR construct/wildtyye mouse receptor
QAPB binding to FLAG-tagged recombinant cells was highly specific at low
concentrations of QAPB, and associated with the plasma membrane as seen in
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cells expressing the wildtype receptor (figure 1.18). The receptor density of this 
cell line, as shown by radioligand binding, was a quarter of that recorded in the 
mouse aib-AR cell line, which is consistent with the reduced staining found.
GFP-tagged human aih-AR construct/wildtyye human receptor 
In NCB20 cells stably expressing low levels of the pEGFP/human aib-AR 
construct, QAPB bound to regions within the cell that represented the receptor, as 
shown by low levels of pEGFP-expression (figure 1.24e), thus validating the 
binding of the fluorescent ligand to specific oci-AR binding sites. GFP-associated 
fluorescence was associated mainly with the plasma membrane (figure 1.24a), 
although, as with QAPB binding alone in wildtype cells (figure 1.5, middle, left), 
some displayed intense fluorescence in an intracellular location (figure 1.24b). 
Attempts made to co-localise QAPB binding with the GFP-tagged receptors also 
resulted in a QAPB induced change in the distribution of the receptive sites 
(figure 1.24d). The image of GFP alone (figure 1.24di) compared to the binding of 
2nM QAPB (figures 1.24dii and iii) over 2 and 5minutes respectively, illustrates 
this. The transient expression of the GFP-tagged construct driven by the mouse 
ttiB-AR promoter in NCB20 cells, which are aie-AR negative, was significantly 
low, in that only a couple of cells from a confluent cover slip were able to express 
the promoter-reporter construct (figure 1.24c).
Lack o f specific immuno staining of Anti-Flag ® M5 monoclonal antibody 
Immunofluorescence analysis
Anti-Flag ® M5 monoclonal antibody had low specificity in binding to the 
epitope-tagged mouse (Xib-AR stably expressed in NCB20 cells. Intense non­
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specific immunostaining was observed on both transfected and non-transfected 
cells (figure 1.22a). A possible explanation could be cross-reactivity between the 
mouse monoclonal antibody and the NCB20 cell line, both of which are of mouse 
origin.
Western blot analysis
A ladder of immunoreactive bands was observed in Western blots using plasma 
membranes or whole cells from both non-transfected and FLAG-tagged cells 
(figure 1.22b). Each band corresponded in size to one another in each preparation, 
indicating that the mouse monoclonal antibody was binding to the same cellular 
proteins in both control and FLAG-tagged blots. This result also suggests cross­
reactivity as the limiting factor in these experiments.
Functionality o f recombinant cell lines
Both wildtype (figures 1.10, 1.12) and conjugated (figures 1.21, 1.27) aib-ARs 
stably expressed in NCB20 cells were found to be functional, as a phenylephrine 
(lOpM)-induced intracellular free calcium respone was observed. Both 
fluorimetric analysis (FLAG-tagged construct) and calcium imaging (wildtype 
and GFP-tagged constructs) were used to demonstrate this. It was noted that 
within a patch of cells (figure 1 .1 2 ), individually, cells responded in a 
quantitatively dissimilar manner, presumably influenced by slight differences in 
their expression levels.
Using the GFP-tagged human aib-AR cell line, and alternating the excitation 
wavelength between 340, 380 and 488nm, Fura-2/GFP emitted fluorescence light 
at 515nm was monitored allowing time-dependent changes in [Ca'*”^ ]i and GFP
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intensity to be recorded in response to agonist (figure 1.28a). An unlabelled cell, 
situated alongside a cell expressing GFP-tagged human aib-ARs, acted as a 
control, and as expected, did not elicit an [Ca'^ '^ ]i in response to the ai-AR 
selective agonist, phenylephrine (figure 1.28a). The possibility of GFP 
photobleaching was assessed, and the overall GFP-intensity of the cell did not 
change during a 3minute control experiment (figure 1.28c). In unstimulated cells, 
small oscillations of movement of receptors was observed between the membrane 
and the intracellular cluster (figure 1.28d). In response to agonist stimulation, 
during the period of time when Ca^^ was being released from intracellular stores, 
the movement of receptors appeard to plateau. After a couple of minutes, 
movement resumed and an overall increase in the GFP intensity inside the cell and 
a concomitant decrease associated with the plasma membrane was observed 
during agonist stimulation (38minutes) (figure 1.28f). This movement of GFP- 
tagged human aib-ARs stably expressed in NCB20 cells can be seen the movie in 
figure 1.28b.
QAPB associating with mouse/human ajjj-ARs
When QAPB bound to aib-ARs stably expressed in NCB20 cells, it was possible 
to monitor the movement of the receptive sites by following the fluorescent 
ligand, acquiring images approximately every 2msec. Using the experimental set­
up described in methods {calcium imaging), it was possible to record 5nM QAPB 
binding to mouse (figure l.lla ,b ) and human (figure 1.13a,b) aib-ARs over 54 
and 41 minutes respectively. The outcome of such experiments suggested that 
QAPB enters cells via an endocytic pathway, as extensive movement of vesicle-
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like structures was observed within the cell. The binding of QAPB to ai-ARs does 
not elicit a calcium response (figure 1.29).
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Discussion
The main aim of this chapter was to stably express recombinant «ib-ARs in a 
mammalian cell line, to assess their functional and pharmacological 
characteristics including their subcellular distribution in live single cells using the 
fluorescent ligand, QAPB. It is thought that the binding of QAPB to ai-ARs may 
be altered post-fixation. Validation of the specific binding of QAPB to ai-ARs 
was therefore imminent in both fixed and live cells. The re-distribution of aib- 
ARs in response to agonist was also of interest.
Radioligand binding assays using plasma membrane fractions eliminate some 
non-specific binding but they do not reflect the true binding of ligands to receptors 
on intact, live cells. The fluorescent ligand approach, using confocal laser 
scanning microscopy (CLSM), allows an estimation of both affinities and specific 
binding to receptor subtypes on single, live cells. In addition, the subcellular 
distribution of receptor populations can be assessed.
Initially, NCB20 cells were screened for a-ARs. Confocal and radioligand 
binding analysis revealed a small population of tt2 -ARs, but null for ai-ARs 
(figures 1,1 and 1.2). Subsequently, NCB20 cells were stably transfected with 
mouse/human aib-ARs, receptor binding capacities of individual clones were 
examined (by radioligand binding), homogeneity (confocal microscopy) and 
functional properties (using [Ca"^ ]^i response) were also assessed.
Cell lines demonstrating low non-specifc and high specific binding of ^H-prazosin 
to plasma membranes bearing mouse and human (Xib-ARs were used as a model. It 
was investigated whether the transfected cells showed the pharmacological 
characteristics similar to other established recombinant ttib-AR cell lines. Both 
species of aib-AR were found to have binding profiles similar to those reported
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previously for 'aib-AR cells' (Kenny et al., 1995; Mackenzie et al., 2000). They 
displayed relatively low affinities for the Œia-AR selective agonist, A-61603 as 
well as for the am-AR selective antagonist, BMY7378, suggesting a 
homogeneous population of ocib-ARs.
Both cell lines bound QAPB (figures 1.5 and 1.7) and ^H-prazosin (figure 1.8) 
with high specificity and affinity. The distribution of QAPB binding was 
predominantly associated with the plasma membrane, although this did vary, 
presumably dependent on the stage each cell was at in their cycle. Interestingly, 
expression of the (Xib-AR at both 4000 and 8000fmol/mg showed no difference in 
the distribution other than intensity of ligand binding at low concentrations of 
QAPB. It is currently thought that populations of recombinant ocib-ARs found 
intracellularly represent excess receptors, either at their site of synthesis (Golgi 
apparatus) or site of degradation (lysosomes). This line of work is currently being 
investigated in our laboratory and will be discussed later.
Recombinant mouse and human ttib-ARs were functional as shown by release of 
Ca"^ "^  from intracellular stores in response to lOp-M phenylephrine (figures 1.10 
and 1 .1 2 ).
In order to validate the binding of QAPB and to assess possible alterations in 
ligand binding post-fixation, the FLAG™ epitope (DYKDDDDK) was attached 
onto the N-terminus of the mouse aib-AR (figure 1.17). The construct was 
thereafter stably expressed in NCB20 cells. From radioligand binding studies 
using plasma membranes, the non-specific component in both wildtype and 
FLAG-tagged cells was the same, taking into consideration the difference in 
expression levels. However, the affinity of prazosin was 30% lower for the 
FLAG-tagged receptors, probably due to steric interference. With respect to
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QAPB binding on living cells, the concentration at which QAPB bound did not 
differ between the wildtype and FLAG-tagged cells indicating that perhaps this 
experimental set-up is more sensitive to ligand-receptor interactions as the cells 
are alive.
The practicability of immunoreactive approaches depends on specific detection of 
FLAG-fusion proteins with no or little cross-reactivity to cellular proteins. 
Unfortunately, analysis of the expression and activity of the epitope by Western 
blot and immunofluorescence studies showed that the monoclonal antibody bound 
non-specifically to cellular proteins within both control and transfected cells 
(figure 1.22). A possible explanation for the lack of specificity could be cross­
reactivity as both the antibody and the cell line were of mouse origin. A report in 
the literature has revealed that monoclonal anti-FLAG antibodies react with a new 
isoform of rat Mg"^ "^  dependent protein phosphatase |3 (MPPP). The occurrence of 
MPPp enzymes in various tissues illustrates that anti-FLAG antibodies have to be 
used with caution when FLAG-tagged proteins are to be investigated in 
mammalian cells (Schafer and Braun, 1995). The next stage with this line of 
investigation will be to express the construct in a non-rodent cell line e.g. HEK 
293 to try and reduce cross-reactivity.
This work is of importance to our group as the possibility that fixation changes the 
binding of QAPB needs further investigation. The immunofluorescence method is 
ideal for us to locate the receptor, post fixation, and prior to QAPB binding.
In an attempt to validate the binding of QAPB to «i-ARs in live cells, the 
construction of a GFP-tagged human aib-AR cell line held the potential for co­
localisation of QAPB with GFP-associated fluorescence. GFP-tagged human aib-
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ARs were stably expressed in NCB20 cells and pharmacological analysis revealed 
that C-terminal fusion proteins do not perturb normal ligand binding. Addition of 
this protein (>200aa) to the C-terminus of the human aib-AR did not alter the 
ligand binding affinity of ^H-prazosin (figure 1.25) or QAPB (live cells only) 
(figure 1.24e) nor affect its functionality (figure 1.27).
a  lb-ARs have a basal-level of movement between the plasma membrane and their 
intracellular location. In the absence of agonist ligand, GFP-tagged aib-ARs are 
predominantly located at the plasma membrane, with a distinct intracellular 
population situated in a non-perinuclear orientation (figure 1.28a, syto 13 stain). 
In response to agonist, during the period of time when [Ca^]i was being released 
from intracellular stores, this movement appeared to cease (figure 1.28e) but 
resumed once calcium levels returned to baseline. During the prolonged period of 
agonist exposure (35minutes), a symmetrical movement of receptors from the 
membrane to an intracellular location was observed with an overall increase in 
receptor density situated intracellularly (figure 1.28f).
GFP fluorescence is usually very pH stable but the variant EGFP is more pH 
sensitive than wt GFP (pH 7.0-11.5 compared with '-pH 5.5-12 for wt GFP). 
When interpreting EGFP-associated fluorescence experiments, one must be 
cautious since movement of EGFP-tagged receptors to intracellular compartments 
(pH < 7.0) may result in artifactual changes in fluorescence.
Attempts were made to co-localise QAPB binding to GFP-tagged receptors. 
Unfortunately, co-localisation of the two fluorophores was hampered as both were 
excited at the same wavelength. By choosing patches of cells expressing low 
levels of GFP, QAPB bound to similar regions within the cell. Although not ideal 
experimental conditions, it was illustrated in the cells chosen here, that intense
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QAPB binding was associated with the plasma membrane in one cell yet 
predominantly intracellular in the other. These cells were taken from the same 
clone, plated onto cover slips at the same time, and incubated for a similar time 
period. The images from these experiments emphasise the point made previously, 
that the subcellular distribution of ajb-ARs in recombinant cell lines is influenced 
by the stage individual cells are at in their cell cycle, not solely dependent on their 
receptor density. Another example of this was seen in figure 1.5, where NCB20 
cells stably expressing mouse aib-ARs also displayed differences in their 
distribution within the same clone.
As an alternative method, attempts were made to subtract QAPB-associated 
fluorescence from GFP-associated fluorescence in the same cell. Interestingly, 
when I tried to subtract the images, the cell in question appeared to have changed 
shape upon QAPB binding, and receptors initially present around the outskirts of 
the cell, appeared to move inside (figure 1.24d). This finding was investigated 
further. The association of 5nM QAPB with mouse (figure 1.11) and human 
(figure 1.12) aib-ARs was monitored, and images captured every 2msec over 54 
and 38minutes respectively. In the patch of cells expressing mouse aib-ARs, 
QAPB bound to receptors that moved around inside the cell in vesicular-like 
structures (figure 1.11b). So, in the absence of agonist, this preliminary data 
suggets that QAPB (ai-AR selective antagonist) enters cells through a 
predominantly endocytic mechanism and not solely via membrane penetration. It 
should also be noted that QAPB does not induce the release of [Ca^]i (figure 
1.29).
Prazosin is lipophilic, so it was logical to assume QAPB was also lipophilic and 
could pass through the cell membrane by diffusion. QAPB appeared to access and
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bind both receptors on the plasma membrane and intracellularly at the same 
instant with confocal analysis, as could be seen when InM QAPB equilibrated 
with human aib-ARs over one minute intervals (figure 1.7b). However, this theory 
is now debateable as some preliminary studies in our laboratory using a more 
sensitive system, suggest that QAPB enters cells via an endocytic pathway. Such 
studies show that QAPB co-localises with a lysosomal marker in acidified 
vesicles, suggesting that QAPB enters cells via an endocytic mechanism as 
opposed to diffusion through the membrane. In fact, QAPB binding has been 
blocked in the presence of sucrose/concanavalin A, inhibitors of clathrin-mediated 
endocytosis (Pediani, manuscript in preparation). However, limited information is 
available for antagonist binding and basal endocytosis. Most of the work has been 
with agonists.
In unstimulated cells, receptors are reported to be slowly endocytosed from the 
cell surface to endosomes (Koenig and Edwardson, 1997). All nucleated cells use 
endocytosis to continuously remodel their plasma membranes and membrane 
endocytic recycling acts as a mechanism to balance the internalisation of 
membrane components. This recycling process is assumed to be constitutive. 
Cells also use the endocytic pathway to deliver newly synthesised receptors from 
the golgi complex to the cell surface (Koenig and Edwardson, 1997). This 
phenomenon would explain the movement of vesicular structures seen when 
QAPB associated with aib-ARs, also the basal level of movement of GFP-tagged 
receptors in unstimulated cells between the membrane and inside the cell.
Tolbert and Lameh. (1998) used an epitope-tagged (EYMPME) human 
muscarinic cholinergic subtype 1 receptor, transefected into HEK 293 cells, 
together with an antibody to the epitope (anti-EE), to study internalisation. In their
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studies, they found that the antibody to the epitope tag could induce 
internalisation of the tagged-receptor in the absence of agonist. This study is an 
example of an atypical ligand interacting with a GPCR in a manner distinct from 
that of an agonist, capable of inducing internalisation, without initiating an 
intracellular signal. This group have also shown that the path of internalisation 
induced by the antibody is identical to that resulting after agonist treatment. 
Similarly, Roettger et al. (1997) have shown that an antagonist of the 
cholecystokinin receptor is capable of mediating its internalisation in the absense 
of both receptor phosphorylation and second messenger signalling.
Such reports, including the preliminary done work in our laboratory, suggest that 
the signal for internalisation is independent of second messenger production. 
Perhaps GPCRs are capable of adopting different conformations, allowing 
internalisation, with only one (agonist-activated) capable of inducing an 
intracellular response.
Such fluorescence microscopical methods combined with GFP-tagged receptor 
cell lines can provide valuable information on the distribution and functional 
response ([C a^i) of receptors in the absence or presence of ligands.
Another construct became available to us during this time, similarly tagged with 
GFP, except the receptor was under the control of a promoter specific to the 
mouse aiB-AR gene. In this chapter, the fidelity of this construct, transiently 
expressed in NCB20 cells, which were previously shown to be aie-AR negative, 
was assessed. Minimal GFP-expression was detected in these cells, confirming the 
fidelity of this promoter.
I l l
In summary, the present study shows that the ligand binding properties, 
pharmacological characteristics and intracellular transduction mechanism of aib- 
ARs stably expressed in NCB20 cells appear to be similar to those defined in 
other recombinant aib-AR cell lines. Thus, they can be a useftil model system for 
further characterisation of this ai-AR subtype. The methods developed in this 
chapter were used to study the pharmacological properties of ai-ARs in native 
cells.
Internalisation of a cell surface receptor from the plasma membrane into 
intracellular compartments, such as vesicles, endosomes, or lysosomes, constitutes 
one of several processes, which regulates cell surface receptors. The mechanisms 
by which such receptor internalisation occur is beginning to unfold.
Several lines of evidence indicate that current models of GPCR signalling are 
insufficient to account for all the intracellular signals associated with GPCR 
activation. It is now known that many GPCRs regulate MAPK cascades, leading 
to activation of the ERKs, Jun amino-terminal kinase/stress-activated protein 
kinase, and p38 MAPK, which function as transcriptional regulators. These Ras- 
dependent signals are frequently dissociated from the regulation of classical G- 
protein effectors, such as PLC. Rather, mechanisms whereby GPCRs regulate 
tyrosine protein kinase activity and induce the formation of mitogenic signalling 
complexes are involved (see reviews by Luttrell et al., 1999; Hall et al., 1999).
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Figure 1.1 (a) QAPB binding on non-transfected NCB20 cells. Cells 
were plated on coverslips and examined by confocal microscopy with 
timelapse photography. Increasing concentrations (0.4-30nM) were 
added cumulatively and images were collected at 1 -minute intervals. 
Images are shown in pseudocolour, where black indicates no staining 
and blue, green, yellow and red indicate increasing levels of 
saturation of the fluorophore. (b) Saturation binding of ^ H-Prazosin to 
membranes Ifom non-transfected NCB20 cells. Non-specific binding 
was determined in the presence of 10p,M phentolamine. Results are 
the mean (±SEM) of at least three experiments performed in 
duplicate.
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Figure 1.4 The structure of quinazolinyl piperazine (top) and the various 
substituents (R) that distinguish prazosin, doxazosin and QAPB. This 
particular form of BODIPY is excited at 488nm and emits above 515nm. The 
compound was obtained from Molecular Probes and is listed in their 
catalogue as "BODIPY FL-prazosin" but since it lacks the furan group which 
defines prazosin, as opposed to other compounds which share the 
quinazolinyl piperazine group, such as doxazosin, we refer to it by an 
acronym, "QAPB", derived from its chemical name (quinazolinyl piperazine 
borate-dipyrromethene).
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pcDNA3
5428/5427
Comments for pcDNAS.1 (+)
5428 nucleotides
CMV promoter: bases 232-819 
T7 promoter/priming site: bases 863-882 
Multiple cloning site: bases 895-1010 
pcDNA3.1/BGH reverse priming site: bases 1022-1039 
BGH polyadenylation sequence: bases 1028-1252 
f1 origin: bases 1298-1726 
SV40 early promoter and origin: bases 1731-2074 
Neomycin resistance gene (ORF): bases 2136-2930 
SV40 early polyadenylation signal: bases 3104-3234 
pUC origin: bases 3617-4287 (complementary strand)
Ampicillin resistance gene (b/a): bases 4432-5428 (complementary strand) 
ORF: bases 4432-5292 (complementary strand)
Ribosome binding site: bases 5300-5304 (complementary strand) 
bla promoter (P3): bases 5327-5333 (complementary strand)
Figure 1.5 QAPB binding on NCB20 cells stably 
transfected with the mouse a^y-AR. Non-specific binding 
was defined by IpM prazosin. Cells were plated on 
coverslips and examined by confocal microscopy with 
timelapse photography. Increasing concentrations of 
QAPB, as indicated, were added cumulatively and images 
were collected at 1 -minute intervals. Images are shown in 
pseudocolour, where black indicates no staining and blue, 
green, yellow and red indicate increasing levels of 
saturation of the fluorophore. Images are representative of 
a number of similar experiments carried out using this cell 
line.
Figure 1.6 Diagram of vector pcDNA3.1 (+).
Concentration of QAPB (nM) 
Autofluorescence (Auto) 0.4
0.4 nM 1 nM
Auto 10 20 30
Figure 1.7 QAPB binding on NCB20 cells stably transfected with 
the human a^y-AR. Non-specific binding was defined by IpM 
prazosin. Cells were plated on coverslips and examined by confocal 
microscopy with timelapse photography, (a) Increasing 
concentrations of QAPB, as indicated, were added cumulatively and 
images were collected at 1-minute intervals, (b) Equilibration of InM 
QAPB binding to receptive sites over a 5 minute time period. Images 
are shown in pseudocolour, where black indicates no staining and 
blue, green, yellow and red indicate increasing levels of saturation of 
the fluorophore. Images are representative of a number of similar 
experiments carried out using this cell line.
Auto
Concentration o f QAPB (nM)
P ra /o s in
I liM
Equilibration of InM QAPB over time (mins) 
1 2  3 4
0.4nM
I
150n
I I  100-
S S
f i  » .
9 •8 ■6 •4 3 ■2•7 ■5
150-,
I I  100-
50-
■8 6 4 -3 ■2-10 -9 7 ■5
Concentration o f A-61603 (log M) Concentration o f BMY7378 (log M)
150-1
O
P 50-
13 -12 -11 -10 -9 8 6•7
150-,
•s
ÿ
1 I
a
I
ia
w
Î 50-
-12 -11 -10 9 8 67 5
Concentration ofPrazosin (log M) Concentration o f QAPB (log M)
Figure 1.9 Displacement of 0.2nM ^H-Prazosin binding to mouse (■) 
and human (A )  a^y-AR subtype membranes by increasing 
concentrations of prazosin, QAPB, A-61603, and BMY-7378. Non­
specific binding was determined in the presence of 1 OpM 
phentolamine. Values are the mean (±SEM) of at least three 
experiments performed in duplicate.
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Figure 1.10 Intracellular calcium respone to lOpM phenylephrine in NCB20 
cell stably expressing the mouse a,y-AR. Cells were loaded with the 
fluorescent indicator dye Fura-2/AM ( 1.5pM) as described in the methods text. 
Time-dependent changes in [Ca^ j^j were calculated from the ratio of two 
background subtracted images. A transmission image is also shown.
&Figure 1.11a 5nM QAPB binding to mouse a,y-ARs stably 
expressed in NCB20 cells. Association is over a 54min time 
period.
Figure 1.11b A movie of QAPB binding to mouse a,b- 
ARs stably expressed in NCB20 cell. The movement of 
these receptors over a 54min time period.
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Figure 1.12 Intracellular calcium respone to lOpM 
phenylephrine in NCB20 cells stably expressing the human 
(Xiy-AR. Cells were loaded with the fluorescent indicator 
dye Fura-2/AM (1.5pM) as described in the methods text. 
Time-dependent changes in [Ca^ ]^j were calculated from the 
ratio of two background subtracted images.
a)
r
b) Transmission
Figure 1.13 (a) 5nM QAPB binding to human a,j,-ARs stably expressed 
in NCB20 cells. Association is over a 41min time period, (b) A movie of 
the intracellular movements of the bound receptor, alongside a 
transmission image.
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actccgagag
cagggggaaa
ggatcccctg
gtctccaagc
ttgcccccta
gtgcagtcag
gaaggcaccg
ccgctcctcc
tggacgtgcc
gggtgcaggc
ggaggtacgc
ctttggtcgc
atgatgaatc
ttgaaagatg
ctggacgtca
gtgggcaaca
aactacttca
ttctccgcta
tgggcagcgg
attgaccgct
aaggccatct
ctccttggat
cccttctaeg
gtcatgtact
gtcatgaagg
catgaggaca
gtcaaacttt
ggaatgttca
tccaccctaa
agctgcctca
cgtatcctgg
gcgtgcgctt
cggaaggact
tcggcgtcac
gccttccccg
ggccgcctcg
gggaccgaag
ccccattaga
aaaataatcc
ctctgctccc
cgactagcgt
gtgccgcaca
cccagaggcg
cggtccgtag
ccgcgctccc
gcctcgtccc
aggcgtcgag
ctctggaaag
agcccttccg
ccgatctgga
ccaacttcac
ccagggccat
tcttggtcat
ttgtcaacct
ccctggaagt
ttgatgtcct
acattggggt
tggcgctcct
ggaaagaacc
ccctcttttc
gccgagtcta
aaatgtccaa
ccctcagcag
ttaagttctc
tcttatgttg
agcccccgga
accccatcat
ggtgccagtg
acacctaccg
ctctggatga
ccagcccggg
agtggaaacc
actccgggcc
gcgacgccag
ggtaagcatc
agcgggcccc
cgccccatcc
ggcgctggcg
gagtcagggc
gctcattgaa
acccgccgcg
gcgcagccca
ctctctcctc
ctgctgggct
aagaccacgg
agcccaatct
caccggccac
tggccccaac
ctctgtgggc
cctgtcggtg
ggccattgct
gctcggctac
gtgttgcacg
gcgttactct
cagtgtgtgg
tgcgcccaat
ctccctgggc
catcgtggca
ctccaaagag
taccaaggcc
cagggaaaag
gctccccttc
cgcggtattc
ctacccgtgc
ccgcggtggc
gccgtggacc
cagtggcagc
atacctgggt
cggagcgctg
actcttcact
caatgggggc
cccaccctac
tggggtgtat
ccgcagaggg
tcggggctgc
gcccgggctt
agcagaccct
ggccggcacg
accagcgcgc
ctcctccctc
aggctgccgg
agggagcaaa
cctccctggc
aacacatcag
cagacctcga
tgtctgggcg
gcctgcaacc
gacctgctgt
tgggtgctgg
gcctccatcc
ctgcagtacc
gtcctctcca
gacgacaaag
tccttctaca
aagaggacca
ctgaccctga
aagggccaca
aaagcagcca
ttcatcgctc
aaggtagtgt
tccagcaagg
cgtcgccgcc
cgcggcggct
tgcatgagcg
cgtggaacgc
ctcagcctgc
ttcaagctcc
tgcgacacca
cttttaactg
gaaccgggat
agcggtgccg
gctccttggc
ccccgcctga
cctcgcgatc
gccgaccccc
ctgacgtgga
tgacaggcga
gggagatgac
gtttcagggc
tatggagggc
cacctgccca
gcaactccac
ccttcatcct
ggcacctgcg
tgagcttcac
ggcgcatctt
tgagcctatg
ccacgctggt
cggtcatctc
aatgtggggt
tcccactggc
ccaagaatct
gaatccactc
accccaggag
aaaccttggg
tcccacttgg
tctggctggg
agttcaaacg
gccgccgtcg
cgctggagag
gcagccagcg
agccacccgt
cagagcctcc
tgggcgagcc
caactgacct
aagcgtgaaa
gcccacaccc
ggcgcggcag
tggacccgca
tgtcaccgcc
gctgggcgga
gggcgcgcgc
ccattaaact
gcgagccgca
tttctcgcca
agctgaggag
ggactctaaa
ctggggagag
actgccccag
ctttgccatc
gacgccaacc
agacctgccc
ctgtgacatc
tgccatctcc
cacccgcagg
catcgggcct
cacagaagaa
ggtcatcctg
ggaggcggga
taagaacttt
ttccatagct
cattgtagtc
ctccctgttc
ctacttcaac
cgccttcatg
ccgtctagga
gtcgcagtcg
gaccctgccc
ggagctgtgc
tggccgccgc
tgagagcccg
ggccaacggg
cagccgggct tcaagagcaa catgcccctg gcgcccgggc acttttag
Figure 1.14 Nucleotide sequence of the full length mouse «ib-AR
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Figure 1.15 (a) PCR reaction products were 
analysed by agarose gel electrophoresis followed 
by ethidium bromide staining. Lane 1; 
separation of molecular weight markers (0.07- 
12.2kbp). Lane 2; separation of PCR products 
amplified with FLAG-primers. Lane3; mouse 
ttjb-AR cDNA subcloned into pRK-5 (b) 
Restriction analysis to check the activity of Nhel 
and Xbal sites within the MCS of pcDNA3.1 (+). 
Lane 1 ; separation of molecular weight markers 
(0.07-12.2kbp). Lanes 2-5 represent Nhel/ Xbal, 
Xbal, Nhel digested, and uncut, pcDNA3.1(+) 
respectively.
a)
4000 bp
-1600 bp
b)
-4000 bp 
-4600 bp
Figure 1.16 Positive colonies from the subcloning of the 
FLAG-tagged mouse a^y-AR into the MCS of pCR®2.1. 
Digests were analyzed by agarose gel electrophoresis 
followed by ethidium bromide staining, (a) Lane 1; 
separation of molecular weight markers (0.07-12.2kbp). 
Lanes 2-6; EcoRl digests of FLAG-tagged insert from the 
MCS of pCR®2.1. (b) Lane 1; separation of molecular 
weight markers (0.07-12.2kbp). Lanes 2-5; Nhel / Xbal 
digest of FLAG-tagged insert from pCR®2.1.
Figure 1.17 Nucleotide sequence of N-terminally tagged 
mouse a,y-AR. 81-86; Nhel site, 87-92; KOZAC sequence, 
93-95; start codon, 96-119; FLAG epitope, 120-980; partial 
sequence of mouse a,y-AR.
lacZ
M13 Reverse Primer
ATG
Mini III Kpn I Sac I fiamH I Spe I
CAG GAA ACA GOT ATG AC C ATG ATT ACG CCA AGC TTG GTA CCG AGC TCG GAT CCA GTA
GTG CTT TGT CGA TAG TG GTAC TAA TGC GGl TCG AAC CAT GGC TCG AGC GTA GGT GAT
BsfX I EcoR I
I  !
GTA ACG GCC GCC AGT GTG CTG CAA TTC  GGC TTj
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A va I 
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PCR Product
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Nsi I Xba I Apa II I I
GCA TGT AGA QGG CGC AAT TCG
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T7 Promoter
AGT GAG TCG TAT TA 
TCA CTC AGC ATA AT
M13 Forward (-20) Primer M13 Forward (-40) Primer
CAAT TCA 
G TTA AGT
CTG GCC GTG GTT TTA C 
GAC CGG CAG CAA AAT G
AA C 
TT G
GT GGT GAC TGG GAA AAC 
CA GCA CTG ACC CTT TTG
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Figure 1.18 QAPB binding on NCB20 cells stably 
transfected with FLAG-tagged mouse a,y-AR. Non­
specific binding was defined by IpM prazosin. Cells were 
plated on coverslips and examined by confocal 
microscopy with time lapse photography. Increasing 
concentrations of QAPB, as indicated, were added 
cumulatively and images were collected at 1 -minute 
intervals. Images are shown in pseudocolour, where black 
indicates no staining and blue, green, yellow and red 
indicate increasing levels of saturation of the fluorophore.
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Figure 1.19 Specific saturation binding of 
^H-Prazosin to membranes tfom NCB20 
cells, stably expressing mouse (top) and 
FLAG/mouse (bottom) a^y-ARs. Non­
specific binding was determined in the 
presence of lOpM phentolamine. Data are 
the mean (±SEM) of at least three 
experiments performed in duplicate.
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Figure 1.20 Displacement of 0.2/2nM 3H-Prazosin 
binding to mouse (A) and FLAG-tagged (# ) «ly-AR 
subtype membranes, respectively, by increasing 
concentrations of prazosin and QAPB. Non-specific 
binding was determined in the presence of lOpM 
phentolamine. Values are the mean (±SEM) of at least 
three experiments performed in duplicate.
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Figure 1.21 Intracellular calcium respone to lOjxM 
phenylephrine in NCB20 cell stably expressing the FLAG- 
tagged mouse (X|y-AR. Cells were loaded with the 
fluorescent indicator dye Fura-2/AM (IpM) as described in 
the methods text. The peak calcium elevation was 
quantified by the dual wavelength ratio method following 
addition of the indicated concentration of agonist.
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Figure 1.22 (a) Demonstration of the lack of
immunostaining specificity of Anti-Flag ® M5 monoclonal 
antibody in NCB20 cells stably transfected with FLAG- 
tagged mouse a,y-AR (top panel) and non-transfected cells 
(bottom panel). Immunostaining procedures were performed 
as described in Methods, (b) Western blot showing lack of 
specificty of Anti-Flag ® M5 monoclonal antibody to the 
FLAG-tagged mouse 0 C;y-AR. (Lanes 2, 3) FLAG-tagged 
plasma membranes; (Lanes 4, 5) contain non-transfected 
NCB20 plasma membranes; (Lanes 6 , 7) contain non- 
transfected NCB20 cells. The dilution of both Anti-Flag ® 
M5 monoclonal antibody and secondary antibody (Goat anti­
mouse IgG-HRP) was 1:2000. Molecular mass (kDa) is given 
at the left.
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Figure 1.23 Diagram of vector pEGFP-Nl
Figure 1.24 NCB20 cells were transfected with GFP-tagged 
human oc^ y-AR constructs, (a, d) GFP-associated fluorescence 
represents the stable expression of pEGFP/human a^y-AR in 
NCB20 cells, (di) GFP-associated fluorescence alone, (d ii, 
iü) 2nM QAPB binding to the same cell, (b) GFP-associated 
fluorescence represents the transient expression of 
pEGFP/human a^y-AR. (c) GFP-associated fluorescence 
represents the transient expression of pmouseajg-AR /human 
a^y-AR. (e) QAPB binding to NCB20 cells stably expressing 
low levels of pEGFP/human a^y-AR. Non-specific binding 
was defined by IpM prazosin. Cells were plated on 
coverslips and examined by confocal microscopy with 
timelapse photography. Increasing concentrations (0.4-10nM) 
were added cumulatively and images were collected at 1 - 
minute intervals. Images are shown in pseudocolour, where 
black indicates no staining and blue, green, yellow and red 
indicate increasing levels of saturation of the fluorophore.
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Figure 1.25 Specific saturation binding of ^H- 
Prazosin to membranes from NCB20 cells, stably 
expressing human (top) and GFP-tagged (bottom) 
a^y-ARs. Non-specific binding was determined in 
the presence of lOjxM phentolamine. Data are the 
mean (±SEM) of at least three experiments 
performed in duplicate.
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Figure 1.26 Displacement of 0.2nM 3H-Prazosin binding 
to human (A) and GFP-tagged (■) a^y-AR subtype 
membranes, respectively, by increasing concentrations of 
prazosin and QAPB. Non-specific binding was 
determined in the presence of lOpM phentolamine. 
Values are the mean (±SEM) of at least three experiments 
performed in duplicate.
(0 00
ttib-AR construct Kj (nM)
(nM) (fmol/mg) prazosin QAPB A-61603 BMY7378
mouse ttib-AR 0.7±0.16 4467±363.4 0.09±0.1 3.4 ±0.09 3651±0.07 532 ±0.05
human ttjb-AR 0.9±1.67 7781±566.5
0.9±0.17 5501±346.7 0.10 ±0.1 11 ±0.1 2458 ±0.09 499 ±0.07
FLAG/mouse ttjb-AR 2.3±0.83 608.9±94.74 1.83 ±0.08 119 ±0.2-
pEGFP/human «ib-AR 0.6±0.26 203.7±28.19 0.44 ±0.06 75 ±0 .2 -
Table 1 (i) -Prazosin saturation binding parameters in 
membranes from NCB20 cells stably transfected with 
ttib-AR constructs, (ii) Comparison of affinity estimates 
from NCB20 cells stably transfected with «jb-AR 
constructs. Data are means ±SEM of a minimum of 
three experiments.
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Figure 1.27 Intracellular calcium respone to lOpM 
phenylephrine in NCB20 cell stably expressing GFP-tagged 
human «ib-ARs. Cells were loaded with the fluorescent 
indicator dye Fura-2/AM (l.SpM) as described in the 
methods text. Time-dependent changes in [Ca^ ]^j were 
calculated from the ratio of two background subtracted 
images.
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Figure 1.28a Changes in [Ca^ ]^j and GFP intensity in response to 
phenylephrine (lOpM) in NCB20 cells stably expressing GFP- 
tagged human aib-ARs. Cells were loaded with the fluorescent 
indicator dye Fura-2/AM (1.5pM) as described in the methods text. 
Time-dependent changes in [Ca^ ]^. were calculated from the ratio of 
two background subtracted images. Changes in GFP intensity in the 
membrane and intracellular region were also recorded over time. 
The nucleus was labelled with SYTO 13.
IFigure 1.28b Movie showing movement of 
GFP-tagged human a^y-ARs stably expressed 
in NCB20 cells in response to lOpM 
phenylephrine
Figure 1.28c Overall GFP-intensity in the cell prior to agonist stimulation.
l 'ura-2  ( 0  m i n )  I I i ira-2 (I n i in)  I ITira-2 (2  in in )  I ITira-2 (3  n u n )  | M o \  ic ( 0 - 3  n i in )
I lira-2 siuiial (ill* si LI lia I
Purple inside clustci
lOiiv in.-rnia-.iiiL
24 28 32 36 40 ! 12 16 20 24 28 32 3: 
TmF'lvTlLtBSi
Figure 1.28d Measurement of Fura-2 and GFP signals in unstimulated NCB20 
cells stably expressing GFP-tagged humanajy-ARs (0-3 mins).
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Figure 1.28e Combined effects produced during initial 90sec exposure to 
agonist ( 1 OpM Phe).
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Figure 1.28f Combined effects produced during prolonged (35 min) agonist 
exposure (lOpM Phe).
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Chapter 2.
Subcellular distribution, characterisation and modulation of 
ai-ARs in cultured hepatocytes.
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Chapter 2
Introduction
The previous chapter dealt with the use of fluorescence based methods to enable the 
analysis of the subcellular distribution of recombinant aiy-ARs. Initially, a 
fluorescent ligand method was employed to locate ttib-ARs stably expressed in live, 
NCB20 cells. Localisation of receptive sites was validated with the use of GFP- 
tagged aib-ARs. Coupled with calcium imaging, this allowed the study of 
distribution and active properties of these molecules. The methods developed in the 
previous chapter were then used to examine the properties of native receptors on 
isolated hepatocytes.
The rationale behind using hepatocytes was based on their ease of isolation, and 
reports that aie-ARs are the main oti-AR subtype present in murine liver (although 
the possibility that other oci-AR subtypes could be present cannot be ruled out) 
(Garcia-Sainz et al., 1994). Since colonies of mice (Cavalli et al., 1997) were 
available, the liver was therefore of great interest to us from a 
pharmacological/physiological point of view. Our main interest was to assess the 
subcellular distribution of native ai-ARs in isolated hepatocytes and to hypothesise 
as to their functional location.
The possibility of up regulation of another ai-AR subtype to compensate for the 
loss of the ttiB-AR in the knockout model would indicate a lack of subtype-specific 
function of ai-ARs in the liver. In fact, although it has been shown that the genes 
for the three subtypes of oti-AR are expressed in discrete, tissue-specific patterns in 
the same organism (e.g.. Price et al., 1994a), evidence is available suggesting that 
the liver may express distinct ai-AR subtypes in different species (see general
114
introduction). The reason for such variability in the liver is unknown, and reports 
concerning the regulation of the expression of these receptors are limited. However, 
it is clear from such data that there is no ‘tissue-specific’ pattern of expression and 
that data cannot be extrapolated without verification from one species to another. 
Therefore, the characterisation of hepatic adrenoceptors expressed in different 
species is considered of great interest since it may give insight into the 
physiological and evolutionary significance of such variation. Characterisation of 
the « 1-AR subtype(s) expressed in the ais-AR knockout liver will also be of 
interest, as it raises the possibility that ai-AR subtypes may be interchangeable 
within one species. In fact, a recent study by Gonzalez-Espinosa et al. (1999) has 
shown that cell isolation alters oci-AR mRNA expression. A transition from aiA-AR 
to aiD-AR occurs during the isolation procedure of guinea pig hepatocytes 
(Gonzalez -Espinosa et al., 1999).
Since apAR subtype modulation/transition can occur with age (Gurdal et al., 
1995a,b; Xu et al., 1997; Ibarra et al., 1997; Rudner et al., 1999; Yamamoto et al., 
2 0 0 1 ), it seems plausible that a similar situation could occur in the liver.
Although there have been no reports of the ontogenic transition between oti-AR 
subtypes in the liver, studies beginning in the early 80's, have reported ontogenic 
modulation (McMillan et al., 1983) as discussed in the general introduction.
Another interesting feature regarding hepatic apARs is the existence of sites with 
low affinity for prazosin. The human liver has been shown to predominantly 
contain mRNA for Œia-AR, although that for the aiB-AR subtype has been detected 
(Weinburg et al., 1994; Price et al., 1994b). With reference to the splice variant aiA- 
1 , found in human liver (Chang et al., 1998), it is interesting to note that when these
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isoforms are expressed in cell lines and IP3 accumulation measured, they display 
ociL-AR pharmacology (Ford et al., 1997; Chang et al., 1998).
Shibita et al. (1995) have detected low and high affinity sites for the « ia-AR using 
selective ligands KMD-3213 and 5-MU in human liver membranes. This low 
affinity population of ai-ARs corresponds to the aiL-AR, with an abundance of 40- 
46% of the total oci-AR population.
Another interesting observation made by Ohmura and Muramatsu, is the existence 
of 2 distinct (Xi-AR subtypes in rabbit liver membranes. Using rat liver as a control, 
because exclusive expression of ttie-AR subtype was demonstrated, they found that 
-prazosin bound to two distinct affinity sites. Competition experiments with a 
series of antagonists indicated pharmacological characteristics of high and low 
prazosin sites suggesting their identity as ttiA and aiL-subtypes respectively 
(Ohmura and Muramatsu, 1995).
Most mRNA distribution studies in the rat have detected only ttiB-AR mRNA in the 
liver, with no detection of an aiA-AR signal (Lomasney et al., 1991; Price et al., 
1994a; Rokosh et al., 1994). However, Scotfield et al. (1995), using RT-PCR, 
detected a minor component of the Œia-AR in rat liver. Other pharmacological 
studies of liver plasma membranes from rodents, namely rat and hamster have 
suggested an essentially homogeneous population of ai-ARs of the « ib-AR subtype 
(Garcia-Sainz et al., 1994). However, an exception to this was observed in 
competition binding curves with prazosin using mice liver membranes. Analysis of 
these data indicated that the competition curve with prazosin in mice liver 
membranes was best fitted to a two-site model (Garcia-Sainz et al., 1994).
Reports thus far have indicated that although one subtype predominates in the livers 
of various species, it is apparent that sites exist that have a low affinity for prazosin.
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There is however no indication as to a functional role for these receptors or ‘affinity 
state’ as yet.
To identify and characterise tti-ARs present in liver of diverse species, several 
approaches have been employed; mRNA analysis, radioligand binding in plasma 
membranes and functional studies using whole cells. However, these approaches do 
not complement each other as detection of mRNA for an (Xi-AR subtype, does not 
necessarily signify the expression of receptor protein, nor that it mediates a specific 
action. An example of this is seen in the carcinoma cell line, HepG2. Northern 
analysis indicated the presence of both aiD-AR and aie-AR mRNA, yet this cell 
line lacked ai-ARs in radioligand binding assays (Kost et al., 1992). Furthermore, 
the ai-AR subtype expressed in the guinea pig liver has been especially difficult to 
characterise. Pharmacological and radioligand binding analysis of guinea pig 
hepatocytes indicated the presence of aiA-ARs (Garcia-Sainz et al., 1992a,b, 
1995a). However, Northern analysis revealed a hybridisation signal with the am  but 
not with the aiA-AR probe (Garcfa-Sainz et al., 1992b). It has since been observed 
that during isolation of guinea pig hepatocytes with collagenase, degradation of 
ttiA-AR mRNA occurs with a concomitant increase in the transcription of the am- 
AR gene (Gonzalez -Espinosa et al., 1999).
It is well documented that adrenoceptor mechanisms in the liver display a unique 
form of plasticity. In the male adult rat liver, the best studied hepatic model, 
adrenoceptors of the a% and p2 subtypes are present, but functionally ai-ARs 
mediate the adrenergic effects almost exclusively (Exton et al., 1980). The same 
effect, however, is mediated by a predominantly p-adrenergic mechanism in the 
liver of the foetus (Sherline et al., 1974). This transition is a logical adaption to the 
development of sympathetic innervation, as there is an increased switch from
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circulating AD from the adrenal medulla to NA derived from sympathetic nerves 
(McMillian et al., 1983). This changeover is metabolically appropriate to the 
substitution of milk for a mature diet that is carbohydrate rich. The consequent 
climb in glycogen stores requires the substitution of gluconeogenesis (closely 
linked to P-adrenergic function) for glycogenolysis (tti-AR dependent) as the 
source for mobilization of glucose (McMillian et al., 1983; Huff et al., 1991; 
Morgan et al., 1983). This maturational change in adrenergic-mediated glycogen 
phosphorylase activation from P2 - to predominantly ai-adrenergic control is related 
to concomitant changes in the respective receptor densities (Bendeck and Noguchi, 
1985).
The aiB-AR mediates the acute metabolic effects of catecholamines in the liver and 
is also involved as a comitogen in the regenerative response after loss or injury of 
liver tissue (Cruise et al., 1985 and 1987; Kunos et al., 1987 and 1995).
Expression of the a^-A R  gene in the rat liver is controlled by hormonal and 
developmental factors in a tissue-specific manner as exemplified in 
hypothyroidism, which increases the level of ociB-AR mRNA in the rat heart but 
decreases it in the rat liver (Lazar-Wesley et al., 1991). In primary cultures of rat 
hepatocytes, high cell density prevents the decline in a^-A R  expression observed 
at low cell densities (Kajiyama and Ui, 1994) whereas in primary cultures of 
myocardiocytes, increasing cell density decreases Qib-AR expression (Bishopric et 
al., 1991).
Several other reports exist in the literature showing changes in « ib-AR expression 
due to conditions that are associated with hepatocyte dedifferentiation (Bevilacqua 
et al., 1991; Kost et al., 1992; Kunos et al., 1987, 1995; Rossby et al., 1991). Such 
regulation has been shown to occur at the transcriptional level under many of these
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conditions, such as after partial hepatectomy (Kunos et al., 1995), during primary 
culturing of hepatocytes (Ishac et al., 1992), and in response to glucocorticoids 
(Sakaue et al., 1991), cyclohexamide (Hu et al., 1993), phorbol esters (Hu et al., 
1993), thyrotropin, and cAMP (Kanasaki et al., 1994).
As mentioned above, in vitro incubation of hepatocytes acutely isolated from adult 
male rats leads to a rapid conversion of the adrenergic activation of glycogenoylsis 
from an ai-AR to a P2 -AR mediated response within 4 hours. Incubation of 
hepatocytes for 4hours results in a decrease in phosphorylase activation and IP3 
accumualtion in response to phenylephrine, a 40% decrease in ai-AR density, and a 
70% decrease in aie-AR mRNA levels. This is accompanied by an emergence of a 
phosphorylase response to isoproterenol, no significant change in P2-AR density, 
and a twofold increase in P2 -AR mRNA levels (Ishac et al., 1992). Evidence 
suggests that this conversion is related to changes in the expression of the 
respective genes (Lazar-Wesley et al., 1991; Ishac et al., 1992), although it is clear 
that additional mechanisms, such as selective changes in the coupling of these 
receptors to their respective G-proteins (Kunos et al., 1987; Itoh et al., 1984), or 
changes in G-protein expression (Rapeijko et al., 1989), are also involved. It is 
interesting that this switch is prevented when cell-cell contacts through plasma 
membranes are favoured during culture by increasing the cell density (Kajiyama 
and Ui, 1994). Such cell-cell interactions were reported to be an important factor in 
inhibition of cell growth, in favour of cell differentiation or expression of liver- 
specific characteristics (Nakamura et al., 1983, 1984).
The inverse regulation of am-AR and P2 -AR has been observed in a number of 
different physiological and pathological conditions (Aggerbeck et al., 1983; Chan et 
al., 1979; Preiksaitis et al., 1982; Garcia-Sâinz et al., 1986; Christoffersen and
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Berg, 1975; Blair et al., 1979; Itoh et al., 1984; Kunos et al., 1984; Nakamura et al., 
1984; Schwartz et al., 1985; Sandes et al., 1986). Reports have shown remarkable 
similarity of the altered response pattern under these various conditions, suggesting 
that it represents a unique form of receptor regulation. Furthermore, there is a close 
parallel between the conversion of the AR response and a shift from liver-specific 
to growth-related functions suggesting a role in the process of liver cell growth and 
differentiation. Whereas the activation of glycogenolysis by ocis-AR or p2-AR is a 
unidirectional response, this is not the case for effects on liver cell proliferation. 
(XiB-ARs are mitogenic, increase DNA synthesis, and their inhibition can prevent 
liver regeneration after partial hepatectomy (Michalopoulos, 1990). In contrast, in 
proliferating liver cells stimulation of P2-ARS strongly inhibits the Gl-S phase 
transition (Refsnes et al., 1992), and thus may be involved in the termination of the 
proliferative process. This, and the reported shift from ai-AR to P2 -AR in human 
hepatocellular carcinoma (Bevilacqua et al., 1991), could suggest that this form of 
regulation is important in terminating hepatocyte proliferation in order to prevent 
potential progression into malignant transformation (Kunos et al., 1995).
The work in this chapter shows preliminary studies of the subcellular distribution, 
characterisation, and modulation of ai-ARs during culture of hepatocytes isolated 
from wildtype and a^-A R  knockout liver. Firstly, basic binding properties and 
general distribution of ai-ARs was assessed using fluorescent ligand binding. Since 
reports in the literature state that ontogenic modulation of ai-ARs occur, studies 
were carried out in both strains at a specified age. Further caution was taken when 
interpreting this data as reports maintain that rapid changes in (Xi-AR density occur 
during culture of acutely isolated cells (Ishac et al., 1992). Animals were initially 
sacrificed at 4months then due to availability and time constraints; work began on
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3month-old animals. Comparisons of specific QAPB binding in hepatocytes from 
both strains at both ages were subsequently carried out.
Since culturing of hepatocytes has been reported to modulate ai-ARs, I therefore 
began some preliminary work looking at changes in cci-AR density after 4, 24 and 
48 hours in culture.
Confirmation that these receptors correspond to the binding sites for QAPB and 
display ai-AR pharmacology was established. Thereafter characterisation of oci-AR 
subtype(s) expressed was assessed by quantitative competition versus the 
development of fluorescence employing the discriminatory antagonists BMY-7378 
and RS100329. Such experiments allowed me to determine whether a 
compensatory up-regulation of one of the other ai-AR subtypes had been 
established in the knockout. The possibility of re-introducing the aib-AR into 
knockout cells and restoring ‘normal’ pharmacological function was also 
considered.
Little is known about the functional location of ai-AR subtypes seen in native 
systems, especially in hepatocytes. Our main aim was therefore to uncover the 
functional location of native ai-ARs in hepatocytes. Although the specificity of 
QAPB binding to recombinant ocib-ARs was confirmed in chapter 1, it was also 
necessary to validate the location of the fluorescent ligand with that of the native 
receptor. A GFP-tagged aib-AR construct designed to mimic the expression and 
localisation of the native receptor would therefore prove invaluable. Coincidentally, 
at this time, cloning of the promoter from the mouse ttie-AR gene came to fruition 
in Dianne Perez's laboratory, and confirmation of its fidelity and tissue-specific 
expression (Zuscik et al., 1999) paved the way forward using GFP as a valuable 
reporter tool. A promoter-reporter construct was designed (Perez) and thereafter
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employed to locate the «ib-AR in its native environment. The competency of any 
given cell/tissue to activate transcription of the «ib-AR gene and hence express the 
GFP-tagged receptor allowed us scope to visualise expression and location at a 
subcellular level. It was anticipated that such studies would indicate a possible cell- 
specific functional location of the aie-AR.
A recent finding has indicated a role for the multifunctional protein, gClq-R, in the 
regulation of subcellular distribution and expression of Œ ib -A R s (Xu et al., 1999; 
Hirasawa et al., 2001). gClq-R was found to bind with the carboxyl-terminal 
cytoplasmic domain of the aiB-AR in a yeast two-hybrid screen of a cDNA library 
prepared from rat liver. The interaction was confirmed by specific co- 
immunoprecipitation of gClq-R with full-length (Xib-ARs expressed in transfected 
COS-7 cells. Using tagged-constructs and fluorescence confocal microscopy co­
localisation of these proteins in intact cells was also visualised. Interestingly, the 
aib-ARs were exclusively localised to the region of the plasma membrane in COS- 
7 cells that expressed the ttib-AR alone, whereas gClq-R was localised in the 
cytoplasm in COS-7 cells that expressed gClq-R alone; however, in cells that co­
expressed aib-ARs and gClq-R, most of the aib-ARs were co-localised with gClq- 
R in the intracellular region, and a remarkable down-regulation of receptor 
expression was observed (Xu et al., 1999). Further work by this group has revealed 
that this protein appears to regulate the expression level and cellular localisation of 
the ociB-AR through its carboxyl terminal. These data strongly suggest that gClq-R 
plays a regulatory role in the function of the « ib -A R . However, since species 
heterogeneity exists in hepatic ai-AR expression, the specificity of gCl-qR must be 
questioned.
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Chapter 2
Methods
Hepatocyte isolation and culture
The time between sacrifice of the animal and isolation of hepatocytes did not exceed 
1 hour, during which the liver was maintained at 37°C under sterile conditions. 
Mouse hepatocytes were isolated by a non-perfusion procedure performed without 
vascular access by multiple injections into the hepatic parenchyma (Adapted from 
David et al., 1998). The liver portion was placed in a sterile universal containing 
Hepatocyte Perfusion Media (Life technologies, Inc) and incubated for -Ihour at 
37°C in a water bath. This same buffer was then injected using a 10ml syringe via an 
18G needle into all areas of the piece of liver until the tissue softened and a cell 
suspension was released. The flow rate was approximately lOml/min. The solution 
was not re-circulated. The cell suspension was centrifuged at 50g for 1 minute at 
room temperature. The cell pellet was then washed twice with Hepatocyte 
Attachment Media (Life technologies, Inc) at 50g for 1 minute to isolate hepatocytes 
from other cell types. Cell viabilty was determined by trypan blue exclusion (0.04% 
final concentration in protein-free medium). The cell pellet was finally resuspended 
in a minimal volume of Attachment Media and cells were allowed to attach to glass 
cover slips. After this attachment period, the medium was removed and replaced with 
HepatoZYME-SFM (Life technologies, Inc). Cultures were maintained at 37°C in a 
humidified atmosphere (95% air, 5% CO2 ). Cells were analysed at 4, 24, and 48 
hours post isolation.
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Transient transfection o f primary hepatocytes
Hepatocytes were isolated, plated and cultured overnight prior to transfection, 5pg of 
plasmid DNA per well was complexed with 15pg DOTAP transfection reagent 
(Boehringer, Mannheim), diluted to a volume of 250pl with culture medium, and 
allowed to sit for 15 minutes at room temperature. A further 2mls of culture medium 
was added to the complex, gently mixed, added drop-wise to the cells in culture 
which were then incubated for 36 hours from the start of the transfection to allow for 
expression of the plasmid.
Confocal Microscopy
Identical parameters (brightness, contrast, laser intensity, excitation and emission 
wavelengths, slit size and frame averaging) were set in every experiment, unless 
stated otherwise. The objective used throughout this chapter was a Nikon x40, oil. 
Whole cell imase analysis
Images were collected and analysed using Universal Imaging's 'Metamorph' 
software. Cells were grown on cover slips for 4, 24, and 48 hours prior to use, as 
indicated. Cover slips were mounted in a flow chamber (WPI) and placed on the 
stage of an invert (Nikon Diaphot) microscope fitted with a Noran Odyssey Laser 
Scanning Confocal Module. Fluorophores were excited using a 488 nm argon laser 
and detected with a 515 nm band pass filter. In all experiments, a 15pm slit was used 
and all other parameters were kept constant.
QAPB
Using cell autofluorescence as an indication, a suitable group of cells was selected 
and the focal plane fixed by locking the focus motor. The system was then set to
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acquire images (64 frame averages; 2.56-s exposure) at 1-min intervals, unless stated 
otherwise) at 1 minute intervals. After a baseline was established, typically 5-6 
minutes, the first concentration of fluorescent ligand was added and allowed to 
equilibrate (i.e., until no further increase in fluorescence) for at least 5minutes. After 
equilibration the next concentration of fluorescent ligand was added, without 
washing, and given time to equilibrate as before. Once saturation has been reached 
the individual cells were outlined using Metamorph's define-region tool and the 
fluorescent intensity values representative of each concentration at equilibrium were 
recorded. Non-specific binding was defined as fluorescent binding in the presence of 
lOpM prazosin. The composition of the Hepes buffer used in all single cell work was 
as follows: NaCl 130mM, KCl 5mM, HEPES 20mM, Glucose lOmM, MgCl ImM, 
CaCl ImM.
Inhibition of QAPB-associated fluorescence bindins
Cells were mounted on a flow chamber bath and experiments carried out in a similar 
manner to that described above. Hepatocytes were pre-incubated for 30 minutes with 
inhibitors, BMY-7378 or RS 100329 (Dr, Michelson, Roche Bioscience, Palo Alto, 
CA) prior to addition of QAPB. Characterisation of tti-AR subtypes expressed was 
estimated as a measure of the ability of either drug to inhibit the development of 
QAPB-associated fluorescence.
GFP detection
Using GFP-associated fluorescence, suitable cells were chosen and images acquired. 
Non-transfected cells were cultured alongside as a comparison.
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ArrayScan analysis
Hepatocytes were isolated from 3 and 4month-old wildtype and knockout mice, 
plated onto Grenier 96 well clear view plates and cultured overnight at 37°C. 
Approximately 24hours post-isolation, cells were incubated with the appropriate 
inhibitory antagonist for 30minutes prior to loading with 5nM QAPB and lOpg/ml 
Hoechst 33342 (bisBenzamide).
After a further Ihour at 37°C, images of cells were acquired using the ArrayScan™ 
HCS system. Images were converted to the appropriate format and thereafter; 
average fluorescent intensity values were measured using Metamorph Imaging 
software.
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Chapter 2
Introduction to results
My initial objective was to transfect labelled ttib-ARs into native cells in order to 
visualise the natural population enabling study of their distribution, co-localisation 
with QAPB and transposition in response to stimuli. It was also anticipated that 
comparisons would be made between the distributions of the aib-AR populations 
under the control of a viral versus mouse aiB-AR-specific promoter. The liver was 
chosen because it is reported to express only Œib-ARs, for which much knowledge is 
available at a molecular level. The objective in using aiB-AR knockout mice was to 
produce a situation where only the labelled receptors were present.
This primary objective was frustrated for the unforeseen technical reason that 
primary cultures of hepatocytes acquire a strong green autofluorescence when 
cultured for the several days required for transfection studies.
An alternative study was to focus on existing populations of native ai-ARs in 
wildtype and knockout cells, and attempt to identify and characterise them using a 
combination of QAPB and subtype-selective antagonists.
Prior to this work, a colleague had carried out ^H-prazosin binding studies on mouse 
liver plasma membranes, to confirm previous findings regarding the expression of 
the ttiB-AR in both wildtype and knockout tissue (Cavalli et al., 1997; Yang et al., 
1998). From previous reports, it was anticipated that the knockout liver would not 
possess an ai-AR population. Cavalli et al. (1997) reported a 98% decrease in ai-AR 
density in the knockout liver when compared to the wildtype. In contrast, my 
colleague discovered only a 40% decrease in ai-AR density in knockout liver tissue. 
The population of oti-ARs found in the wildtype liver was 50fmol/mg, identical to 
that of Yang et al. (1998). However, Cavalli et al. (1997) found only 20 fmol/mg of
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tti-AR protein in the wildtype liver. This discrepancy may explain the lack of tti- 
ARs seen in the knockout by this group. Our data revealed that the ai-AR density 
remained as high as 30fmol/mg in the knockout. The calculated Kd values in both 
strains were similar, and comparable to those of Cavalli et al. (1997) and Yang et al. 
(1998). Basing our expectations on the literature, to find a population of ai-ARs, 
replacing the aie-AR subtype, was exciting.
The binding data from wildtype and knockout liver revealed a pure population of 
aiB-ARs in the wildtype, as expected, and a pure population of ociA-ARs in the 
knockout (C.Deighan, PhD thesis). All radioligand binding studies up to this point 
were carried out using 4month-old mice. Surprisingly, preliminary experiments 
carried out in 3month-old animals revealed only 8 fmol/mg of ai-AR protein in the 
knockout, yet 76fmol/mg in the wildtype. Although the Kd values remained 
unaltered in the wildtype, a 1 0 -fold difference was noted in the knockout, with the 
affinity increasing from 1.0 (3months) to 0.1 nM (4months). These results suggested 
to us that the compensatory up-regulation of the Œia-AR must occur at some stage 
between 3 and 4months in the development of the mouse. The possibility of an age- 
dependent pattern of subtype expression was likely.
These outcomes thereafter dictated new objectives that had to be set at the single cell 
level. Initially, analysis of QAPB binding to tti-ARs at a cellular level was assessed 
using isolated hepatocytes. The next objective was to assess whether subtypes could 
be identified at this level and whether the following questions could be answered. Do 
the aiB-ARs (wildtype) and aiA-ARs (knockout), as indicated by the ^H-prazosin 
binding, have the same or different subcellular distribution?
The next stage was to consider the above issues at different ages, given the indication 
from the ^H-prazosin binding that the knockout liver differs at 3 and 4months.
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In addition, several factors had to be considered arising from the practicability of 
performing fluorescent binding on primary hepatocytes.
One of the issues that had to be considered was the time of pre-culture before 
carrying out the QAPB binding studies. A period of at least a few hours was 
necessary for the cells to 'stick down' and equilibrate in the their new environment. It 
is well documented in the literature that culturing of hepatocytes changes the 
expression and functionality of oci-ARs. Therefore, since our objective was to 
understand the natural disposition of these receptors, prolonged incubation might 
lead to de-differentiation with consequent changes in distribution, function and 
eventually, changes in expression of receptor subtypes. A recent finding has shown 
that oti-AR subtype transition occurs during the isolation of guinea pig hepatocytes 
(Gonzalez -Espinosa et al., 1999). This opens up another possibility for alterations in 
subtype expression with this procedure. These issues were considered.
Other factors, not considered to represent a natural environment for hepatocytes, 
based on studies in the literature, were the ingredients of the culture media (see 
chapter 2 discussion). For example, the presence of nicotinamide, which is converted 
to endogenous fluorophores: NAD/NADP would probably contribute to the 
autofluorescence observed after several days in culture. However, all of these factors 
remained constant throughout so that direct comparisons could be made where 
applicable.
As for the functionality of oci-ARs in cultured hepatocytes, it is well documented that 
within 4hours post-isolation, there is a switch from an ai- to (3-AR response and that 
reported changes in functionality do not necessarily reflect a corresponding change in 
receptor density (Kunos et al., 1995). Attempts were made to assess the functionality 
of ai-ARs in hepatocytes. Unfortunately due to technical limitations with this cell
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type, in their ability to withstand the flow system and remain attached to the cover 
slip during the experiment, this was not possible.
Another important experimental issue was how to identify ai-AR subtypes on/within 
these cells. Several factors made the 'before and after' effect of antagonists on QAPB 
binding impractical. Due to photolytic 'fade' and prolonged protocols including a 
long wash phase, it was deemed impractical to carry out more than a single binding 
curve on each cell. In practice, this meant identifying suitably healthy cells by a 
combination of low autofluorescence and their bright field appearance, then applying 
sequentially increasing concentrations of ligand, capturing images at one minute 
intervals, and acquiring equilibrium data for each concentration of ligand applied. 
The difficulty that presented itself was the variability in the amount of fluorescence 
produced in each cell at the highest concentration of ligand used. This made it 
impossible to normalise the data to any 'control' level or to make a quantitative 
assessment of 'specific' binding. Essentially, a judgement had to be made for each 
cell: The 'maximum' fluorescence of the experimental cell at a specified 
concentration, relative to other cells under identical conditions. Also the resulting 
'range' of binding levels under these conditions had to be compared with other data 
sets, the objective being to assess the 'amount of receptors'. Saturation binding curves 
of individual cells were constructed where applicable, and the fluorescence 
dissociation constant, FKd was used as a general indicator of whether QAPB binding 
was to oci-ARs. A criterion had to be applied in order to accept or reject binding 
according to whether it fell into the first line definition of ai-ARs (that they had a 
high affinity for prazosin, or, in this case, a high affinity for QAPB). However, it
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became evident that QAPB also bound to prazosin-sensitive sites, at concentrations 
higher than normally associated with 'typical' ai-AR pharmacology.
Lastly, a judgement had to be made for each cell in the presence of subtype-selective 
antagonists in an attempt to identify the receptor subtypes. The variation in ai-AR 
expression between individual cells was so high, difficulties arose when trying to 
establish inhibition of QAPB-associated fluorescence in the presence of antagonists. 
Taken together, the data produced two general types of complication. Variability in 
the 'amount' of maximum binding within a given situation, and secondly, variability 
in the estimate of affinity by a larger degree than expected. QAPB appeared to bind 
to 'high' and 'low' affinity populations in this cell type. In some cases, the rise and fall 
of fluorescence intensity levels during increasing concentrations of QAPB gave rise 
to saturating and non-saturating sites within the concentration range used, suggesting 
that the 'low' affinity sites might have been considered 'non-specific'. However they 
were in fact sensitive to cold prazosin and thus 'specific' in this sense.
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Chapter 2 
Results
Fluorescent ligand binding on hepatocytes isolated from livers o f 3month-old 
knockout mice, cultured for ~4hours.
QAPB binding to hepatocytes isolated from 3month-old knockout mice showed that 
cells could express either high or low affinity populations of cti-AR. Some cells 
expressed low, some high and others both populations (figure 2.1a). QAPB- 
associated fluorescence binding to high affinity (FKd l.OOnM-cell 1, O.lOnM-cell 2), 
low density (0.12 and 0.03 (fluorescence intensity), respectively) populations was 
saturable (figure 2.1b) and completely abolished in the presence of l|xM prazosin 
(figure 2.1a, bottom panel). Binding to low affinity sites was non-saturable within the 
concentration range (0.4-20nM QAPB). However, the programme used to quantify 
these data, GraphPad Prism, gave estimated values where applicable. FKd values of 
21.80nM (cell 5) and 29.22nM (cell 6 ) were estimated for these populations of 
receptors. In the presence of prazosin, the residual fluorescence seen at 20nM QAPB 
represented non-specific binding, but only in the cell in question. It did not prove 
practical to carry out two binding curves on one cell making it impossible to define 
the non-specific component in individual cells. Since the ai-AR complement of 
hepatocytes was so varied, it was not possible to quantify non-specific binding per 
se. However, since so little fluorescence was found in cells incubated with QAPB in 
the presence of prazosin (IpM) (figure 2. le), it was assumed that at this age, under 
these culture conditions, QAPB binding was specific below 20nM. The overall 
density of ai-ARs between individual cells varied considerably, emphasising the 
quantitative heterogeneity of ai-AR expression in this cell type.
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The distribution of QAPB binding was diffuse throughout the cytoplasm of all cells, 
although 'holes' were present suggesting organelles that did not contain receptors or 
were impermeant to the ligand. In fact, a report in the literature describes the 
appearance of vacuoles that arise from cellular reorganisation as hepatocytes become 
active in lipid glyconeogenesis (May et al., 1982).
Comparison o f fluorescent ligand binding on hepatocytes isolated from livers o f 
3month-old wildtype and knockout mice, cultured for ~4hours.
QAPB bound to different cells in a manner indicating either high or low affinity sites 
both in wildtype and knockout hepatocytes isolated from 3month-old mice. The 
overall density of ai-ARs within these populations was much greater in cells isolated 
from the wildtype animal. It was observed in both wildtype and knockout cells, at 
3months, that the ai-AR populations with low affinity for QAPB did not saturate at 
concentrations up to 20nM (figure 2.2).
Comparison between hepatocytes isolated from livers o f 3 or 4month-old knockout 
mice, cultured for ~4hours.
The pattern of QAPB binding in the knockout at 4months differed from that seen at 3 
months, in that the population of non-saturating, low affinity sites seen in younger 
animals became more apparent allowing a more straightforward quantification of 
these sites (figure 2.3). Estimations of ligand affinities and receptor densities were 
made, as indicated in the table (figure 2.3d).
133
Comparison o f hepatocytes from wildtype mice at 3 and 4 months (cultured for  
~4hours).
The fluorescent binding to individual hepatocytes isolated from 4month-old wildtype 
liver was very variable and created difficulty when trying to draw comparisons with 
cells from the 3month-old animal (figure 2.4). However, quantification revealed that 
specific binding of QAPB at low concentrations was higher in cells from the 4month- 
old animal. The appearance of QAPB binding to high and low affinity populations 
was evident at both ages, as also seen in the knockout.
Comparison of hepatocytes from 4month-old wildtype and knockout mice (cultured 
for 4 hours or 24 hours).
QAPB binding on hepatocytes isolated from 4month-old wildtype and knockout 
mice was variable for reasons mentioned above, although no obvious differences 
were apparent between the strains (figure 2.9). After 24 hours in culture, the overall 
increase in receptor density allowed the visualisation of two separate populations of 
oci-ARs more readily (figure 2.9). Quantification of the density and affinity of high 
or low affinity ai-AR populations seen in individual cells was possible in some 
cases, but not all. Therefore, to draw conclusions from comparisons made between 
the 2 strains at this age was not feasible. General conclusions about the nature of 
QAPB binding to either wildtype or knockout hepatocytes at 4months could not be 
made until a more substantial study was carried out to account for the extensive 
heterogeneity seen in this native cell type.
Effect of varvin2 the duration of pre-culture for ~4. 24 or 48 hours on hepatocytes 
from 4month-old wildtype mice
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Hepatocytes demonstrating high affinity binding showed a greater amount of specific 
binding of QAPB when cultured for 24 compared with 4hours (2,20 and 0.24 
(fluorescence intensity) respectively). The fluorescent affinity for QAPB binding to 
high affinity ai-ARs did not alter significantly during this time period (0.37and 
0.3 InM respectively). The density of low affinity populations of «i-ARs also 
increased over time in culture. However this was likely to be accompanied by a 
proportional increase in non-specific binding at higher concentrations of QAPB. The 
pattern of QAPB binding to low affinity sites, after each time point, was very similar, 
suggesting that there is no change in the affinity of QAPB binding to «i-ARs after 
culturing of hepatocytes.
Effects on fluorescent ligand binding o f pre-culturing hepatocytes from 3month-old 
knockout mice for different times.
Cells cultured for 24 or 48hours, and showing a high affinity for QAPB, showed an 
increase in the amount of specific binding compared with that seen at 4hours (2.79, 
7.58, and 0.12/0.03 (fluorescence intensity), respectively). The fluorescence binding 
affinity for QAPB on cells cultured for different time periods did not alter 
significantly (figure 2 .6 b).
A similar situation was observed in a population of cells expressing low affinity sites 
(figure 2.6c): the density of «i-ARs also increased over time in culture, but this was 
difficult to quantify since a high degree of binding in cells pre-incubated with 
prazosin, suggested a proportional increase in non-specific binding of QAPB at the 
high concentration range necessary. At this age, and at each culture time, these low 
affinity sites remained non-saturable within the concentration range.
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The pattern of QAPB binding to both populations of ai-AR after each time point was 
very similar, showing an overall increase in (Xi-AR density, with no obvious changes 
in affinity. Again, quantification of the non-specific component in each experimental 
cell was not possible, and estimates were made.
Effects on fluorescent ligand binding o f pre-culturing hepatocytes from 4month-old 
knockout mice for different times.
The effects of extending the pre-incubation period on the pattern of QAPB binding to 
hepatocytes isolated from 4 month-old mice, were similar to those at 3 months. 
Overall, culturing hepatocytes for between 4 and 24 hours caused an increase in the 
density of oci-ARs (figure 2.8b), although direct comparisons could not be made in 
individual cells. Estimates of ligand affinity values were also variable at each time 
point.
Culturing for 24 hours did however have the advantage of emphasising the difference 
in QAPB binding to ai-AR populations at 3 and 4months (figure 2.7). In 3month-old 
animals, after 24hours in culture, it was not possible to quantify the low affinity sites 
within the concentration range used. A population of 'lower' affinity sites did 
however appear in cells from the older animals, which were easily quantified. This 
observation was made after both 4 (figure 2.3d) and 24 (figure 2.7b) hours in culture.
Identification o f native aj-AR subtype(s) on cultured hepatocytes isolated from 3 and 
4month-old knockout mice by inhibition o f QAPB-associated fluorescence. 
Hepatocytes isolated from 3 and 4month-old knockout mice bound QAPB in a 
concentration dependent manner (figures 2.1 and 2.3). Cultured (~4hours) 
hepatocytes (3month-old) were pre-incubated with InM RS 100329 or BMY-7378.
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On addition of cumulative concentrations of QAPB, the appearance of fluorescence 
was significantly inhibited in the presence of RS 100329 yet unaffected by BMY- 
7378 (figure 2.11). Similarly, in cells from a 4month-old knockout mouse, pre­
incubation with InM RS 100329 resulted in complete blockade of QAPB-associated 
fluorescence up to 5nM QAPB but was unaffected by BMY-7378 (figure 2.13c). 
These data suggest that in hepatocytes isolated from the aiB-AR knockout mouse, 
the oci-AR subtype expressed is predominantly Qia-AR. The presence of aio-ARs 
could not be completely ruled out since they may have been masked by the 
fluorescence from Œia-AR, but there was no evidence to support its presence.
Identification o f native CCj-AR subtype(s) on cultured hepatocytes from 4month-old 
wildtype mice by inhibition o f QAPB-associated fluorescence.
Hepatocytes isolated from 4month-old wildtype mice bound QAPB in a 
concentration-dependent manner. Cultured (4 or 24hours) hepatocytes were pre- 
incubated for 30minutes with InM RS 100329 or BMY-7378. On addition of 
cumulative concentrations of QAPB, either RS 100329 or BMY-7378 reduced, but 
did not completely block the appearance of fluorescence (figure 2.12c). This was 
analysed at 5nM QAPB. Comparison of wildtype and knockout hepatocytes (figure 
2.13c) demonstrated that BMY-7378 had minimal effect and that RS 100329 reduced 
specific binding of QAPB to wildtype hepatocytes, but abolished it in the knockout. 
Collectively, these results suggest that the ai-AR subtype expressed in wildtype 
hepatocytes has an cciB-AR component (sensitive to prazosin, resistant to RS 100329 
and BMY-7378) while the RS 100329-sensitive component suggests that some cells 
express the aiA-AR subtype. In the knockout mouse at 4months-old, the binding of 
QAPB (abolished by RS 100329) is exclusively to the Qia-AR. Pre-culturing cells for
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a longer period increases the amount of receptors expressed but no obvious changes 
in subtype expression were observed.
ArrayScan analysis to provide quantitative data.
Hepatocytes were isolated from 3 and 4month-old wildtype and knockout mice and 
cultured overnight prior to analysis. The following day, cells were incubated for 
30minutes with the appropriate subtype-selective antagonist prior to oci-AR detection 
using 5nM QAPB. After a further Ihour QAPB equilibration period, images were 
captured of control cells (5nM QAPB only) and those in the presence of either BMY- 
7378 or RS 100329 (InM). After images were collected, they were converted to the 
appropriate format and average fluorescence intensity values were measured using 
Universal Imaging's 'Metamorph' software.
After 24hours in culture, oci-AR density was at a level suitable to carry out 
comparative inhibition experiments. In the presence of either RS 100329 or BMY- 
7378, a statistically significant decrease in the average fluorescence intensity was 
observed in both wildtype or knockout cells at both ages (figures 2.14b, and c). In 
addition, a statistically significant increase in oti-AR density was observed in 
knockout cells between 3 and 4months, the opposite of which was observed in 
wildtype cells (figure 2.14a). Interestingly, the lower ai-AR density seen in the 
3month knockout compared to the wildtype at the same age, appeared to balance out 
by the time the animal reached 4months, as the average fluorescence intensity values 
in both strains were similar (figure 2.14a).
Transient transfection o f knockout hepatocytes with GFP-tagged ajb-AR constructs.
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Hepatocytes were isolated from knockout liver and cultured overnight prior to 
transfection. The following day, cells were transiently transfected with the following 
aib-AR constructs: pEGFP/human aib-AR or pmouseociB-AR/human aib-AR-GFP. 
After a further 72 hours in culture to allow for expression of the plasmids, GFP- 
associated fluoresence was compared to that of non-transfected control cells. 
Unfortunately expression of the GFP-tagged constructs could not be distinguished 
from autofluorescence created by extensive culturing of the hepatocytes (figure 
2.15).
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Discussion
The aim of the work in this chapter was to identify, localise and characterise oci-ARs 
expressed in hepatocytes isolated from wildtype and aiB-knockout liver. Several 
technical limitations arose however, as discussed in the 'introduction to results' 
section, although a general picture was eventually established, complementing the 
radioligand binding studies done in the intact liver. In addition, some interesting 
observations were made, regarding the plasticity of oci-ARs in cultured hepatocytes. 
The ability to draw general conclusions about the nature of QAPB binding to 
hepatocytes was problematic from confocal analysis alone. A more substantial study 
was carried out using the ArrayScan™ system, from which an overall picture was 
formed. Due to low tti-AR density post-isolation, it was necessary to culture cells for 
24hours to allow for inhibition of QAPB-associated fluorescence studies to be 
carried out. Since the aim of this study was to understand the natural disposition of 
oci-ARs in hepatocytes, this prolonged culture period was not ideal, but nonetheless 
unavoidable.
Comparison of the radioligand binding versus ArrayScan data indicated that 
prolonged culture had altered the expression of the cti-AR subtypes. After 24hours in 
culture, inhibition studies revealed that both wildtype and knockout cells, at 3 and 
4months, expressed «ia- and «id-ARs (figures 2.14b and 2.14c). This was in sharp 
contrast to studies done on intact liver where a pure population of aiB- and « ia -A R s 
were found in 4month-old wildtype and knockout tissue, respectively. These 
observations suggested that although in the intact liver, only one subtype of «i-AR 
appeared to be present and therefore presumably required for function, culturing 
demonstrated the ability of hepatocytes to potentially express all three. 
Unfortunately, subtyping immediately post-isolation was not feasible.
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Another interesting observation was that the up-regulated subtypes, post-isolation, 
appeared to take over from the « ib-AR population in wildtype cells. The residual 
fluorescence seen after equilibration of 5nM QAPB ± BMY-7378 or RS100329 
(InM) was specific, as indicated by prazosin-sensitivity (figure 2.9a). The identity of 
this residual fluorescence was unknown. In the knockout, one would imagine that it 
represented either aiA- or Œid-ARs, depending on the subtype-selective antagonist 
used. However, in the wildtype, as to whether a mixture of all three subtypes exists 
remains to be answered.
Future experiments using a combination of both BMY-7378 and RS 100329 will be 
informative.
CC]-AR subtype transition
Alterations in hepatocyte ai-AR subtype expression, post-isolation have previously 
been reported at the mRNA level in guinea pig hepatocytes (Gonzalez -Espinosa et 
al., 1999). This study showed that the subtype expressed in the liver was aiA-AR, but 
when the liver cells were isolated, the mRNA coding for this receptor was degraded 
and the mRNA for a different subtype (aio-AR) was markedly induced by the cell 
isolation procedure (Gonzalez -Espinosa et al., 1999). Such data indicate that cell 
isolation can modulate very rapidly, the expression and degradation of ai-AR 
subtype mRNAs in hepatocytes. However, in that study, changes in ai-AR subtype 
expression were not assessed at the level of receptor protein, and it is well known 
that mRNA levels do not necessarily correlate with protein expression.
My work is thus the first report to date of changes in the expression of ai-AR 
subtype receptor protein upon isolation of hepatocytes. However, it is well 
documented that post-isolation of rat hepatocytes (best model studied), the ais-AR
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response decreases, and at the same time, a strong P2 -AR response emerges. These 
responses are accompanied by corresponding changes in receptor density (Kajiyama 
and Ui, 1994).
It is interesting to note that changes in the expression of aiB- and p2 -ARs during 
culture are modulated by cell density and that addition of cell membranes to the 
culture may also modulate such effects (Kajiyama and Ui, 1994). Such data suggests 
that cell-cell interactions are important in determining the type of AR gene 
expressed, as shown for other genes (Rana et al., 1994). It could therefore be possible 
that the changes in expression of ai-AR subtypes during isolation could be 
influenced by disruption of cell-cell interactions. This will be discussed in more 
detail later.
Decline in ccjb-ARs in regenerating liver
It is well documented that isolated hepatocytes display a similar response pattern as 
regenerating liver, in that control of various hepatic functions in the normal, adult 
male rat are mediated exclusively by the aiB-AR. After partial hepatectomy 
(Aggerbeck, 1983), the same response is rapidly converted to a predominantly P2 -AR 
mediated event. A similar conversion from ai- to P2 -type response occurs in isolation 
of hepatocytes (Itoh et al., 1984; Kunos et al., 1984; Nakamura et al., 1984; Schwartz 
et al., 1985; Sandes et al., 1986). Therefore, the down-regulation of the «m-AR gene 
expression seen in regenerating liver (Gao et al., 1996) is also likely to occur in 
isolated hepatocytes. Activation of the a^-A R  is one of the first events that initiate 
regenerative DNA synthesis after partial hepatectomy (Cruise et al., 1985, 1987; 
Michalopoulos, 1990). However, the number of cciB-ARs is thereafter down- 
regulated when hepatocytes de-differentiate.
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It has been shown previously that 3 promoters, which generate three mRNA 
transcripts, control the transcription of the hepatic aie-AR (Gao et ah, 1994). Gao et 
al., (1996) have shown that partial hepatectomy results in a rapid and marked 
reduction in all 3 mRNA species, which can be attributed to a corresponding 
decrease in the rate of transcription of the ttiB-AR gene. They also demonstrated for 
the first time that the tissue level of NFl (positive activator of aiB-AR in liver), 
declined, and its binding to the P2 promoter was attenuated in the remnant liver. An 
analogous decrease of NFl binding to the P2 promoter was also observed in primary 
hepatocytes after several hours in culture (Gao, unpublished observations by this 
group). Since NFl enhances P2 promoter activity in Hep3B cells and primary 
hepatocytes, the decline in the tissue level of the NFl protein is likely to be one of 
the factors responsible for the decreased expression of the aiB-AR gene during 
culturing of hepatocytes. Multiple factors, including cell-cell contact (Hartig et al., 
1993) are known to regulate the activity of NFl. Interestingly, Kajiyama and Ui. 
(1994) demonstrated that the transition from an «%- to P-AR mediated response in 
cultured hepatocytes did not occur unless the cells were cultured under conditions 
favourable for cell growth i.e., at low cell density. The switch was prevented 
progressively as the cell culture density was increased up to 2 0 -fold or a high-density 
culture was achieved by addition of increasing amounts of liver plasma membranes. 
Increases in cell-cell interactions were reported to be an important factor in inhibition 
of cell growth, in favour of cell differentiation, or expression of liver-specific 
characteristics (Nakamura et al., 1983, 1984). In my own experience, hepatocytes 
were plated at a maximum density so that a suitable density remained after the initial 
attachment period, washes, and replacement with culture medium.
So what is the biological significance of this attenuation of « ib-AR transcription?
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It has been shown in rat liver that isolation of hepatocytes under conventional 
conditions results in activation of the immediate-early growth program and an 
extensive down-regulation of most hepatic functions (Rana et al., 1994).
NA acting through hepatic aie-ARs is a strong comitogen (Cruise et al., 1985). The 
decline in aiB-AR expression in the early stages of regenerating liver's response may 
therefore serve to turn off a mitogenic signal and limit the extent of hepatic 
proliferation (Gao et al., 1996). A failure to suppress the expression of hepatic aiB- 
ARs after partial hepatectomy could promote abnormal growth and differentiation. 
Indeed, in an experimental model, the over-expression of ttiB-AR, induced agonist- 
dependent focus formation and disordered growth (Allen et al., 1991). Thus the 
decline in the concentration of NFl may play a part in a tightly regulated cell 
program aimed to ensure a brief burst of proliferative activity immediately followed 
by differentiation (Gao et al., 1996). A similar situation seems likely in cultured 
hepatocyes.
An important consideration for future work would be: Based on the literatue, it 
appears that the aiB-AR is down-regulated when hepatocytes are put into culture, 
and a diminished Ca"^ "^  response is likely. So would that same change happen in the 
knockout, given that the ttiB-AR is replaced by aiA-AR?
In vitro incubation (4hours) of hepatocytes acutely isolated from adult male rats can 
lead to a 40% decrease in aiB-AR density, and a 70% decrease in aiB-AR mRNA 
levels (Ishac et al., 1992). Work in this chapter suggests that hepatocytes are capable 
of increasing their ai-AR density (aiA- and am-AR subtypes) during prolonged 
culture. Basing our findings on the literature, it appears that activation of the 
immediate-early growth program, "and down-regulation of ais-AR is likely to be 
intrinsic to the cell whereas increased expression of ttiA- and aio-ARs was probably
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influenced by mitogenic factors in the culture media. For these reasons, information 
regarding the natural disposition of ai-ARs at a single cell level could only be 
hypothesised.
Functional heterogeneity o f hepatocytes
In an attempt to understand the reasons for heterogeneous expression of ai-ARs in 
isolated hepatocytes, it was necessary to consider the possible existence of functional 
heterogeneity between individual cells within the liver. An important factor that was 
obvious from reading all the existing literature was that the phenotype of adult 
hepatocytes exhibit great plasticity.
Extracellular signals are capable of generating responses that titrate existing gene 
expression to meet new environmental demands (Higgins and Anderson, 1931; 
Fausto, 1990; Xanthopoulos and Mirkovitch, 1993). In addition, the structure of the 
liver lobule ensures that hepatocytes in different parts of the hepatic acinus receive 
different extracellular signals. This permits heterogeneous local responses to any 
given systemic signal (Gebhart, 1992). Functional heterogeneity among hepatocytes 
is instructed by zonal differences in the cellular microenvironment. Factors carried 
by portal venous and hepatic arterial blood, in turn, regulate many aspects of the 
microenvironment, as hepatic function is generally varied along the portal (zone 1 ) to 
central (3) gradient of afferent blood flow (Coleman et al., 1993). In addition to 
microenvironmental differences in the 'maturity' of individual hepatocytes, different 
parts of the liver may also contribute to normal functional heterogeneity within the 
liver (Sigal et al., 1992). Even though the proliferative activity of adult hepatocytes is 
low, some hepatocyte replication does occur, which is both time and 'position'
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dependent. Proliferation tends to be greater in zone 1 than in zone 3 (Post and 
Hoffman, 1964). As the aie-AR has been reported to be involved in proliferation of 
hepatocytes, are hepatocytes from this area within the liver more densely populated 
with t tiB -A R s?  Are a iA -A R s  able to perform similar proliferative roles in the 
knockout?
Mitogenic factors in the culture media
Hepatocytes do not enter into DNA synthesis when kept in chemically defined media 
or in media supplemented with foetal bovine serum (Michalopoulos, 1990).
Earlier studies have demonstrated that primary culturing of rat hepatocytes plated in 
serum-containing media leads to a several-fold increase in P2 -AR density (Nakumura 
et al., 1984; Schwartz et al., 1985; Refsnes et al., 1987) and a parallel marked 
decrease in ai-AR density (Nakamura et al., 1984; Schwartz et al., 1985) within 8 - 
48hours. Ishac et al. (1992) found similar but smaller changes detected in 
hepatocytes suspended in a serum-free buffer after 4hours.
It has recently been reported that epidermal growth factor (EGF), insulin, hepatocyte 
growth factor (HGF), platelet-derived growth factor (PDGF), insulin-like growth 
factor I, and II on their own can rapidly stimulate hepatocyte DNA synthesis and 
proliferation during short-term culture (4hours) in defined media (Kimura and 
Ogihara, 1997a-c; Kimura and Ogihara, 1998a,b). The rapid proliferative responses 
of hepatocytes to these growth factors were found to be dependent on such culture 
conditions as hormones in the media and initial plating density. The presence of the 
amino acid proline in the medium (Houck and Michalopoulos, 1985) is also required 
for DNA synthesis in hepatocytes.
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Since there was an increase in ai-AR density during prolonged culture, it was 
necessary to assess the possible contribution of the contents of the media used to 
perfuse, attach and culture the hepatocytes in this study. Unfortunately, the three 
media used, from the 'Hepatocyte product line' from Life technologies. Inc. were 
patented and only limited information was available.
Nicotinamide was present in the culture media, and since it is converted to 
NAD/NADP, endogenous fluorophores, this was likely to be responsible for high 
autofluorescence observed during extensive incubation periods as seen during 
transfection. Nicotinamide is also known to enhance cyclic replication of DNA. 
Growth hormone was also contained in all three media used and is a known stimulant 
of protein synthesis.
Similarly, gluococorticoid was present in all three media. Glucocorticoids have been 
reported to induce the transcription and expression of both the (%iB- (Sakaue and 
Hoffman, 1991) and pi-AR (Collins et al., 1988; Hadcock and Malbon, 1988; 
Jazayeri and Meyer, 1988) genes in smooth muscle cells. However, a report by Huff 
et al. (1991), indicated that glucocorticoid administration in vivo was able to program 
the ontogenic disappearance of hepatic P-ARs, which reaches a peak of sensitivity 
just before the period in which natural adrenocortical function matures (Miyabo et 
al., 1980; Lamers and Mooren, 1981). The hypothesis that the development of 
adrenal steroid secretion provides a normal maturational cue for hepatic AR 
expression has been supported by preliminary evidence that neonatal adrenalectomy 
delays the switch from P to oci-ARs (McMillan, 1983). The failure of glucocorticoids 
to evoke a similar irreversible shift in the programming of ai-AR ontogeny suggests 
that other factors, possibly the development of sympathetic innervation (Slotkin et 
al., 1986), provides the major input for that subtype.
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From these reports, it would seem that the effects of glucocorticoids are cell-type 
specific and its effects on hepatocytes are non-comparable with smooth muscle cells. 
They are likely, however, to increase the expression of ai-ARs, although no direct 
mitogenic responses have thus far been reported.
The media used to perfuse the liver was a balanced salt solution that initiated the 
loosening of cell-cell contact. The media used to attach cells to glass cover slips was 
an enriched Williams E media, supplemented with Foetal Bovine Serum for the 
adherence of hepatocytes (0-4hours). Hepatozyme-SFM, a serum-free media was 
used for short-term (4-48hours) and maintenance of hepatocyte phenotypic 
expression.
Ontogenic differences in expression o f aj-ARs
The studies done at the single cell level contradicted some, but not all, of the 
radioligand binding data. Regarding overall changes in oti-AR density at different 
ages, both techniques reported a significant increase in ai-AR density in the 
knockout between 3 and 4months, the opposite of which was observed in the 
wildtype. Interestingly, at some point between 3 and 4months, the biological 
discrepancy observed between QAPB binding to hepatocytes from 3 and 4month-old 
mice seemed to balance out. At 4months, the difference between average 
fluorescence intensity values for wildtype and knockout cells was no longer 
statistically significant.
Although not as obvious after prolonged hepatocyte culture, it was evident from 
radioligand binding studies that the ai-AR density at 3months in the knockout was 
considerably lower than in the wildtype liver. Since ai-ARs play such a major role in
148
this organ (see general introduction), what compensatory mechanisms are present 
before the animal reaches 4months?
The only available information on the developmental changes that occur in the liver 
are based on the rat. In crude membrane preparations from rat liver at different ages, 
the (Xi-AR density increased upon maturation (from birth until 2months), and 
decreased slightly till the age of 24-26months (Van Ermen and Fraeyman, 1992).
It cannot be assumed that the same ontogenic pattern of ai-AR expression exists in 
mice, especially when the 'normal' subtype expressed has been removed from the 
equation. There may be fundamental differences between wildtype and knockout 
animals since the aie-AR gene has been absent since conception onwards. The bulk 
of evidence from other AR knockout models has revealed that basal physiological 
functions are not significantly perturbed, and that alternative control points may exist 
for critical physiological functions such as cardiac rate and contractility, vascular 
tone, and metabolic state, which can be altered to compensate for the knocked out 
receptor (Roher and Kobilka, 1998). An example of this was observed in a P1/P2 -AR 
double knockout where cardiac muscarinic receptor density was reduced, a 
counterbalancing reduction in a receptor that is known to functionally antagonise 
stimulatory P-ARs (Roher et al., 1999). Such knockout models are not likely to 
reveal the 'true' roles of the subtype in question, as compensatory mechanisms are 
likely to take effect at specific time points in the development of the animal.
Species heterogeneity o f aj-AR subtype expression
According to the literature, as mentioned in the general introduction, oci-AR subtype 
heterogeneity exists between species. These differences may be age-related. With the 
exception of the guinea pig, animals that are studied early in their life span
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(<4months) i.e., rats, mice, hamsters, and chickens, all appear to predominantly 
express the aie-AR. In contrast, those species that are studied at a later point, 
ranging from 6-14months (rabbit, cat, and dog) to several years (monkeys and 
humans), express the Œia-AR.
Since the aie-AR has been implicated in growth, it seems logical that this subtype 
would be present at an early age, with its importance, and hence receptor protein, 
declining over time. The emergence of the cciA-AR subtype may occur at a specified 
time point, for example, between 3 and 4months in the mouse.
If the rat liver is capable of altering its ai- and P-AR populations then it seems 
plausible that it would also be capable of changing the subtype of cci-AR expressed 
in vivo. Although this has not yet been reported in any model.
The possibility that the wildtype mouse liver would predominantly express the ttiA- 
AR at a later stage in its life cycle, say after 1 year, would be very interesting. Such 
age studies should answer these queries regarding the relationship between subtype 
expression and age of the animal when studied.
Compensatory mechanisms
It appears that oti-AR subtype redundancy may be involved in the regulation of 
hepatic functions. The presence of a pure population of « ia-ARs in the knockout 
liver at 4months would suggest that this subtype is able to compensate for the lack of 
the aiB-AR present in the wildtype at this age. However, the existence of only a 
small population of ai-ARs at 3months in the knockout, compared to the wildtype, 
suggests that a non-«i-AR mechanism is compensating for the lack of the ociB-AR 
subtype, at that time. At a specific time point between 3 and 4months, a replacement
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population of Œia-ARs becomes established. In the knockout at 3months, few high 
affinity ai-ARs are present (8 fmol/mg), at this time, which in the rat, represents the 
start of post-maturational decline. If the aiB-AR plays such an important role in the 
growth and development of the rat liver from 3/4 weeks (post-switch from P to a) to 
2-3months (mature), then what compensates for the lack of high affinity tti-ARs in 
the knockout mouse at 3months? Are events mediated through P-ARs until «ia-ARs 
are up-regulated? This seems plausible since hepatocytes isolated from adult female 
rats are responsive to both a\- and P2 -AR stimulation, whereas adult male rat 
hepatocytes respond only to «i-AR stimulation (Studer and Borle, 1982). Perhaps 
changes in hormone levels compensate accordingly and mediate hepatic functions 
via a different mechanism. An interesting avenue would be to localise P-ARs in 
isolated hepatocytes using BODIPY®TMR (±) CGP 12177 (Arribas et al., 1997). 
Further investigation is required to determine the ai-AR subtype expressed at 
3months in both strains, in the intact liver, and to establish whether a population of 
aiA-ARs similar to that in the aiB-knockout is present in the wildtype mouse at 
3months. Such future work should shed light on the ontogenic pattern of «i-AR 
subtype expression.
'High' and 'low' affinity binding o f QAPB to aj-ARs in hepatocytes 
In wildtype and knockout hepatocytes, QAPB bound to high (typical ai-AR 
pharmacology) and low affinity populations. The estimated Kd values for these low 
affinity sites however, did fluctuate. At 3months, they were non-saturable within the 
concentration range, yet at 4months, they did saturate (<20nM QAPB), and were 
easily quantified.
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The binding of QAPB to tti-ARs at >5nM, in recombinant cell lines (chapter 1), is 
normally considered relatively 'non-specific', with specific sites saturating at low 
concentrations of QAPB (<2nM). It has become obvious, as mentioned in chapter 1, 
that QAPB will bind 'non-specifically' in cells densely populated with ai-ARs, as 
indicated by the similar pattern of binding to prazosin-insensitive sites.
In hepatocytes, a different pattern of QAPB binding was observed compared to 
recombinant oci-ARs. QAPB bound to low density, high affinity receptive sites, 
saturating by InM QAPB. A further increase in specific binding of QAPB 
commenced from 5nM upwards. The identity of these sites remains unknown. As 
these low affinity sites are also present in wildtype hepatocytes, and partially blocked 
by RS 100329, these results indicate that there is a minor population of ociA-ARs in 
the wildtype liver. After 24hours in culture, the ArrayScan work demonstrated that 
both strains were capable of expressing a iA -  and « id- A R s . The confocal studies 
using BMY-7378 indicated that ccio-ARs were present after 4hours in culture. 
However, this was only evident from one cell, and when average fluorescence 
intensity values from several cells were compared, BMY-7378 showed minimal 
effect.
If the ociA-AR is expressed in small amounts in the wildtype, then perhaps this 
represents the small population of (Xi-ARs observed in the knockout at 3months, yet 
to be characterised by radioligand binding.
Is the ttiA-AR perhaps present at all times, in a low affinity state (« il)? Low affinity 
binding was seen at 3months in both strains. After the mouse had aged by a further 
month, cells appeared to bind QAPB with higher affinity, thus displaying typical 
aiA-AR pharmacology. Studies using 1 year-old mice will hopefully shed light on
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this. It is obvious from the work in this chapter that a more substantial, higher density 
aiA-AR population appears between 3 and 4months.
Does low affinity binding o f QAPB represent aji-ARs?
Ohmura and Muramatsu, (1995) reported prazosin-sensitive low affinity binding 
sites in rabbit liver plasma membranes. This group considered these receptors 
belonged to the aiL-AR subtype. The same study showed the coexistence of 2 
distinct «i-AR subtypes (aiA and « il) in the rabbit liver and the higher density of 
aiL-AR compared with the Œia-AR subtype.
Similarly, in the present study, QAPB bound to high density, low affinity and low 
density, high affinity sites in mouse hepatocytes.
ai-ARs with low affinity for prazosin («il) are evident from pharmacological studies 
in many tissues (Muramatsu et al., 1995). Therefore it is interesting to compare the 
characteristics of aiL-ARs between liver and other tissues. Affinity estimates for 
prazosin are similar in a wide range of tissues, whereas the affinities of WB4101 
(pKi 7.57) and 5-MU (6.75) determined in rabbit liver are much lower than those 
determined in rabbit aorta or human prostate (8.2-8.5) (Oshita et al., 1993; 
Muramatsu et al., 1994). This may suggest heterogeneity of Œil-A R s .
Supporting the theory that the aiL-AR is in fact a conformational variation of the 
(XiA-AR (Williams et al., 1996; Ford et al., 1997), and that further subdivisions may 
exist, it would not be surprising that conformational variants of the Œil-AR exist, 
when you consider the existence of splice variants of the ajA-AR (Chang et al., 
1998) which can lead to functional variations.
Perhaps there are sites in the liver that have low affinity for ligands in general?
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Effects o f temperature on hepatic aj-ARs
Using liver plasma membrane fractions, Borst and Scarpace, (1990) observed, as did 
Lynch et al. (1985), a mixed population of high and low affinity ai-ARs in binding 
studies conducted at 25°C. Both groups report conflicting data however at 2°C 
(Lynch) and 4°C (Borst and Scarpace), where they found a homogeneous population 
of high affinity and mixed population of oci-ARs, respectively. At 37°C, a 
homogeneous population of low affinity binding sites was observed (Borst and 
Scarpace, 1990; Schwartz et al., 1986). However, an artifactual partial reduction in 
affinity is also seen when tissue is incubated at 37°C in the absence of agonist. Post 
incubation at 37°C, hepatocyte analysis in this study was at room temperature.
Subcellular distribution ofaj-ARs in hepatocytes
The majority of studies in the literature, regarding ai-ARs in the liver, are based on 
radioligand binding using plasma membranes. The general consensus regarding the 
functional-location of aiB-ARs is that they reside at the plasma membrane. The work 
detailed in this chapter demonstrates that cci-ARs are distributed throughout the 
cytoplasm in hepatocytes, with densely populated areas surrounding nuclei, 
presumably networks of golgi apparatus (Nagata, 2001). The functional role of oci- 
ARs in hepatic metabolism suggests that perhaps their cytoplasmic distribution is 
relevant to the distribution of glycogen granules, which are similarly distributed 
diffusely throughout the cytoplasm of the cell (Stryer, 1988). Contained within each 
granule are the enzymes that catalyse the synthesis and degradation of glycogen, and 
also those that regulate these processes (Stryer, 1988).
The consequence of such a distribution is that ligands have to gain access to such 
sites by diffusion through the membrane, an endocytic mechanism or via a
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transporter. Interestingly, the distribution of «i-AR subtypes is the same in wildtype 
(aie) and knockout (Œia) hepatocytes, the subtypes indicated from radioligand 
binding data (4months), suggesting subtype redundancy in this tissue. An important 
point to note however, is the appearance of both (XiA and aio-ARs in both strains 
after culturing hepatocytes for 24hours, as evident from the ArrayScan study. Since 
the QAPB binding sites are mainly aiA and ttm-ARs, could this explain why no 
differences were observed in the distribution of oci-ARs between the two strains at 
the single cell level?
A recent report, regarding the interaction of the « ib-AR with the multifunctional 
protein, gClq-R, has created a route for us to locate the aiB-AR in wildtype cells 
after acute isolation. We hope to use a rabbit polyclonal antibody to gCl-qR (Sigel 
and Schaerer) and colocalise with QAPB binding, combined with subtype-selective 
antagonists. gCl-qR, isolated from rat liver, has been reported to retain the ttiB-AR 
inside the cell and mediate the down-regulation of ociB-AR receptor protein (Xu et 
al., 1999; Hirasawa et al., 2001). In this report, although the Kd value was not 
significantly altered by co-expression of the ttiB-AR with gCl-qR, the Bmax value of 
the aiB-AR dramatically decreased. So what is the role for this previously identified 
complement regulatory molecule in the regulation of the cellular localisation and 
expression of the aiB-AR?
An important consideration is that this protein-ai-AR complex was isolated from rat 
liver, which has been reported to express a pure population of aiB-ARs. In view of 
the aiB-knockout mouse expressing aiA-ARs, how does this compare? Is this protein 
specific to the ociB-AR, or is it liver-specific, and able to regulate the ai-AR 
component, irrespective of subtype?
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It is interesting to note that data from radioligand binding studies using liver plasma 
membranes indicates that ai-ARs are located at the plasma membrane. The work in 
this chapter, at the single cell level, suggests otherwise. However, basing our 
interpretation on the literature regarding hepatic «i-ARs, it seems plausible that 
whilst in vivo, hepatocytes, up to a certain age, may express « ib - A R s , which may be 
situated at the plasma membrane.
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Figure 2.1 (a) QAPB binding on hepatocytes isolated from livers of 
3month-old knockout mice, cultured for ~4hours. Non-specific binding 
was defined by IpM prazosin. Cells were plated on coverslips and 
examined by confocal microscopy with timelapse photography. 
Increasing concentrations (0.4-20nM) were added cumulatively and 
images were collected at 1 -minute intervals. Image data was collected at 
equilibrium time points for each concentration of QAPB (added at 
Sminute intervals). Images are shown in pseudocolour, where black 
indicates no staining and blue, green, yellow and red indicate increasing 
levels of saturation of the fluorophore. (b-d) The QAPB-associated 
fluorescence intensity was calculated by Metamorph software and plotted 
against increasing concentrations of QAPB to estimate the levels of 
specific binding of QAPB in sample cells. The estimated specific binding 
affinity (FK^) of QAPB was measured as nanomolar (nM) and the 
estimate of specific binding (ESB) was measured as fluorescence 
intensity (FI). Estimates for cells 1,2,5 and 6  were (0.976, 0.121), (0.097, 
0.032), (21.80, 1.496) and (29.22, 6.77) respectively, (e) Bar chart 
representing 20nM QAPB binding to 3month-old knockout hepatocytes 
cultured for 4hours pre-incubated with IjiM prazosin. Cells were plated 
on coverslips, incubated for 30minutes with non-fluorescent antagonist, 
then equilibrated with 20nM QAPB. Inhibition of QAPB binding was 
measured as average fluorescence intensity of the cell compared to the 
absence of inhibitor (control).
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Figure2.2 (a) Comparison of QAPB binding to 3month-old wildtype 
and knockout hepatocytes cultured for ~4hours. Cells were plated on 
coverslips and examined by confocal microscopy with timelapse 
photography. Increasing concentrations (0.4-20nM) were added 
cumulatively and images were collected at 1-minute intervals. Image 
data was collected at equilibrium time points for each concentration of 
QAPB (added at Sminute intervals). Images are shown in pseudocolour, 
where black indicates no staining and blue, green, yellow and red 
indicate increasing levels of saturation of the fluorophore. (b) The 
QAPB-associated fluorescence intensity was calculated by Metamorph 
software and plotted against increasing concentrations of QAPB to 
estimate the levels of specific binding of QAPB in a sample cell, (c) The 
estimated specific binding affinity (FK^) of QAPB was measured as 
nanomolar (nM) and the estimate of specific binding (ESB) measured 
as fluorescence intensity (FI). Estimates made for cells are presented in 
the table.
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Figure 2.3 (a) QAPB binding on hepatocytes isolated from livers of 
4month-old knockout mice, cultured for ~4hours. Non-specific binding 
was defined by l|xM prazosin, (c) Comparison of QAPB binding on 
hepatocytes isolated from 3 and 4month-old animals, cultured for 
~4hours. Cells were plated on coverslips and examined by confocal 
microscopy with timelapse photography. Increasing concentrations 
(0.4-20nM) were added cumulatively and images were collected at 1- 
minute intervals. Image data was collected at equilibrium time points 
for each concentration of QAPB (added at 5minute intervals). Images 
are shown in pseudocolour, where black indicates no staining and blue, 
green, yellow and red indicate increasing levels of saturation of the 
fluorophore. (b) The QAPB-associated fluorescence intensity was 
calculated by Metamorph software and plotted against increasing 
concentrations of QAPB to estimate the levels of specific binding of 
QAPB in a sample cell, (d) The estimated specific binding affinity 
(FKd) of QAPB was measured as nanomolar (nM) and the estimate of 
specific binding (ESB) measured as fluorescence intensity (FI). 
Estimates made for cells are presented in the table.
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Figure 2.4 (a) QAPB binding to 3 and 4month-old wildtype hepatocytes cultured for 4 hours. 
Non-specific binding was defined by IpM prazosin. Cells were plated on coverslips and 
examined by confocal microscopy with timelapse photography. Increasing concentrations (0.4- 
20nM) were added cumulatively and images were collected at 1-minute intervals. Image data 
was collected at equilibrium time points for each concentration of QAPB (added at 5minute 
intervals). Images are shown in pseudocolour, where black indicates no staining and blue, green, 
yellow and red indicate increasing levels of saturation of the fluorophore. (b) The estimated 
specific binding affinity (FKp) of QAPB was measured as nanomolar (nM) and the estimate of 
specific binding (ESB) measured as fluorescence intensity (FI). Estimates made for cells are 
presented in the table.
Figure 2.6 (a) Comparison of QAPB binding to ‘high’ affinity sites 
on hepatocytes isolated from livers of 3month-old knockout mice, 
cultured for 4, 24 and 48 hours, (c) Comparison of QAPB binding to 
‘low’ affinity sites on hepatocytes isolated from livers of 3month-old 
knockout mice, cultured for 4, 24 and 48 hours, (d) Non-specific 
binding after 48 hours in culture was defined by IpM prazosin. Cells 
were plated on coverslips and examined by confocal microscopy with 
timelapse photography. Increasing concentrations (0.4-20nM) were 
added cumulatively and images were collected at 1 -minute intervals. 
Image data was collected at equilibrium time points for each 
concentration of QAPB (added at Sminute intervals). Images are 
shown in pseudocolour, where black indicates no staining and blue, 
green, yellow and red indicate increasing levels of saturation of the 
fluorophore. (b) The estimated specific binding affinity (FKg) of 
QAPB was measured as nanomolar (nM) and the estimate of specific 
binding (ESB) measured as fluorescence intensity (FI). Estimates 
made for cells expressing ‘high’ affinity sites are presented in the 
table.
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Figure 2.7 (a) Comparison of QAPB binding to 3 and 4month-old knockout 
hepatocytes cultured for 24hours. Cells were plated on coverslips and 
examined by confocal microscopy with timelapse photography. Increasing 
concentrations (0.4-20nM) were added cumulatively and images were 
collected at 1-minute intervals. Image data was collected at equilibrium time 
points for each concentration of QAPB (added at 5minute intervals). Images 
are shown in pseudocolour, where black indicates no staining and blue, green, 
yellow and red indicate increasing levels of saturation of the fluorophore. (b) 
The estimated specific binding affinity (FK^) of QAPB was measured as 
nanomolar (nM) and the estimate of specific binding (ESB) measured as 
fluorescence intensity (FI). Estimates made for cells are presented in the 
table.
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Figure 2.8 (a) Comparison of QAPB binding to 4-month knockout
hepatocytes cultured for 4 and 24hours. Cells were plated on coverslips and 
examined by confocal microscopy with timelapse photography. Increasing 
concentrations (0.4-20nM) were added cumulatively and images were 
collected at 1-minute intervals. Image data was collected at equilibrium time 
points for each concentration of QAPB (added at 5minute intervals). Images 
are shown in pseudocolour, where black indicates no staining and blue, green, 
yellow and red indicate increasing levels of saturation of the fluorophore. (b) 
The estimated specific binding affinity (FK.^) of QAPB was measured as 
nanomolar (nM) and the estimate of specific binding (ESB) measured as 
fluorescence intensity (FI). Estimates made for cells expressing ‘high’ and 
‘low’ affinity receptors are presented in the table.
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Figure 2.9 (a) QAPB binding to 4month-old wildtype hepatocytes
cultured for 24hours. Non-specific binding was defined by IpM prazosin, 
(b) Comparison of QAPB binding to 4month-old wildtype and knockout 
hepatocytes cultured for 24hours. Cells were plated on coverslips and 
examined by confocal microscopy with timelapse photography. 
Increasing concentrations (0.4-20nM) were added cumulatively and 
images were collected at 1-minute intervals. Image data was collected at 
equilibrium time points for each concentration of QAPB (added at 
Sminute intervals). Images are shown in pseudocolour, where black 
indicates no staining and blue, green, yellow and red indicate increasing 
levels of saturation of the fluorophore. (c) The estimated specific binding 
affinity (FK^) of QAPB was measured as nanomolar (nM) and the 
estimate of specific binding (ESB) measured as fluorescence intensity 
(FI). Estimates made for cells are presented in the table.
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Figure 2.10 (a) Comparison of QAPB binding on 4month-old 
wildtype hepatocytes cultured for 4, 24 and 48hours. Cells were 
plated on coverslips and examined by confocal microscopy with 
timelapse photography. Increasing concentrations (0.4-20nM) were 
added cumulatively and images were collected at 1 -minute 
intervals. Image data was collected at equilibrium time points for 
each concentration of QAPB (added at Sminute intervals). Images 
are shown in pseudocolour, where black indicates no staining and 
blue, green, yellow and red indicate increasing levels of saturation 
of the fluorophore. (b) The estimated specific binding affinity (FK^) 
of QAPB was measured as nanomolar (nM) and the estimate of 
specific binding (ESB) measured as fluorescence intensity (FI). 
Estimates made for cells are presented in the table.
Figure 2.11 (a) Inhibition of QAPB binding to native apARs on 3month-
old knockout hepatocytes cultured for 24hours. Figure illustrates inhibition of 
QAPB-associated fluorescence from specific ttpAR binding sites using the 
tti^-AR selective antagonist, RS100329 (InM). The a^g-AR selective 
antagonist, BMY-7378 (InM) was without effect, (b, c) Inhibition of QAPB 
binding to native ttpARs on 4month-old knockout hepatocytes cultured for 4 
and 24hours, respectively. Figure illustrates inhibition of QAPB binding to 
specific ttpAR binding sites using the a^^-AR selective antagonist, 
RSI00329 (InM). Cells were plated on coverslips, pre-incubated for 
30minutes with antagonist, then examined by confocal microscopy with 
timelapse photography. Increasing concentrations (0.4-20nM) were added 
cumulatively and images were collected at 1 -minute intervals. Image data 
was collected at equilibrium time points for each concentration of QAPB 
(added at 5minute intervals). Images are shown in pseudocolour, where black 
indicates no staining and blue, green, yellow and red indicate increasing 
levels of saturation of the fluorophore.
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Figure 2.12 (a) Inhibition of QAPB binding to 4month-old wildtype 
hepatocytes cultured for 4hours by InM RSI00329. (b) Inhibition of 
QAPB binding to 4month-old wildtype hepatocytes cultured for 
24hours by InM RSI00329 and BMY-7378. Cells were plated on 
coverslips and examined by confocal microscopy with timelapse 
photography. Increasing concentrations (0.4-20nM) were added 
cumulatively and images were collected at I-minute intervals. Image 
data was collected at equilibrium time points for each concentration 
of QAPB (added at Sminute intervals). Images are shown in 
pseudocolour, where black indicates no staining and blue, green, 
yellow and red indicate increasing levels of saturation of the 
fluorophore. (c) Bar chart representing 5nM QAPB binding to 
4month-old wildtype hepatocytes cultured for 4hours pre-incubated 
with InM BMY7378 or RS100329. Cells were plated on coverslips, 
incubated for 30minutes with non-fluorescent antagonist, then 
equilibrated with 5nM QAPB. Inhibition of QAPB binding was 
measured as Average Fluorescence Intensity of the cell compared to 
the absence of inhibitor (control).
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Figure 2.13 (a, b) Inhibition of QAPB binding to 4month-old wildtype and 
knockout hepatocytes cultured for 4 and 24hours by InM RS 100329. Cells 
were plated on coverslips and examined by confocal microscopy with 
timelapse photography. Increasing concentrations (0.4-20nM) were added 
cumulatively and images were collected at 1-minute intervals. Image data 
was collected at equilibrium time points for each concentration of QAPB 
(added at Sminute intervals). Images are shown in pseudocolour, where black 
indicates no staining and blue, green, yellow and red indicate increasing 
levels of saturation of the fluorophore. (c) Bar chart representing SnM QAPB 
binding to 4month-old wildtype and knockout hepatocytes cultured for 
24hours pre-incubated with InM BMY7378 or RSI00329. Cells were 
plated on coverslips, incubated for 30minutes with non-fluoresent antagonist, 
then equilibrated with SnM QAPB. Inhibition of QAPB binding was 
measured as Average Fluorescence Intensity of the cell compared to the 
absence of inhibitor (control).
Figure 2.14 (a-c) Hepatocytes were isolated and treated as described in 
methods. Images from the ArrayScan™ system were transferred to 
Metamorph software and average fluorescence intensity values for 30 cells 
(n=30), representing each of the experimental parameters, were recorded and 
graphed as shown. The distribution of intensity values within each parameter 
is also shown (•). P values indicating statistical significance are also 
presented.
200n
e  ^  100- <u c
OX) —
5nM QAPB 5nM QAPB
3 month wt
3 month ko
P<0.0001
200i
c  « 100- 
V sUD •—
5nM QAPB 5nM QAPB
4month wt 
4month ko
P=0.2895
200-1
<uu
E ^
§1e  « 1 0 0
S(jD •—
I
3month ko 
4month ko
5nM QAPB 5nM QAPB
p = 0 .0 0 0 2
200i
isil!
c  «  100- 
V s on •“>
5nM QAPB 5nM QAPB
3month wt 
4month wt
P=0.0011
a)
200n 3 mo nth ko
3month ko
5nM QAPB control + 1nM BM Y7378
p < 0 .0 0 0 1
2 0 0 1
5nM QAPB control + 1nM R S 10 0 3 2 9
3m onth ko 
3 mo nth ko
p < 0 .0 0 0 1
2 0 0 1
0>
«
g ^
0
«  ^  1 0 0
1
4 month ko 
4 month ko
5nM QAPB control + 1nM BM Y7378 
p < 0 .0 0 0 1
200 n
I
0 ^
e  I  100
V e
1
4 month ko 
4 month ko
5nM QAPB control + 1nM R S I0 0 3 2 9  
p < 0 .0 0 0 1
b)
200-,
5nM QAPB control + 1nM BMY7378
3 month wt
3month wt
P<0.0001
200
SVu(A _« ^
3 'S
e  "  100V e on —
I
3 month wt 
3 month wt
5nM QAPB control +1nM RSI 00329  
P<0.0001
200n
c  « 100-V e
OX) • —
5nM QAPB control + 1nM BMY7378
4month wt 
4month wt
P<0.0001
200 n
0>w
§ 1
c  « 100 e 
0£ —
I
4month wt 
4month wt
5nM QAPB control + 1 nM R S I00329  
P<0.0001
C)
Figure 2.15 Comparison of GFP-associated fluorescence and 
autofluorescence of knockout hepatocytes transiently 
transfected with pEGFP/humana,yAR (top) and 
pmousettjgpromoter/humanajjj-AR-GFP (middle). Cells 
were plated on coverslips, transiently transfected, then left 
for a further 3 days in culture to allow for expression of the 
plasmid. Control experiment is represented by cells cultured 
alongside under the same conditions (bottom).
Chapter 3.
Subcellular distribution and characterisation of ai-ARs in 
vascular smooth muscle cells.
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Chapter 3
Introduction
The work in the previous chapter dealt with the characterisation of oti-AR subtypes 
expressed in isolated hepatocytes. Subcellular distribution, age-related differences, 
and culture-induced changes in expression levels were also assessed. The issues that 
arose regarding ai-AR subtype distribution in hepatocytes (see chapter 2  discussion), 
relates to the work in this chapter, which focuses on the subcellular distribution of 
cci-ARs in vascular smooth muscle cells (VSMCs); freshly dissociated, in culture and 
in situ, and addresses the issue of functional location of ai-AR subtypes. Does each 
subtype have a common distribution in different cell types, or is the distribution cell 
specific?
The study of the subcellular distribution of ai-ARs within smooth muscle cells, has 
until recently, been restricted, due to technical limitations. Previous work in our 
laboratory has shown the localisation of ai-ARs on VSMC, within the media of a rat 
mesenteric resistance artery, using QAPB (McGrath and Daly, 1995).
Although QAPB is non-selective, the study of ai-AR subtype distribution in SMCs 
has since been extended to the subcellular level, and in conjunction with non- 
fluorescent competitive inhibitors, the characterisation (aiA-AR) and subcellular 
distribution (40% intracellular) of ai-ARs, expressed in SMCs dissociated from 
human prostate tissue (Mackenzie et al., 2000), have been quantified. It is well 
documented that the cti-AR subtype responsible for contraction of human prostate is 
aiA-AR (Marshall et al., 1995; Ford et al., 1996a; Takeda et al., 1997).
In contrast, studies in VSMCs cultured from femoral and renal arteries have 
demonstrated the expression of all three cti-AR subtypes using subtype-selective
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antibodies (Hrometz et al., 1999; McCune et al., 2000). This group have also shown 
that despite this, only a single subtype mediates the contractile response in the 
femoral ( « id -A R ) and renal ( « ia -A R ) artery (Hrometz et al., 1999). So what roles 
do the other two subtypes play in the function of these blood vessels?
The functional response in the carotid artery and thoracic aorta of the mouse is 
mediated predominantly via (Xm-ARs (Daly et al, in press). Therefore, one would 
anticipate expression of this subtype at the single cell level.
Such work, and that of others (see general introduction), has indicated a defined 
subcellular distribution for each of the three subtypes of oci-AR in SMCs. 
Interestingly, studies in recombinant cell lines have been shown to represent a similar 
distribution pattern to that seen in native VSMCs (McCune et al., 2000). This group 
have shown that aiB- and aio-ARs are predominantly associated with the cellular 
periphery and intracellularly, respectively, in both recombinant cells and native 
VSMCs. Comparisons between SMCs from vascular/non-vascular tissues also show 
a similar distribution pattern, e.g., Œia-ARs expressed in VSMCs/prostate SMCs are 
found predominantly intracellularly.
In smooth muscle, ai-ARs were previously thought to reside at the plasma 
membrane, where they mediate contraction via activation through extracellular 
stimuli. The ctis-AR is the only subtype shown to reside predominantly at this 
location, yet it plays a limited role in mediating contraction.
The overall objective of this chapter was to demonstrate receptor distribution within 
the walls of small resistance arteries, to extend this to the subcellular level and to 
determine whether receptor internalisation could be demonstrated in the intact vessel 
in response to agonist. Using methods developed initially in a recombinant cell line 
(chapter 1 ) and primary hepatocytes (chapter 2 ), the work in this chapter takes on the
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study of the subcellular distribution and characterisation of native ai-ARs in freshly 
dissociated and cultured VSMCs. Initially, the distribution and binding properties of 
the ai-ARs expressed in smooth muscle cells were established. Cells were grown 
from an explant of thoracic aorta from the Œib-AR knockout mouse, or dissociated 
from the carotid artery of either wildtype or knockout mice. As already demonstrated 
in the previous chapter, QAPB binding in the presence of non-fluorescent 
competitive antagonists allows the identification and visualisation of ai-AR subtypes 
within native cells. Does the ai-AR subtype(s) expressed at the single cell level 
correlate with the subtype-mediated (Daly et al, in press) functional response in these 
blood vessels?
Further to this, employing the ociB-AR knockout mouse and in vitro transfection of 
aortic segments, we were able to manipulate the aib-AR population enabling 
expression in situ. Using GFP-tagged constructs and CLSM, direct visualisation, at a 
subcellular level was permitted.
The GFP-tagged constructs used were pEGFP/humanaib-AR (Tsujimoto) and 
pmouseaiB-AR/human aib-AR- GFP (Perez). The latter construct is regulated by the 
mouse aiB-AR promoter, which was cloned recently by Zuscik et al. (1999). As 
mentioned earlier, this group have confirmed that this mouse promoter fragment is 
able to regulate reporter gene expression in response to the competency of a given 
cell to express ociB-ARs, thus able to mimic the distribution of their natural 
environment.
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Chapter 3 
Methods
Primary Smooth muscle cell dissociation
Cells were dissociated by a method adapted from Kamishima et al., 1997. Briefly, 
the arteries (carotid, thoracic aorta) were removed from the animal, dissected free 
from fat and connective tissue, weighed, briefly doused in 70% ethanol then 
placed in buffer 1 (NaCl 147mM, KCl 5mM, MgClz ImM, CaCl2 1.8mM, HEPES 
lOmM, BSA 0.1%, pH 7.4). Arteries were washed once in buffer 1, resuspended 
in pre-heated (35°C) buffer 2 (sodium glutamate 80mM, NaCl 54mm, KCl 5mM, 
MgCU ImM, CaCE O.lmM, HEPES lOmM, glucose lOmM, EDTA 0.2mM, BSA 
0.1%, pH 7.3) with papain (28.9units/mg tissue. Sigma) and dithioerythritol 
(1 mg/mg tissue. Sigma) and incubated at 35°C for 30 minutes. Arteries were then 
centrifuged at 1 2 0 0 g for 2  mins at room temperature and the supernatant 
discarded. Arteries were then resuspended in buffer 2 with collagenase II (425 
units/mg tissue. Sigma) and hyaluronidase (330 units/mg tissue. Sigma) and 
incubated at 35°C for a maximum of 2-3 minutes, then the SMCs were dispersed 
immediately with a fire polished Pasteur pipette. Cells were washed in buffer 2 
containing 40% foetal bovine serum (Life technologies, Inc), then plated onto 
cover slips, stored at 4°C and analysed within 24-48hours.
Cultured Vascular Smooth Muscle Cells 
Dissociated
Arteries were treated in a similar manner as above, except that the dispersed cells 
were washed and thereafter cultured in DMEM (Life technologies, Inc)
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supplemented with 20% (v/v) foetal calf serum (Life technologies, Inc), penicillin 
(100 units/ml) / streptomycin (100 p-g/ml) (Life technologies, Inc), bovine insulin 
(10 pg/ml. Sigma), L-glutamine (ImM, Life technologies, Inc), sodium pyruvate 
(ImM, Life technologies, Inc), Fungizone (2.5pg/ml, Life technologies, Inc), 
geneticin (knockout cells only) (400|Xg/ml, Life technologies, Inc) in a 95% air, 
5% CO2 atmosphere at 37°C. Cells were fed every 2-3 days and split at 
confluency. Smooth muscle cells were immunohistochemically stained with a cy3 
conjugated a-actin monoclonal antibody (Sigma). The stained specimens were 
then examined with a Zeiss Axiphot microscope.
Explant
Briefly, arteries were removed from the animal, aseptically dissected free from fat 
and connective tissue, cut longitudinally, and spread out flat on a sterile culture 
dish. After 5 days in culture, SMCs that had grown from the vessel were 
trypsinised, replated and maintained as above.
Measurement of[Ca^^]i 
Calcium imasins
Vascular smooth muscle cells were removed from culture flasks using 
trypsin/EDTA (Sigma), washed by centrifugation/resuspension in fresh DMEM 
and aliquots of this suspension were plated onto glass cover slips. Experiments 
were performed on cells that had been passaged a minimum of one and a 
maximum of ten times. Cells were grown overnight and then loaded (15 min at 
37°C), with Fura-2 AM (1.5 |xM). Fura-2 loaded cells were then mounted in a 
chamber attached to the stage of a Nikon Diaphot inverted microscope where the
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cells were superfused with physiological saline solution (NaCl, 130mM; KCl, 
5mM; CaCl2 , ImM; MgCl2 , ImM; 4-(2-hydroxyethyl)-l-piperazine sulphonic
acid (HEPES), 20mM; D-glucose, lOmM; pH adjusted to 7.4 using NaOH). An 
Optoscan monochromator (Cairn Research, Faversham, Kent U.K.), positioned 
between a 75W Xenon lamp and the epifluorescence port of the microscope, was 
used to alternate the excitation wavelength between 340, 380 and 488 nm (band 
pass 10 nm) and to control the excitation frequency. Excitation light was reflected 
from a custom designed dichroic mirror through a Nikon 40x oil immersion 
FLUOR objective (NA=1.3). Fura-2 emitted fluorescence light at 515 nm was 
monitored either by a low noise COHU CCD camera or a photomultiplier tube 
with a bialkali photocathode. Images acquired with the CCD camera were stored 
and analysed digitally under the control of Meta Fluor imaging software 
(Universal Imaging Corp., West Chester, PA, USA). Images acquired for each 
excitation wavelength were collected every 1 sec; exposure to excitation light was 
always 80ms/image and the time interval between the acquisition of each image 
was ~2 msec. Cells were delimited by producing a mask that contained pixel 
values above a threshold applied to the 380 nm image and time-dependent 
changes in [Ca^ j^i was calculated from the ratio of two background subtracted 
images.
Confocal Microscopy
Identical parameters (brightness, contrast, laser intensity, excitation and emission 
wavelengths, slit size and frame averaging) were set in every experiment, unless 
stated otherwise. The objectives used throughout this chapter were Nikon x40, oil
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and Zeiss x40, water, in conjunction with the inverted and upright systems, 
respectively.
Whole cell imase analysis
Images were collected and analysed using Universal Imaging's 'Metamorph' 
software. Cells were grown on cover slips for 24 hours prior to use, unless 
otherwise stated. Cover slips were mounted in a flow chamber (WPI) and placed 
on the stage of an invert (Nikon Diaphot) microscope fitted with a Noran Odyssey 
Laser Scanning Confocal Module. Fluorophores were excited using a 488 nm 
argon laser and detected with a 515 nm band pass filter. In all experiments, a 
15|im slit was used and all other parameters were kept constant. All cells were 
checked for viability using Propidium Iodide staining prior to every experiment. 
QAPB
Using cell autofluorescence, a suitable group of cells was selected and the focal 
plane fixed by locking the focus motor. The system was then set to acquire images 
(64 frame averages, unless stated otherwise) at 1 minute intervals. After a baseline 
was established, typically 5-6 minutes, the first concentration of fluorescent ligand 
was added and allowed to equilibrate (i.e., until no further increase in 
fluorescence) for at least 5minutes. After equilibration the next concentration of 
fluorescent ligand was added, without washing, and given time to equilibrate as 
before. Once saturation had been reached the individual cells were outlined using 
Metaporph's define-region tool and the fluorescence intensity values 
representative of each concentration at equilibrium were recorded. Non-specific 
binding was defined as fluorescence binding in the presence of 10|liM  prazosin. 
The composition of the HEPES buffer used in all single cell work was as follows:
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NaCl 130mM, KCl 5mM, HEPES 20mM, Glucose lOmM, MgCI ImM, CaCl 
ImM.
Inhibition of OAPB-associated fluorescence bindins
Cells were mounted in a flow chamber bath and experiments carried out in a 
similar manner to that described above. VSM cells were pre-incubated for 30 
minutes with inhibitors, BMY-7378 or RS100329 prior to addition of QAPB. 
Characterisation of ai-AR subtypes expressed was estimated in terms of the 
ability of these drugs to inhibit the development of QAPB-associated 
fluorescence.
Since it was evident from preliminary experiments that BMY-7378 was unable to 
access intracellular sites in this cell type, Streptolysin O (SLO, Sigma) was 
employed to permeabilise the plasma membrane permitting cellular uptake of 
large or charged molecules. Cells plated on cover slips, were covered, drop wise, 
with SLO (1 unit/cover slip) and BMY-7378 (InM) in PBS (pH 7.4) and 
incubated for 30minutes at 37°C. After this incubation period, cell membranes 
were allowed to reseal in the presence of their culture medium, the active 
ingredient being; foetal bovine serum, for 5minutes. Following a brief wash with 
HEPES, cover slips were mounted in the flow chamber as before and allowed a 
further ISminute incubation with BMY-7378 alone, to allow for any binding on 
the plasma membrane.
Experiments were performed on cells that had been passaged a minimum of 3/4 
and a maximum of 1 0  times.
Transient transfection
Carotid Artery cultured smooth muscle cells
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Smooth muscle cells were grown routinely and plated on cover slips 24 hours 
prior to transfection. Transient transfections were carried out via a lipofection 
method with a variety of commercially available reagents. DOTAP (Boehringer 
Mannheim), Transfectam®, Transfast^^ and Tfx^'^-50 (Promega) were all used 
according to the manufacturers instructions. To optimise the transfection 
conditions, various alterations to the protocol were carried out. Promega’s 
’transfection assistant' database (www.Dromeea.com) was used to try to determine 
optimal transfection conditions for this cell type. Specific factors determine the 
efficiency of transfection of smooth muscle cells, including the reagent used, 
charge ratio (ReagentiDNA), amount of DNA used, ± serum, time of transfection, 
confluency of cells, medium exchange etc. In all cases, prior to transfection, the 
medium was aspirated and the cells were washed twice in serum-free DMEM. 
Post-transfection, cells were overlayed with complete medium and assayed after a 
further 60 hours in culture.
Thoracic aorta
Briefly, the arteries were removed from the animal, aseptically dissected free from 
fat and connective tissue, cut longitudinally, and spread out flat on a sterile culture 
dish. The vessel segment was flushed with serum-fi-ee DMEM, then the 
transfectant mix (2.5pg/ml vector, Tfx™-50 ratio 4:1, 6:1) was added, sufficient 
to cover the segment for 2 hours and finally overlaid with complete DMEM. After 
the appropriate incubation period, 5 days, with medium changes every day, the 
segments were removed from the culture dish, mounted on a microscope slide in 
fluorescent mounting medium (DAKO) ready for analysis.
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Vascular tissue analysis 
GFP detection
Arteries (thoracic aorta) were removed from culture dishes and visualised 
mounted on microscope slides in fluorescent mounting medium (DAKO). The 
majority of the vessel work was performed on an upright (Nikon Optiphot) 
microscope. As mentioned previously, all parameters were kept constant to ensure 
that comparisons could be made between different specimens.
Using GFP-associated fluorescence, a suitable region was chosen, and a stack of 
images collected by selecting a start plane within the specimen. Setting the stepper 
motor interval (z) to 0.5p,m, serial confocal z-sections of GFP/aib-AR distribution 
within SMCs/adventitial cells in situ were acquired. Movies and 3D- 
reconstruction of some transfected cells were made and can be visualised on the 
CD enclosed.
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Chapter 3 
Results
Fluorescent ligand saturation binding on cultured vascular smooth muscle cells. 
Smooth muscle cells grown from an explant of thoracic aorta from the aie-AR 
knockout mouse, or dissociated from the carotid artery of either wildtype or 
knockout mice, were cultured for indicated passages, and the specific binding of 
QAPB to ai-ARs was assessed. Cells from wildtype aorta were not studied due to 
time constraints. Bright field images of the cells were used to fix the focus to 
allow image capture at one focal point as autofluorescence was negligible. QAPB- 
associated fluorescence binding was concentration-dependent in smooth muscle 
cells from carotid artery and aorta (figures 3.1, 3.5 and 3.10). Fluorescence 
intensity in most cells reached saturation within the concentration range, although 
some cells displayed little or no QAPB staining indicating heterogeneity in 
expression levels between individual cells. In the presence of IpM prazosin, 
fluorescence due to increasing concentrations of QAPB was significantly lower 
(figure 3.5a) and this remaining binding was used to estimate non-specific binding 
for all cultured cells. Specific binding curves were constructed: examples are 
shown in figures 3.2a, 3.5b, and 3.10b. The estimated specific binding and affinity 
(FKo) of QAPB (nM) was estimated where applicable. Heterogeneity in the 
morphology of individual cells prevented comparisons of FKd values to be made 
in this cell type. The calculated FKd values were consistent with the affinity of 
QAPB at tti-ARs in other native cells.
The image of concentration-dependent binding of QAPB detected in cultured 
smooth muscle cells was dependent on the morphology of individual cells. In
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spindle-like cells, binding was composed of diffuse, intense staining throughout 
the entire cell, excluding the nucleus. In 'fried egg' shaped cells, clusters of QAPB 
binding were focused around the nuclear membrane. Some cells showed binding 
predominantly at the plasma membrane only (figure 3.9). No obvious differences 
between wildtype and knockout cells were observed. Phenotypic heterogeneity 
did exist within each cell line including ai-AR expression levels, cell morphology 
and growth rates, hindering simplistic conclusions.
Cells were stained with a cy3 conjugated a-actin monoclonal antibody to verify 
SMC origin (figure 3,11).
Fluorescent ligand saturation binding on freshly dissociated vascular smooth 
muscle cells from mouse carotid artery.
Smooth muscle cells were dissociated from both wildtype and knockout carotid 
artery. Due to greater availability of these mice, most work was done on wildtype 
cells. Post dissociation, cells were plated on cover slips and incubated in buffer 
containing 40% FBS overnight or for 48hours at 4°C. The specific binding of 
QAPB to native ai-ARs was assessed using a nanomolar concentration range as 
indicated. Bright field images of cells that were sufficiently stuck to the cover slip 
were used to fix the focus to allow image capture at one focal point. QAPB- 
associated fluorescence binding was concentration-dependent in cells from both 
wildtype and knockout carotid artery, although heterogeneity did exist between 
individual cells in their expression levels and in the concentration at which these 
sites saturated (figures 3.3 and 3.4c). Another interesting observation was that the 
initial concentration at which QAPB bound to these cells varied quite 
considerably. If QAPB enters cells via an endocytic mechanism, then it seems
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plausible that this may be due to a lag period while cells adjust to the temperature 
change from 4°C (overnight) to room temperature (HEPES). In the presence of 
IpM prazosin, fluorescence due to QAPB was significantly reduced (figure 3.4c) 
and the remaining binding was used to estimate non-specific binding for all 
freshly dissociated cells. Specific binding curves were constructed: an example of 
which is shown in figure 3.4b. The specific affinity (F K d ) o f  QAPB (nM) and 
average fluorescence intensity for cells was estimated where applicable (figure 
3.4a). The calculated FKd values for most of the fresh cells were consistent with 
the affinity of QAPB at ai-ARs in other native cells (Mackenzie et al., 2000), 
although there was variation between cells.
Two patterns of QAPB-associated fluorescence were observed over a 
cumulatively increasing concentration range. At the lowest concentration at which 
QAPB bound to specific sites, binding appeared to be diffuse throughout the cell. 
At higher concentrations, diffuse staining became stronger in an intracellular 
location (figure 3.3 and 3.4c). In a patch of wildtype cells, equilibrated with lOnM 
QAPB, this intracellular binding was clearly distributed in a perinuclear 
orientation (figure 3.9c). In a knockout cell (figure 3.4c), a similar specific 
binding pattern was observed.
Identification o f native aj-AR subtypes on cultured smooth muscle cells by 
inhibition of QAPB-associated fluorescence.
Cultured aortic and carotid artery smooth muscle cells were passaged as indicated 
in the figure legends. Cells were pre-incubated with InM RS 100329 or BMY- 
7378. Initial studies using BMY-7378 and knockout carotid artery SMCs 
indicated that no am-ARs were expressed in these cells (figure 3.6b). Since this
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did not correlate with the functional response from this vessel (Daly et al, in 
press), I presumed that BMY-7378 was unable to access intracellular sites. 
Therefore, streptolysin O (SLO) was employed to form pores within the plasma 
membrane. Post incubation with antagonist, the membrane was resealed in the 
presence of foetal bovine serum. QAPB binding was unaffected by the action of 
SLO alone (figure 3.6a).
On addition of cumulative concentrations of QAPB to knockout cells from both 
types of vessel, the appearance of fluorescence was significantly inhibited in the 
presence of BMY-7378 (five of out five tested) (figures 3.6 and 3.7 and 3.10), 
with the occasional cell (one out of two tested) showing blockade by RS 100329 
(figure 3.8). Addition of a single concentration of QAPB to patches of knockout 
carotid artery smooth muscle cells, pre-incubated as above, also illustrated a 
significant reduction of QAPB-associated fluorescence in the presence of InM 
BMY-7378 yet in this case RS 100329 was not effective (figure 3.8).
In knockout aortic cells, the overall fluorescence intensity was lower than in 
identically treated cells from the carotid artery, hindering interpretation of 
antagonist experiments, although BMY-7378 appeared to inhibit to a greater 
extent than RS 100329. Collectively, these data suggest that in knockout smooth 
muscle cells cultured from both the thoracic aorta and carotid artery, the tti-AR 
subtype expressed is predominantly aio-AR, although the presence of the Qia-AR 
cannot be completely ruled out.
Cultured wildtype carotid artery smooth muscle cells were pre-incubated for 
30minutes with InM RS 100329 or BMY-7378. On addition of cumulative 
concentrations of QAPB, the appearance of fluorescence was reduced, but not 
completely blocked, in all cells in the presence of BMY-7378 (figure 3.1).
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RS 100329 significantly reduced the binding of QAPB in the chosen experimental 
cell in figure 3.1. Addition of 30nM QAPB to patches of wildtype cells pre- 
incubated as above, resulted in a similar reduction of QAPB-associated 
fluorescence in the presence of either BMY-7378 or RS 100329, indicating that at 
least two, namely aiA-AR and aio-AR are predominantly expressed in wildtype 
cells (figure 3.2). The question of whether individual cells express one or the other 
or perhaps all three subtypes remains unanswered. Such inhibition experiments 
are open to misinterpretation as differences in expression levels can suggest that 
the antagonist in question is lowering or blocking QAPB binding, when actually 
the tti-AR complement of that cell could be low or negative.
Comparison of bar charts representing QAPB binding to both wildtype and 
knockout smooth muscle cells in the presence of BMY-7378 (figures 3.8) 
demonstrated the ability of this antagonist to reduce specific QAPB binding to a 
greater extent in knockout cells. This suggests that the residual fluorescence seen 
in wildtype cells is due to binding to aie-ARs.
Collectively, these results suggest that oci-AR subtype expressed in knockout cells 
is predominantly ocio-AR, with the possibility that some cells express the « ia-AR 
subtype. In the wildtype there is evidence for aiA-AR and aio-AR plus a residual 
binding after antagonists greater than in aie-AR knockout that is likely to be aiB- 
AR.
This illustrates that, when comparing wildtype and knockout cells, removing one 
subtype may lead to up-regulation of another subtype. In this case am-AR 
replacing aie-AR. There was no obvious differences in the distribution of QAPB 
in either cell type, indicating that ai-ARs could be localised in a defined region in
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cultured vascular smooth muscle cells, irrespective of their subtype, yet 
influenced by their morphology in culture.
Expression ofGFP-tagged ajb-ARs in situ.
Tfx™-50 mediated transfection facilitated the delivery of the GFP-tagged «ib-AR 
gene into segments of thoracic aorta from the aiB-AR knockout mouse. Analysis 
of vessel segments, mounted in fluorescent mounting medium, 5days post­
transfection showed patches of cells displaying GFP-associated fluorescence 
(figure 3.12). The GFP-expression in SMCs was distributed throughout the cell, 
with the non-fluorescent nucleus being clearly defined in most cells. Adventitial 
cells within the vessel wall also expressed the construct that was controlled by the 
viral promoter (figure 3.13a, bottom). Dividing cells in the culture media 
surrounding the transfected vessel also appeared to express the GFP-tagged 
construct, but to varying degrees (figure 3.13a, top). Movies representing 0.5|xm 
sections through the blood vessel wall encompassing transfected SMCs (figure 
3.12), and an adventital cell (figure 3.13b) are presented. 3D reconstructions 
representative of these cells are also shown (figures 3.12 and 3.13b). Culturing of 
vessel sections alone increased autofluorescence levels (figure 3.14), although 
GFP-associated fluorescence was sufficiently more intense to allow transfected 
cells to be distinguished from non-transfected cells. For this reason the laser 
power used to detect GFP was much lower, explaining the low levels of 
autofluorescence apparent in the transfected vessel images.
173
Chapter 3 
Discussion
The work in this chapter took on the study of the subcellular distribution and 
characterisation of native oci-ARs in VSMCs; freshly dissociated, in culture, and 
in situ. Initially, the distribution and binding properties of the oci-ARs in SMCs 
grown from an explant of thoracic aorta from the knockout mouse, or dissociated 
from the carotid artery of either wildtype or knockout mice were established.
The difficulty of studying VSMCs in vitro, and in interpreting such data, is due to 
their ability to modulate phenotype rapidly when removed from in vivo 
conditions. The degree of alteration is dependent on the methods used for isolating 
the cells, length of time in culture, and culture conditions. Bower and Dahm, 
(1993) have carefully examined these factors in cultured avian amniotic SMCs, 
and concluded that serum-derived adhesion factors alter SMC morphology, 
causing cells to take on a flattened phenotype and lose contractile ability. In 
contrast cells cultured in the absence of serum maintain a spindle-shaped 
morphology and the ability to contract. Additionally, individual VSMCs from 
different vessels and organisms may not respond similarly to identical in vitro 
conditions (Owens, 1995).
QAPB-asssociated fluorescence binding demonstrated that specific, high affinity 
cti-ARs were present on mouse carotid artery and thoracic aorta VSMCs, both 
freshly dissociated (carotid artery only) and cultured up to a maximum of ten 
passages. Cultured cells were used for quantitative, competitive analysis of 
subtypes since this provided a population of cells that could withstand prolonged 
protocols giving reliable, high affinity binding.
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QAPB binding to freshly dissociated cells was informative in that it showed 
specific, predominantly intracellular binding. The distribution of ai-ARs was 
consistent in all cells that were analysed. Similarly, no differences were observed 
between wildtype or knockout cells, indicating a similar pattern was likely within 
the vessel wall, irrespective of subtype. In contrast, the distribution of QAPB 
binding in the cultured cells differed significantly, and was influenced by the 
morphology of individual cells. These differences were observed in both wildtype 
and knockout cells.
Information on native ai-AR subtype distribution is very limited. A recent study 
looked at the distribution of the aiA-AR in freshly dissociated human prostatic 
SMCs (Mackenzie et al., 2000). Quantitative imaging revealed that 40% of QAPB 
binding sites were intracellular, particularly around the nucleus, with the 
remainder residing at the plasma membrane. Equilibration of prostatic SMCs with 
low concentrations of QAPB (<2nM) revealed fluorescence predominantly 
associated with the cell membrane. At higher concentrations, intracellular binding 
sites around the nucleus were identified.
These observations were also made in the specific binding of QAPB to freshly 
dissociated carotid artery SMCs. Two patterns of QAPB-associated fluorescence 
were observed over a cumulatively increasing concentration range. At the lowest 
concentration at which QAPB bound to specific sites, binding appeared to be 
diffuse throughout the cell. At higher concentrations, diffuse staining became 
stronger in an intracellular location (figure 3.3 and 3.4c). This intracellular 
binding was clearly distributed in a perinuclear orientation (figure 3.9c).
Due to technical limitations, SMCs had to be cultured in order to establish the 
subtype(s) of ai-AR present on these cells.
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The compound used to discriminate between the aiA-AR and the other two 
subtypes was RS 100329. The compound was used at InM, a concentration 5 
times higher than its inhibitory constant versus aiA-ARs but still 1 0  times lower 
than versus aie-ARs or ctm-ARs and thus it should inhibit only «ia-ARs. This 
concentration of RS 100329 reduced the specific binding of QAPB in some cells 
from both blood vessels, indicating the presence of this subtype in selected cells. 
The compound used to discriminate between the am-AR and the other two 
subtypes was BMY-7378. It was used at InM, a concentration slightly higher than 
its inhibitory constant versus am-ARs (pKi 8 .5-9.5) but still 100 times lower than 
versus aiA-AR or a^-ARs and thus it should inhibit only am-ARs. This 
concentration of BMY-7378 greatly reduced QAPB in knockout SMCs from both 
aorta and carotid artery, but reduced it less in wildtype carotid artery cells.
The ai-AR subtype identified in prostate SMCs was the aiA-AR (Mackenzie et 
al., 2000). In carotid artery SMCs, the predominant subtype was am-AR in the 
knockout, and a mix of all three in the wildtype is likely. The current situation in 
the literature leads us to believe that differences in receptor distribution might 
allow subtypes to be distinguished. However, in this case, the characterisation of 
ai-AR subtypes and analysis of their distribution, suggests that different subtypes 
adopt a common location in freshly dissociated SMCs.
The pattern of QAPB binding in cultured carotid artery SMCs was dependent on 
the morphology of the differentiated cells. In spindle-like cells, binding was 
composed of diffuse, intense staining throughout the entire cell, excluding the 
nucleus. In 'fried egg' shaped cells, clusters of QAPB binding were focused 
around the nuclear membrane, with some cells showing binding predominantly at 
the plasma membrane (figure 3.9).
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The only other work that has been done on oci-AR subtype distribution in cultured 
VSMCs, used ai-AR subtype selective antibodies (Hrometz et ak, 1999; McCune 
et al., 2000). VSMCs cultured from renal and femoral artery stained positive with 
all three antibodies, but to varying degrees. Staining with the Œia-AR and ttm-AR 
antibodies were predominantly focused around the nuclear membrane. Staining 
with the otiB-AR antibody was detected around the cell periphery and also in a 
perinuclear orientation. The morphology of VSMCs in this study was similar to 
the 'fried egg' appearance seen in some of the cells cultured from the carotid 
artery/aorta. Similarly, the distribution of QAPB binding to (Xi-AR subtypes in 
cells with such morphology was predominantly associated with the nuclear 
membrane.
Our objective was to understand the natural disposition of «i-ARs in VSMCs, but 
prolonged incubation, and culture, leads to de-differentiation with possible 
changes in distribution and receptor types. In fact, using the same cells as 
mentioned previously, Hrometz et al. (1999) observed differences in the 
immunostaining pattern that were dependent on the receptor, cell type and the 
time in culture. This indicates that the expression of the ai-ARs can be affected 
by culture conditions, and that caution should be taken in using cultured SMCs to 
delineate a%-AR function in vivo. Strong immunostaining was obtained in frozen 
sections from intact blood vessels using all three antibodies. In cultured cells, 
strong immunostaining was observed only when using the a^-A R  antibody. The 
indication that culturing of SMCs can depress oti-AR subtype expression is not 
ideal, since our objective is to understand their natural distribution.
The observed in vitro cellular diversity of SMCs in culture is now thought to be 
attributed to the existence of intrinsic heterogeneity rather than to the process of
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phenotypic modulation. The work of several groups (reviewed by Frid et al., 
1997), supports the idea that heterogeneity of different SMC subpopulations exists 
and that these differences are intrinsic to the cell type. Evidence demonstrates that 
the arterial media in systemic vessels is not composed of a phenotypically 
homogeneous population of SMCs but rather of heterogeneous subpopulations of 
cells with unique developmental lineages.
It has been demonstrated that structural and cellular heterogeneity exists between 
three layers of bovine arterial media (Bochaton-Piallat et al., 1996). Therefore it 
seems plausible that the difference in distribution of tti-ARs seen in cells with 
varying morphologies could be explained by their orgin from within the vessel 
wall. Perhaps cells belonging to a particular layer have a specific role within the 
vasculature and therefore the functional distribution of ai-ARs may be cell- 
specific. An example of this would be the 'fried egg' shaped cells, described 
previously as senescent, characterised by large vacuoles and unable to reach 
confluence (Bochaton-Piallat et al., 1996), the localisation of QAPB binding in 
such cells is perinuclear, and from traditional models of GPCR signalling, this 
would suggest that these cells are not primarily involved in contraction. So what 
purpose do they serve? The spindle-shaped cells, form tightly packed monolayers, 
divide at a much faster rate than 'fried egg' cells, and have a distribution of tti- 
ARs in close proximity to the plasma membrane, suggesting a possible role for 
these cells in contraction. Another interesting observation in this study was that 
SMCs cultured from the wildtype carotid artery were almost quiescent, in that 
after passage 1/2, no further proliferation was obvious to the eye. This was in 
sharp contrast to knockout SMCs, which grew at an enormous rate. Unfortunately,
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the growth rates could not be quantified due to the quiescent nature of the 
wildtype cells.
A common technique that has been used to assess growth potential of VSMCs has 
been to isolate VSMCs from different regions along the length of one vessel (e.g. 
the aorta) and/or to remove cells from one particular vessel type at different 
developmental time points and culture them separately. Results suggest that cells 
derived from different regions have distinct growth patterns and different 
metabolic needs in addition, authors suggest that mitogenic factors regulate the 
growth of SMCs dependent on the stage in development of the blood vessel (see 
review Hungerford and Little, 1999).
Studies by Paglin et al. (1987) indicated a heterogeneous distribution of ANG II 
receptor density in enriched VSMCs from rabbit aorta, and Absher et al. (1989) 
reported a high degree of heterogeneity in proliferative behaviour among cell lines 
derived from bovine carotid artery. The present findings with cci-ARs are 
consistent with this.
The phenotypic diversity displayed here includes cell size, proliferation rate, and 
tti-AR density. In the light of previous work, and the work presented in this 
chapter, it is possible that the cells described represent the heterogeneity of VSM 
tissue found in vivo. These features may reflect a specialised function related to 
location in the blood vessel wall. However, because these analyses have been 
performed in vitro, phenotypic modulation of the individual cells remains 
uncontrolled and it is impossible to draw direct conclusions regarding the parental 
cells in situ.
A possible solution to this problem was to employ the Œib-AR knockout mouse 
and in vitro transfection of intact blood vessel. It was possible to manipulate the
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«ib-AR population enabling expression and visualisation of GFP-tagged 
constructs in situ. Using GFP-tagged constructs and CLSM, direct visualisation, at 
a subcellular level was permitted.
The efficiency of successful gene transfer using cationic liposomes, however, is 
variable and highly dependent on the cell type. Previous studies have established 
that the efficacy of liposome-facilitated transfection may vary up to 1 0 0 -fold, 
depending on the cell line used (Feigner et al., 1987). Most in vitro experience to 
date has been with continuous/immortal animal cell lines. The results of studies 
using these types of cells, however, have uncertain implications for the likelihood 
of success in native cells.
In this study, it has been shown that using the commercially available liposome, 
Tfx™-50, it was possible to transfer and express GFP-tagged aib-ARs into 
VSMCs in situ. The DNA concentration, the ratio of liposome to DNA (which 
affects the net charge of the complexes formed), the transfection time and the 
effect of serum were critical factors in these transfections. The efficiency of GFP- 
expression following the transfection of aortic segments is encouraging but raises 
a number of questions: why do certain cells express high levels of GFP while their 
neighbours appear untransfected? The majority of transfected cells have 
morphology typical of the contractile phenotype, being spindle-shaped, 
corresponding to the hills-and-valleys appearance. It may be possible that the 
efficiency of transfection is clonal in nature. This will be investigated further. In 
order for direct comparisons to be made between the expression of both 
constructs, it would be essential that the transfection protocol is optimal and 
identical in both cases. Further work is also required to establish specific regions 
within the vessel wall that express the aiB-AR.
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In summary, the objective in this chapter was to understand the natural disposition 
of tti-ARs in VSMCs. Initially, the subcellular distribution of native oti-ARs from 
freshly dissociated carotid artery SMCs was assessed. Characterisation of native 
(Xi-ARs in VSMCs from carotid artery and thoracic aorta were thereafter enabled 
post-differentiation, in culture. Further to this, in vitro transfection enabled the 
manipulation of the ai-AR population in segments of thoracic aorta, allowing 
visualisation of GFP-tagged otiy-ARs expressed in VSMCs in situ. Information 
from this work, and that of others, showed that the 'natural' disposition of tti-ARs, 
irrespective of subtype, is similar in freshly dissociated SMCs from vascular/non- 
vascular tissue, but phenotypic modulation does alter this distribution. The 
question that remains unanswered is whether this difference in ai-AR distribution 
is solely due to their differentiated state, or whether it is intrinsic to the cell and 
therefore represents heterogeneity within the vessel wall.
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Figure 3.1 QAPB binding on cultured VSMCs dissociated from 
the carotid artery of wildtype mice. Cells had been passaged a 
maximum of two times. Non-specific binding was defined by 
l|xM prazosin. Inhibition of QAPB binding to specific a^A R 
binding sites was assesed by pre-incubation for 30minutes with 
InM of the a^^-AR and a^^-AR selective antagonists RSI 00329 
and BMY-7378, respectively. Cells were plated on coverslips 
and examined by confocal microscopy with timelapse 
photography. Increasing concentrations of QAPB, as indicated, 
were added cumulatively and images were collected at 1 -minute 
intervals. Image data was collected at equilibrium time points for 
each concentration of QAPB (added at 5minute intervals). 
Images are shown in pseudocolour, where black indicates no 
staining and blue, green, yellow and red indicate increasing 
levels of saturation of the fluorophore.
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Figure 3.2 (a) The QAPB-associated fluorescence intensity was calculated 
by Metamorph software and plotted against increasing concentrations of 
QAPB to demonstrate the levels of specific binding of QAPB in a sample 
wildtype cell. The estimated specific binding affinity (FK^) of QAPB was 
measured as nanomolar (nM) and the estimate of specific binding (ESB) was 
measured as fluorescence intensity (FI), (b) Inhibition of QAPB binding on 
cultured vascular smooth muscle cells dissociated from wildtype carotid 
artery pre-incubated with InM RSI00329 and BMY7378. Cells were plated 
on coverslips and examined by confocal microscopy. Images were captured 
and image data collected after equilibration of 30nM QAPB. Images are 
shown in pseudocolour, where black indicates no staining and blue, green, 
yellow and red indicate increasing levels of saturation of the fluorophore. (c) 
Bar chart representing 30nM QAPB binding to VSMCs pre-incubated with 
InM BMY7378 or RSI00329. Cells were plated on coverslips, incubated for 
30minutes with non-fluorescent antagonist, then equilibrated with 30nM 
QAPB. Inhibition of QAPB binding was measured as average fluorescence 
intensity of the cell compared to the absence of inhibitor (control).
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Figure 3.3 (a) QAPB binding on VSMCs freshly dissociated from the 
carotid artery of wildtype mice. Post dissociation, cells were incubated 
in buffer at 4°C overnight (Cells 1 -4) and for 48hours (Cells 5-7) prior to 
experiments. Non-specific binding was defined by IpM prazosin. Cells 
were plated on coverslips and examined by confocal microscopy with 
timelapse photography. Increasing concentrations of QAPB, as indicated, 
were added cumulatively and images were collected at 1 -minute 
intervals. Image data was collected at equilibrium time points for each 
concentration of QAPB (added at 5minute intervals). Images are shown 
in pseudocolour, where black indicates no staining and blue, green, 
yellow and red indicate increasing levels of saturation of the fluorophore.
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Figure 3.4 (a) The estimated specific binding affinity (FKg) of 
QAPB was measured as nanomolar (nM) and the estimate of 
specific binding (ESB) measured as fluorescence intensity (FI). 
Values for freshly dissociated wildtype carotid artery SMCs 
were estimated where applicable and presented in the table, (b) 
The QAPB-associated fluorescence intensity was calculated by 
Metamorph software and plotted against increasing 
concentrations of QAPB to demonstrate the levels of specific 
binding of QAPB in a sample cell, (c) QAPB binding on 
VSMCs dissociated from the carotid artery of knockout mice. 
Post dissociation, cells were incubated overnight in buffer at 
4®C prior to experiments. Non-specific binding was defined by 
IpM prazosin. Cells were plated on coverslips and examined by 
confocal microscopy with timelapse photography. Increasing 
concentrations of QAPB, as indicated, were added cumulatively 
and images were collected at 1-minute intervals. Images are 
shown in pseudocolour, where black indicates no staining and 
blue, green, yellow and red indicate increasing levels of 
saturation of the fluorophore.
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Figure 3.6 (a) QAPB binding to specific a^-AR binding sites on 
cultured VSMCs dissociated from the carotid artery of knockout 
mice was assesed in cells that had been pre-treated with 
Streptolysin O (SLO). Cells were plated on coverslips and 
examined by confocal microscopy with timelapse photography. 
Increasing concentrations of QAPB (0.4-10nM) were added 
cumulatively and images were collected at 1 -minute intervals, (b, 
c) Demonstration that BMY7378 was unable to access 
intracellular binding sites in the absence of streptolysin O. Images 
are shown in pseudocolour, where black indicates no staining and 
blue, green, yellow and red indicate increasing levels of saturation 
of the fiuorophore. (d) Transmission images of cultured VSMCs 
dissociated from the carotid artery of knockout mice.
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Figure 3.7 (a) Inhibition of QAPB binding to specific a^-AR binding 
sites on cultured VSMCs dissociated from the carotid artery of 
knockout mice was assesed by pre-incubating cells for BOminutes 
with InM of the a^Q-AR selective antagonist BMY-7378. Cells that 
had been passaged a minimum of three and maximum of ten times 
were plated on coverslips and examined by confocal microscopy with 
timelapse photography. Increasing concentrations of QAPB, as 
indicated, were added cumulatively and images were collected at 1 - 
minute intervals. Images are shown in pseudocolour, where black 
indicates no staining and blue, green, yellow and red indicate 
increasing levels of saturation of the fiuorophore.
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Figure 3.8 (a) Inhibition of QAPB binding to specific ttpAR binding 
sites on cultured VSMCs dissociated from the carotid artery of knockout 
mice was assesed by pre-incubating cells for BOminutes with InM of the 
a^^-AR selective antagonist RSI00329. Cells that had been passaged a 
minimum of three and maximum of ten times were plated on coverslips 
and examined by confocal microscopy with timelapse photography, (a) 
Increasing concentrations of QAPB (0.4-10nM) were added cumulatively 
and images were collected at 1-minute intervals, (b) Images were 
captured and image data collected after equilibration of 20nM QAPB. 
Images are shown in pseudocolour, where black indicates no staining and 
blue, green, yellow and red indicate increasing levels of saturation of the 
fiuorophore. (c, top) Bar chart representing 30nM QAPB binding to 
wildtype VSMCs pre-incubated with InM BMY7378 or RSI00329. (c, 
middle) Bar chart representing 20nM QAPB binding to knockout VSMCs 
pre-incubated with InM RSI00329. (c, bottom) Bar chart representing 
30nM QAPB binding to knockout VSMCs pre-incubated with InM 
BMY7378. Cells were plated on coverslips, incubated for BOminutes with 
non-fluorescent antagonist, then equilibrated with the indicated 
concentration of QAPB. Inhibition of QAPB binding was measured as 
average fluorescence intensity of the cell compared to the absence of 
inhibitor (control).
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Figure 3.9 (a, d) lOnM QAPB binding on cultured VSMCs
dissociated from the carotid artery of knockout mice. Cells had been 
passaged four times, (b, top and middle) 10 and 20nM, QAPB binding 
respectively on cultured vascular smooth muscle cells dissociated 
from the carotid artery of knockout mice. Cells had been passaged ten 
times, (b, bottom) 30nM QAPB binding on cultured VSMCs 
dissociated from the carotid artery of wildtype mice. Cells had been 
passaged a maximum of two times, (c) QAPB binding on VSMCs 
freshly dissociated from the carotid artery of wildtype mice. Post 
dissociation, cells were incubated in buffer at 4°C overnight prior to 
experiments, (e) 20nM QAPB binding on cultured VSMCs 
dissociated from the thoracic aorta of knockout mice. Images are 
shown in pseudocolour, where black indicates no staining and blue, 
green, yellow and red indicate increasing levels of saturation of the 
fiuorophore.
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Figure 3.10 QAPB binding on cultured VSMCs dissociated 
from the thoracic aorta of knockout mice. Cells had been 
passaged a maximum of four times. Inhibition of QAPB 
binding to specific apA R binding sites was assesed by pre­
incubation for 30minutes with InM of the a^^-AR and a^^DAR 
selective antagonists RSI00329 and BMY-7378, respectively. 
Cells were plated on coverslips and examined by confocal 
microscopy with timelapse photography. Increasing 
concentrations of QAPB, as indicated, were added cumulatively 
and images were collected at 1-minute intervals. Image data 
was collected at equilibrium time points for each concentration 
of QAPB (added at 5minute intervals). Images are shown in 
pseudocolour, where black indicates no staining and blue, green, 
yellow and red indicate increasing levels of saturation of the 
fiuorophore. The QAPB-associated fluorescence intensity was 
calculated by Metamorph software and plotted against 
increasing concentrations of QAPB to demonstrate the levels of 
specific binding of QAPB in sample cells. The estimated 
specific binding affinity (FK^) of QAPB was measured as 
nanomolar (nM) and the estimate of specific binding (ESB) 
measured as fluorescence intensity (FI). Estimates made for 
cells are presented in the table.
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Figure 3.11 Representative images of cultured VSMCs stained with a 
cy3 conjugated smooth muscle ot-actin monoclonal antibody
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Figure 3.12 Manipulation and expression of recombinant GFP-tagged a,b- 
AR constructs in mouse a^g-AR knockout thoracic aorta in situ. Arterial 
segments were transfected in vitro as described in Methods, and visualised 
for GFP-associated fluorescence after 5 days in culture post-transfection. 
Images from both segments were collected under identical conditions using 
a x40, oil immersion objective, (a) pEGFP/human a,b-AR. (b) pmouse a,g- 
AR/human a,^,-AR. The above 2D images are also presented as movies and 
3D reconstructions. They are labelled as follows: a) i, ii, iii and iv and b) i, ii, 
iii and iv corresponding to the constructs used, as detailed above.
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Figure 3.13 (a) GFP-associated fluorescence representing cells
transiently expressing pEGFP/human a^y-AR. Arterial segments were 
transfected in vitro as described in Methods, and visualised for GFP- 
associated fluorescence after 5 days in culture post-transfection, (top 
panel) Cells found in the surrounding culture medium, (bottom panel) 
Cells within the transfected vessel wall, situated in the adventita. (b) A 
movie and 3D reconstruction of a transfected adventital cell within the 
vessel wall.
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Figure 3.14 (a, and b) Images representative of mouse thoracic aorta 
before and after 5days in culture, respectively. The laser power used in 
a) and b) was the same but much greater than that used to detect GFP- 
associated fluorescence in transfected SMCs.
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General Discussion and future research
What is the importance of studying ai-ARs? ai-ARs mediate some of the main 
actions of the natural catecholamines, AD, and NA. They participate in many 
essential physiological processes, including sympathetic neurotransmission, 
modulation of hepatic metabolism, and control of vascular tone, cardiac contraction, 
and the regulation of smooth muscle activity in the genitourinary system. It is now 
accepted that they also take part in cell growth and proliferation (see general 
introduction). Since ai-ARs are heavily involved in normal physiological functions, 
it is not surprising that defects in such functions can be attributed directly/indirectly 
to these receptors. As well as understanding their roles in normal physiological 
functions, it is also of great therapeutic interest to be able to manipulate oci-ARs, in a 
subtype-selective manner. Benign prostatic hyperplasia, cardiac hypertrophy and 
hypertension are examples of pathological conditions treated by drugs acting at ai- 
ARs.
Due to the homogeneous structural nature of the three known ai-AR subtypes, the 
lack of subtype-selective agents is a persisting problem in this field of research, and 
will no doubt continue to hinder ai-AR pharmacologists in the years to come. Until 
such time as highly discriminative antagonists become available on the drug market, 
the undesired side effects of non-selective agents will continue to pose a problem. 
Therefore, it is imperative that a continuous study of the properties of ai-ARs is 
carried out, to try to find subtype-specific features that can be modulated with view 
to drug design.
It is thought that the subcellular distribution of oci-AR subtypes may point to a new 
class of pharmacological properties that may distinguish them from each other and 
other GPCRs (Hirisawa et al., 1997). Therefore it is seems likely that this may hold
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as a means for therapeutically targeting individual subtypes. Therefore, an 
understanding of their distribution in native cell types is of great importance. It is 
also possible that by refining methods for the localisation of ai-ARs, new roles will 
come to light.
The subtype initially chosen for study was the aib-AR (see general introduction). In 
chapter 1 , fluorescence based methods were used to enable the analysis of the 
subcellular distribution of recombinant aib-ARs. Initially, a fluorescent ligand 
approach was employed to locate mouse and human aib-ARs stably expressed in 
live, NCB20 cells. Radioligand binding studies demonstrated the expression of a 
homogeneous population of otib-ARs as binding profiles were characteristic of 'aib- 
AR' cells. Fluorimetry and calcium imaging were used to demonstrate the 
functionality of all constructs employed. Thereafter, the main objective was to 
validate QAPB binding to oci-ARs in fixed (FLAG-tagged construct) and live (GFP- 
tagged construct) cells. Coupled with calcium imaging, the GFP-tagged cell line 
allowed the study of the distribution and active properties of ctib-ARs in response to 
agonist. Several key observations were made from the study of recombinant aib- 
ARs, and are detailed and discussed below:
1. The distribution of ajb-ARs stably expressed in NCB20 cells was predominantly 
associated with the plasma membrane. However, in some instances, a predominantly 
intracellular, non-perinuclear location was observed. Interestingly, receptors were 
distributed in a similar manner in cells at both high (8000fmol/mg) and lower 
(4000jmol/mg) receptor densities. In contrast, cells sampled from the same clone, 
and treated in the same manner, displayed a predominantly intracellular distribution 
in one yet plasma membrane distribution in another.
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Based on the traditional model of GPCR activation, it is thought that when expressed 
at high levels, only a fraction of receptors are located at the plasma membrane, thus 
able to respond to extracellular signals, leaving the excess in an intracellular 
compartment for recruitment when required. Previous work has indicated that 
different subtypes of ai-AR adopt different locations in the same cell (COS-7) 
(Hirasawa et al., 1997). In contrast, when expressed in rat-1-fibroblasts, two groups 
have observed a distribution pattern that was similar between subtypes, and 
associated with both the plasma and nuclear membrane (Hrometz et al., 1999; 
Mackenzie et al., 2000). The work in this chapter suggests that the distribution of 
recombinant aib-ARs stably expressed in NCB20 cells is not as clear-cut as first 
thought, and suggests that the same subtype is capable of having different 
distributions within the same host cell line. Such findings have indicated that 
perhaps the distribution pattern is influenced by the stage each cell is at in their 
cycle. Therefore caution must be taken when interpreting such data. Further work is 
required to establish the intracellular location of aib-ARs in these circumstances. 
Fluorescent endosomal/lysosomal markers are available and will be used to confirm 
their intracellular location.
2. An epitope-tagged (FLAG™) mouse aj^-AR construct was generated with a view to 
co-localisation studies with QAPB, to assess alterations in QAPB binding post­
fixation. When stably expressed in NCB20 cells, the fully functional FLAG-tagged 
construct had lower affinity than the wildtype receptor for aj-AR-selective 
compounds in radioligand binding studies, yet seemed unaffected in confocal 
analysis on live cells. Unfortunately immunofluorescence studies were not a success
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due to suspected cross-reactivity with cellular proteins and non-specific binding of 
the FLAG-antibody.
A possible explanation for the higher affinity of QAPB seen in live cells could be a 
conformational change in the tagged-receptor that permitted high affinity binding in 
its native environment (live cells), but caused some degree of steric interference in 
the plasma membrane preparation. It should be noted that QAPB also showed a 
reduced affinity for wildtype mouse/human aib-ARs in radioligand binding assays 
compared to live cell binding. Although not to the same degree, it does suggest that 
the discrepancy may be due to the binding of QAPB in the radioligand binding 
protocol, as well as epitope-tagging. Prazosin also had a lower affinity for the FLAG- 
tagged construct than the wildtype receptor in radioligand binding analysis, 
confirming that steric interference was likely. Regarding the structure of the aib-AR, 
in particular the position of the ligand-binding domain, additions to the N-terminus 
are likely to cause changes in folding and I am assuming this is what has happened in 
this case. The tag has restricted access to the ligand-binding domain.
Although the affinity of ai- selective ligands is reduced slightly in this cell line, it is 
still within the accepted range (nM) and will be useful in future work.
Expression of this construct in a non-rodent cell line will hopefully reduce the cross­
reactivity to cellular proteins and non-specific binding of the FLAG antibody 
observed during this project.
3. A fully functional, C-terminal GFP-tagged human ajb-AR construct was stably 
expressed in NCB20 cells, and demonstrated that such C-terminal fusion proteins do 
not perturb normal ligand binding, or functionality.
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In contrast to the reduced ligand-binding affinity that resulted from the attachment of 
an 8 amino-acid epitope-tag (FLAG) to the N-terminus of the mouse «ib-AR, addition 
of >200amino-acids (GFP) to the C-terminus had no adverse effects on prazosin 
binding affinity. However, regarding QAPB binding, a similar situation was found in 
this cell line as was observed with the FLAG-tagged construct. Such findings 
indicate that the reduced affinity of QAPB binding must be attributed to its activity 
in the radioligand-binding set-up. In the radioligand binding studies, when the 
affinity of every aib-AR construct for prazosin was compared with their respective 
affinities for QAPB, it was obvious that each cell line displayed a much lower 
affinity for the fluorescently labelled compound. In contrast, the studies in live cells 
show that QAPB binds to aib-ARs with the same ability in all cell lines studied. 
Collectively, these observations indicate that QAPB is more suited to the live cell 
protocol and for some unexplained reason gives a wide range of binding affinities in 
the membrane preparation protocol. Such work requires further investigation.
4. ajb-ARs have a basal level o f movement between the plasma membrane and a non- 
perinuclear, intracellular compartment when stably expressed in NCB20 cells. This 
movement ceased upon Ca^^ release from intracellular stores in response to agonist 
stimulation and resumed activity once Ca^^ levels returned to base line. During 
prolonged (35minutes) agonist exposure, there was an obvious overall shift in the 
density o f ajb-ARs residing at the plasma membrane to the intracellular 
compartment.
Several interesting observations were made during this experiment, although arriving 
at logical explanations was perplexing. What surprised me the most was the extent of 
basal movement of these receptors back and forth from inside the cell to the
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membrane. In response to agonist, the balance was shifted and receptors moved from 
the plasma membrane to inside the cell, presumably to prevent over-stimulation. 
Interestingly, during the very short-lived period of Ca"^  ^ release, this movement 
ground to halt, and did not resume until Ca"^  ^ levels had returned to baseline. A 
possible explanation for this could be the cell prioritising its metabolic energy for the 
release of Ca'^ '^ . This is the first report to my knowledge of such an observation, and 
will require further investigation.
5. In NCB20 cells stably expressing the GFP-tagged construct, QAPB bound to the 
same areas within the cell as those associated with low GFP fluorescence, 
representing the location o f the tagged aib-ARs. This was however difficult to 
interpret as QAPB binding caused a change in the shape o f the cell. Rapid vesicular 
movement within the cell indicated that QAPB enters 'ai-AR' cells via an endocytic 
pathway in the absence of agonist. QAPB binding to aj-ARs did not elicit an 
intracellular Ca^^ response.
Preliminary work done by Dr John Pediani has shown that QAPB binding is blocked 
in the presence of sucrose/concanavalin-A, inhibitors of clathrin-mediated 
endocytosis (Pediani, manuscript in preparation). The indications that QAPB gains 
access to intracellular sites via receptor-mediated endocytosis has brought to light 
matters that were not previously foreseen. Does this happen because QAPB is non- 
selective between each of the three ai-AR subtypes? Once it binds to ai-ARs on the 
surface of the cell, and is internalised, what is the fate of the ligand-receptor 
complex? Does it also gain access by diffusion through the membrane, due to its 
structurally lipophilic nature? Is the path of endocytosis seen in QAPB binding to ai- 
ARs the same as that taken by agonist? Since only agonist stimulation is capable of
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mediating an intracellular response, it is unlikley that they are identical. A similar 
observation has been observed with antagonist binding to the cholecystokinin 
receptor, where Roettger et al. (1997) have shown that an antagonist is capable of 
mediating its internalisation in the absence of both receptor phosphorylation and 
second messenger signalling. Another report regarding the p-opioid receptor has 
indicated that the signal for internalisation is apparently independent of second 
messenger production (Segredo et al., 1997). Further work is required to establish the 
route taken by QAPB in these cells.
The reason for studying mouse aib-ARs was to assist our interpretation of data from 
the aiB- knockout mouse model we were using at that time. Human aib-ARs were 
also compared alongside so that ultimately, findings could be related to clinical 
issues.
Thus far, interpretation of observations made in transgenic mouse models has been 
hampered due to the lack of knowledge available regarding the distribution of ai- 
ARs in the normal mouse. However, recent work has shown that in some cases, 
simple comparisons between aiB-knockout and wildtype mice can allow specific 
functional roles to be attributed to the subtype in question (Daly et al, in press), or 
perhaps indicate subtype redundancy, which has been demonstrated for example, in 
the liver (C. Deighan, PhD thesis). In fact, the use of this transgenic mouse model 
has greatly assisted our general understanding of the role of the aiB-AR in this organ, 
as is emphasised below.
The methods developed using recombinant cell lines were then used to examine the 
properties of native receptors on isolated hepatocytes. The main objective was to 
assess the subcellular distribution of native aiB-ARs in wildtype cells, hypothesise as
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to their functional location, and to consider the possibility of the upregulation of 
another aj-AR subtype in knockout cells. Further to this, intriguing findings from 
preliminary radioligand binding experiments (C. Deighan, PhD thesis) on intact liver 
plasma membranes initiated further study at a subcellular level. A series of 
interesting observations were made in preliminary experiments done in isolated 
hepatocytes. Detailed below are key points relating to these findings and intended 
future research:
1. aj-AR subtype expression in hepatocytes is heterogeneous and displays a unique 
form o f plasticity: During prolonged culture, an increase in ai-AR density was 
observed. In both wildtype and knockout cells these sites were sensitive to RS100329 
(aiA) and BMY7378 (aw)-
Cultured hepatocytes are capable of expressing all 3 subtypes of ai-AR, depending 
on their extracellular environment. Since this is likely to be a direct mitogenic effect 
of the culture media, it does not represent the natural disposition of these receptors. 
In view of the fact that our aim was to define ai-AR expression in vivo, the flexible 
nature of this cell type is not ideal. However, such alterations are of interest, and 
further work will be carried out. A combination of the two subtype-selective 
antagonists will demonstrate a role for the aiB-AR subtype in these cultured cells. 
The contribution of specific mitogenic factors in the culture media will also be 
assessed as will cell plating density.
2. aj-AR expression undergoes onto genic modulation during the life cycle o f the 
mouse. In the wildtype, there is a predominantly ais-AR population which shows a 
decrease in density between 3 and 4 months, likely to represent post-maturational
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decline, as seen in the rat. In the 3month-old knockout, only a small population of 
aj-ARs exists compared to the substantial ajB-AR population in the wildtype. The 
knockout mouse shows up-regulation of an Œja-AR population between 3 and 
4months likely to be a compensatory mechanism to replace the Œ jb-A R subtype. By 
4months, a population o f similar aj-AR density is reached in both strains, yet they 
belong to different subtypes.
It is well documented in the literature that ai-AR subtype expression in the intact 
liver varies between species. However, this is the first report to date of such an 
interchange within the same species. This is of great interest to us as it suggests 
subtype redundancy in an organ where «i-AR subtypes are thought to play an 
important role. Interestingly, in the 3month knockout, a p-AR or even a non- 
adrenergic mechanism seems likely to compensate for the lack of «i-ARs seen at this 
age. At a specific time point between 3 and 4months, a replacement population of 
aiA-ARs becomes established. Such findings have led us to suspect that oci-AR 
subtype expression may undergo alterations during the life cycle of the mouse. It is 
hypothesised that the « ib-AR is replaced by the Œia-AR subtype in the mature 
animal. Further studies using I year-old mice will establish this.
3. In both wildtype and knockout cultured hepatocytes, aj-ARs are distributed 
throughout the cytoplasm of the cell. Minimal expression was associated with the 
plasma membrane.
If this represents a similar distribution of the different subtypes found by radioligand 
binding in the two strains then there would be no subtype-dependent differences in 
location. However, since prolonged culture increased the density of «i-ARs (aiA and
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ttio), and ociB-AR expression is likely to be downregulated (Gao et al., 1996), it is 
possible that QAPB binds to similar populations (aiA and a ^ )  in the two strains 
explaining the similar intracellular binding pattern. Further work is required to 
establish the natural disposition of ai-AR subtypes in hepatocytes.
The multifunctional protein, gCl-qR has been reported to bind to the C-terminus of 
the aiB-AR, in rat liver, retaining it in an intracellular location and mediating its 
down-regulation (Xu et al., 1999; Hirasawa et al., 2001). Immunoprécipitation of the 
gCl-qR-tti-AR complex from wildtype and knockout liver will test the specificity of 
this protein. There is a possibility that it is liver-specific, in which case, it may be 
capable of binding to the aiA-AR in the knockout. Once the specificity of gCl-qR 
has been established, further distribution analysis will be permitted. Due to the 
unforeseen alterations in ai-AR subtype expression during prolonged culture of 
hepatocytes, studies regarding the natural distribution of these receptors will require 
to be carried almost immediately post-isolation.
Using techniques developed in the previous chapters, the work in the final chapter 
represents the study of the subcellular distribution and characterisation of native ai- 
ARs in VSMCs, both freshly dissociated and in culture.
In transgenic mouse models, it is likely that the 'knocked out' gene can, at a single 
cell level, be replaced with labelled recombinant versions. The work in chapter 3 
demonstrates how, under the control of a viral or mouse aiB-AR-specific promoter, 
GFP-tagged aib-ARs can be expressed in knockout aortic SMCs in situ. Once 
optimised, such manipulation should allow for expression mimicking that found in 
vivo. In terms of drug action, subtype distribution indicated from such studies will be
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informative. Detailed below are the key findings from the duration of this project 
regarding ai-AR expression in VSMCs:
1. QAPB bound specifically, and with high affinity, to aj-ARs present on freshly 
dissociated (carotid artery) and cultured (carotid artery and thoracic aorta) VSMCs. 
In freshly dissociated cells, QAPB binding was predominantly intracellular; this was 
consistent in both wildtype and knockout cells. In cultured VSMCs, QAPB binding 
varied considerably between individual cells, in both strains, and was influenced by 
the cellular morphology.
Freshly dissociated VSMCs, are likely to represent the natural disposition of ai-ARs 
seen in vivo. The intracellular distribution observed in both wildtype and knockout 
cells, indicated that, in their natural environment, ai-ARs are perhaps situated inside 
the cell and recruited to the membrane for agonist activation. Alternatively, the 
endogenous/exogenous ligand may gain access via a transporter, or endocytic 
mechanism. Such considerations regarding subtype-specific distribution are 
extremely important with a view to prospective therapeutic intervention.
Reports in the literature, combined with studies in this project, indicate that the 
subcellular distribution of oti-AR subtypes in cultured VSMCs is likely to be 
indicative of intrinsic properties of subpopulations of SMCs within the vessel wall. 
In spindle-shaped cells, representative of the contractile phenotype, ai-ARs are 
associated predominantly with the plasma membrane, and hence likely to be 
involved in contraction. A greater proliferative activity was also observed in cells of 
such morphology. Large, 'fried-egg' shaped cells, displayed clustered QAPB binding 
in a perinuclear orientation and a rather quiescent growth rate. Such features indicate
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that perhaps these cells perhaps contribute differently in vascular function. Therefore 
cultured cells are not likely to represent an in vivo situation.
2. RS100329 (aiA-AR-selective) was able to reduce the specific binding o f QAPB in 
some of the cells analysed, from both aorta and carotid artery. BMY7378 (aw-AR- 
selective) was able to block the specific binding o f QAPB in the majority o f knockout 
cells studied, from both strains, and from both vessels. Less o f an effect was observed 
in the wildtype. In knockout VSMCs (aortic and carotid artery), a predominantly 
aioAR population was expressed, whereas a mixture o f all three is likely in the 
wildtype carotid artery.
A more substantial study, using the ArrayScan™ system is required to provide 
quantitative data regarding ai-AR subtype expression at the single VSMC level in 
these vessels.
3. Observations were made that wildtype carotid artery VSMCs appeared to grow at a 
much slower rate that knockout cells.
This may be explained by the presence of 'quiescent' shaped cells in the wildtype 
culture, or is perhaps a feature intrinsic to knockout cells. This requires further 
investigation. Reports in the literature suggest that subpopulations of VSMCs have 
different metabolic and growth rates along the length of a given blood vessel (see 
review Hungerford and Little, 1999)
4. Using the transfection reagent Tfx™-50, it was possible to express GFP-tagged 
aib-ARs in knockout aortic SMCs in situ under the control o f both a viral and mouse 
aiB-AR-specific promoter.
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Further investigation is required to establish if only certain areas in the vessel wall 
are able to express aib-ARs under the control of the promoter specific to the mouse 
aiB-AR gene. Once transfection conditions have been optimised, it will be 
interesting to compare the distribution of aib-ARs expressed in aortic segments 
under the control of the two promoter systems. Will they be expressed uniformly, or 
will they appear in specific regions within the vessel wall? As suggested by 
preliminary studies in chapter 3, adventitial cells are capable of expressing aib-ARs. 
Are they competent to express the aib-AR when under the control of the mouse aiB- 
specific promoter?
I was surprised to find that it was relatively easier to transfect cells within the vessel 
wall than to transfect single cultured SMCs, where the reagent had visibly toxic 
effects. Since blood vessel segments are more robust than single cells, I assumed that 
the need for diffusion of the liposome-DNA complex through the vessel layers 
before reaching the smooth muscle, had allowed a more gentle approach, and 
perhaps less potency compared with the exposed surfaces of cultured cells.
Until recently, typical GPCRs were thought to reside solely at the plasma membrane. 
However, findings contained in this thesis suggest otherwise. Up to this point, 
however, it is still unclear whether subtypes of ai-ARs have essentially a specific 
functional location, irrespective of cell type, or whether their distribution is cell- 
specific? It is also evident from the work in this thesis that during culture native cells 
undergo alterations that obscure their true phenotype whilst in their natural 
environment. These findings emphasise the need for a subtype-expression-system 
that mimics an in vivo environment.
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Results from the confocal studies on VSMCs have also exemplified the problems 
encountered with ai-AR characterisation of blood vessels at present. At the single 
cell level, the possibility of all three subtypes being expressed in the wildtype carotid 
artery was indicated yet only one subtype predominated in the functional response 
(C. Deighan, PhD thesis). Such findings demonstrate the necessity for functional 
analysis. Although information gained from single cell work regarding distribution is 
invaluable, ultimately, the oti-AR subtype(s) that mediate the functional response of 
individual vessels is the key to drug intervention.
The lack of correlation between expression and functional response is best illustrated 
by the ttie-AR. The aie-AR is expressed throughout the vasculature (Piascik et al., 
1997), although several groups have demonstrated a minimal role for this subtype in 
mediating contraction (see general introduction). To add to this frustration, no 'fool­
proof antagonists are currently available for this subtype, distinguishing it from aiA- 
and aiD-ARs. How may this be overcome?
The use of transgenic mouse models has the advantage of simplifying the situation 
by removing individual subtypes from the equation, but they may also have their 
limitations. The lack of a specific subtype from conception onwards may lead, in 
some cases, to compensatory alternative mechanisms that will not allow specific 
functions to be attributed to a particular ai-AR subtype. In addition to up-regulation 
of remaining subtypes, it is possible that decreases in responses known to 
functionally antagonise the subtype of ai-AR in question may occur. An example of 
this has been reported in the pi/P2 -double knockout, where cardiac muscarinic 
receptor density was reduced, a counterbalancing reduction in a receptor that is 
known to functionally antagonise stimulatory p-ARs (Roher et al., 1999).
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The development of a transgenic mouse model, in which all ttiB-competent 
cells/tissues express a GFP-tagged version of this receptor subtype, holds great 
promise for this field of research. Our laboratory has been awarded an MRC 
innovation grant to generate such a model. In collaboration with Professor John 
Mullins, University of Edinburgh medical school (generating mouse model), and Dr 
Dianne Perez, The Cleveland Clinic, Ohio (designed construct), we hope to be able 
to assess the competency of any given tissue/cell to express the aiB-AR. This model 
has the potential to provide invaluable information that has thus far been restricted 
due to frustrating technical limitations.
When the GFP-tagged Œib-AR mouse model becomes available, non-invasive 
agonist stimulation studies of smooth muscle in the intact vessel will hopefully be 
enabled.
In addition, an (Xm-AR knockout mouse has been generated (Tsujimoto), and it is 
hoped that a colony will be established in our laboratory in the coming months. This 
subtype plays a large part in mediating contraction of several blood vessels. 
Therefore, it will be interesting to see what compensatory mechanisms 'kick-in' in its 
absence. Comparison of data from the two ai-AR subtype knockout mice will, no 
doubt, be intriguing.
The methods developed and adapted during this project will hopefully enable further 
study of internalisation of aib-ARs, and hopefully we will be able to extend this to 
native cells and aiB-ARs in situ. Considerations for such work will include the rate at 
which native receptors internalise. Presumably diffusion of drugs through the vessel 
layers will also be rate limiting. From reports in the literature, it appears that the rate 
and extent to which the aiB/b-AR is internalised, in native and recombinant cells, is 
cell-dependent (see general introduction).
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A final set of aims of this project was to demonstrate ai-AR distribution within the 
walls of human small resistance arteries, to extend this to the subcellular level and 
determine whether receptor cycling could be demonstrated in the intact tissue in 
response to agonists. Although this final question still remains unanswered, the 
project did make considerable scientific progress, including the ability to manipulate 
the ttib-AR population and express GFP-tagged constructs in blood vessel segments. 
The biggest hurdle in this project was the development of the FLAG-tagged 
construct. Being an amateur in the field of molecular biology, and having to employ 
unfamiliar techniques in a pharmacology laboratory, was both time consuming and 
challenging. However, generation of the construct was a success, and although it did 
not contribute significantly to the final outcomes of this thesis, it gave the most 
personal satisfaction.
I realise now, in hindsight, that the task in hand was technically challenging, but it 
encouraged me to deal with the situation in a systematic and logical manner. The 
vast number of techniques and practical abilities required by this project has 
broadened my outlook as a prospective research scientist.
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